File Name,Date of Response,Date Comments,Responding FDA Center,Response to Petition,Cited Statutes or Regulations,Justification for Response,Review Comments
FDA-2003-P-0694-0004_Memorandum_for_the_Record_from_FDA_Office_of_Nutri,"Stamped November 18, 2010 and November 20, 2010",,"Office of Nutrition, Labeling and Dietary Supplements, specifically the Food Labeling and Standards Staff (HFS-820)","Closed
The petition was closed at the request of the petitioner (Bob Troyer of Bunker Hill Cheese Co.), who stated that the company had decided not to market a product using the term ‚Äúyogurt cheese‚Äù, rendering the petition moot.","Section 403(i) of the Federal Food, Drug, and Cosmetic Act

21 CFR 133.188(e)(1) (Standard of identity for Semi-Soft Part-skim cheese)
","The petition was voluntarily withdrawn by the petitioner. Bob Troyer communicated on October 29, 2009 that the product would not be marketed, and therefore the request was no longer necessary. FDA accordingly considered the petition moot and formally closed the docket.",
FDA-2003-P-0694-0003_Letter_from_FDA_CFSAN_to_Bunker_Hill_Cheese_Co___I,"Stamped July 21, 2003 and July 22, 2003",,"Center for Food Safety and Applied Nutrition (CFSAN)
üìç Office of Nutritional Products, Labeling and Dietary Supplements","No decision issued at the time
FDA advised the petitioner that it had not reached a decision within the 180-day review period due to prioritization of other matters (notably, rulemaking in response to the Bioterrorism Preparedness and Response Act of 2002).

","Section 403(i)(1) of the Federal Food, Drug, and Cosmetic Act

21 CFR 133.188(e)(1) (Standard of identity for semisoft part-skim cheese)

21 CFR 10.30(e)(2) (Citizen Petition procedures regarding response time)","FDA explained the delay was due to:

The agency being at the height of rulemaking for the Public Health Security and Bioterrorism Preparedness and Response Act of 2002

Other agency priorities and limited availability of resources

They assured the petitioner that a response would be provided in the future, though no specific timeline was given.",From 2003?
FDA-2003-P-0563-0001_Memo_to_File_to_Administratively_close_Citizen_Pet,"April 14, 2022",,"Center for Food Safety and Applied Nutrition (CFSAN)
üìç Office of Regulations and Policy (ORP)
","Administratively Closed
The petition was voluntarily closed because FDA did not approve or deny it within the required 180-day timeframe and no mutual agreement for extended review was made.","Section 10809 of the Farm Security and Investment Act of 2002 (Public Law 107-171)
(This law requires FDA to act on irradiation labeling petitions within 180 days, or the petition is deemed denied.)

","The Farm Security and Investment Act of 2002 was already in effect when the petition was submitted (April 24, 2003).

FDA failed to act within the statutory 180-day window, and there was no mutual agreement for extended review.

Thus, the petition was deemed denied by law and administratively closed nearly two decades later.

The closure was also procedural due to the petitioner (Hawaii Pride, LLC) being acquired by Calavo Growers Inc. in 2008.

",
FDA-2010-P-0012-0007_Alaunus_Pharmaceutical_LLC_re_Patrick_Foster_Citiz.pdf,"Printed November 7, 2010; Stamped November 8, 2010",,Division of Dockets Management,Withdrawn,Not Mentioned,Petition was withdrawn by Alaunus Pharmaceutical LLC on behalf of Patrick Foster.,
FDA-2010-P-0015-0006_Citizen_Petition_Denial_Response_from_FDA_CDER_to_.pdf,"Stamped October 1, 2010 and October 17, 2010",,Center for Drug Evaluation and Research (CDER),Denied,21 C.F.R. ¬ß 10.30; Section 505(j)(2)(C) of the FDCA,"The proposed 7.5 mg strength is not supported by the approved labeling of the reference listed drug (Ambien¬Æ 5 mg and 10 mg).
- The RLD labeling does not contemplate a 7.5 mg dose; instead, it recommends titration only in 5 mg increments (5 mg or 10 mg).
- Allowing a 7.5 mg strength would constitute a new dosing regimen, which is not permitted via a suitability petition under the FDCA.
- Therefore, the proposed change is not petitionable and must instead be submitted under a full NDA process (Section 505(b)).
- The FDA provides an opportunity for reconsideration within 30 days if based on original information",
FDA-2010-P-0016-0003_Interim_Response_to_Hisamitsu_Pharmaceutical_Co__I.pdf,"Stamped July 7, 2010 and July 12, 2010",,CDER,Interim Response,21 CFR 10.30(e)(2),Petition for delaying ANDA approvals of Salonpas patch not yet resolved. Interim notice given per FDA regs.,
FDA-2010-P-0017-0007_Foley___Lardner_LLP___Citizen_Petition_Withdrawal.pdf,"January 27, 2010",,Division of Dockets Management,Withdrawn,Not Mentioned,Petitioner (Foley & Lardner LLP) voluntarily withdrew original petition for replacement.,
FDA-2010-P-0027-0003_Determinations_that_Products_Were_Not_Withdrawn_Fr.pdf,"July 7, 2010",,CDER,Approved,21 CFR 314.161; 21 CFR 314.162,"FDA reviewed its records and found no evidence that ACTONEL (75 mg) or ACTONEL WITH CALCIUM (35/500 mg) were withdrawn for safety or efficacy reasons.
- No petitioners submitted data suggesting such reasons.
- FDA conducted an independent review of literature and postmarketing data and found no safety/effectiveness concerns.

- FDA will maintain both drugs in the Discontinued Drug Product List and allow ANDA approvals if all other requirements are met.",
FDA-2010-P-0027-0004_FDA_CDER_to_Lachman_Consultant_Services__Inc____Le.pdf,"Printed July 7, 2010; Stamped July 12, 2010",,CDER,Approved,21 CFR 314.161; 21 CFR 314.162,"FDA reviewed its records and found no evidence that the discontinuation of Actonel 75 mg or Actonel with Calcium 35/500 mg was for safety or efficacy concerns.
- No data submitted in the petitions supported a withdrawal due to these reasons.
- FDA independently evaluated postmarketing safety data and literature and found no information indicating safety or effectiveness issues.
- Therefore, both products remain listed in the ""Discontinued Drug Product List"" and may be referenced in ANDAs, provided all legal and regulatory requirements are met",
FDA-2010-P-0028-0004_FDA_CVM_Response_to_Parnell_Technologies__Aust__PT.pdf,"Stamped February 30, 2010 and April 8, 2010",,CVM (Center for Veterinary Medicine),Approved,Section 512(n)(3) of the FDCA,"The proposed product, GONABREED (gonadorelin acetate) Injection, 100 ¬µg/mL, differs from the reference listed new animal drug (RLNAD), CYSTORELIN (gonadorelin diacetate tetrahydrate) Injection, 50 ¬µg/mL, only in strength.
- The change does not require new safety or efficacy investigations and is allowable under suitability petition provisions.
- However, a change in dosage discussed in the petition is not permitted under a suitability petition and must be reviewed during the full ANADA evaluation.
- The approval only allows submission of the ANADA and does not guarantee product approval until FDA completes full review",
FDA-2010-P-0045-0038_Memo_and_Combined_Responses_to_Dr_Edlich_Citizen_P.pdf,"April 4, 2018",,CDRH,"Granted in Part / Denied in Part:
- Granted: Ban on powdered medical gloves, removal of glove powder report, final decisions on several older petitions
- Denied: Requests for new regulatory guidelines and reclassification of certain devices (rendered moot by ban)",81 FR 15173; 81 FR 91722,"FDA considered Dr. Edlich‚Äôs petitions and the data he submitted as part of the rulemaking process.
- The agency issued a final rule on December 19, 2016 banning powdered surgeon's gloves, powdered patient examination gloves, and absorbable glove powder, thus achieving the main aims of the petitions.
- FDA removed the ""Medical Glove Powder Report"" from its website as part of this action.
- FDA denied the request to establish new procedural guidelines for petition responses, citing existing adequate rules (21 C.F.R. 10.30).
- Reclassification requests were denied as moot due to the ban effectively removing those products from the market",
FDA-2010-P-0050-0004_Interim_Response_to_Health_Research_Group_Public_C.pdf,"Stamped July 14, 2010 and July 15, 2010",,CDER,Interim Response,21 CFR 10.30(e)(2),"The petition requests the FDA to remove Savella (milnacipran) from the market, citing questionable clinical efficacy and potentially serious risks.
- FDA has not yet completed its evaluation due to the complexity of the issues involved, necessitating extensive review and analysis by agency officials",
FDA-2010-P-0050-0006_Petition_Denial_Final_Agency_Response.pdf,"Stamped July 3, 2016",,CDER,Denied,Section 505(e)(2) of the FDCA,"üß™ Clinical Trial Design & Analysis
Savella (milnacipran hydrochloride) was approved based on two rigorous, randomized, double-blind, placebo-controlled trials (Study 031 and Study 02).

FDA found the statistical analyses, including the use of composite endpoints and post hoc analysis methods, to be valid and appropriate. The agency explained that the same imputation method for both studies increased data reliability and comparability.

üìä Study Endpoints
Composite endpoints (pain reduction, physical function, and patient global assessment) were deemed suitable due to fibromyalgia being a syndrome with multiple symptoms.

The FDA concluded that statistically significant results were achieved when evaluating these combined endpoints.

üíä Benefit-Risk Profile
FDA stated the benefits of Savella outweigh its risks.

The agency cited updates to product labeling with enhanced safety information and postmarketing safety analyses that supported continued marketing.

üõë Rebuttal to Petitioner‚Äôs Claims
FDA addressed concerns about changing study protocols, exclusion of severely depressed patients, and efficacy thresholds.

The agency rebutted the claim that the benefit was marginal (7‚Äì9%) and provided context for interpreting composite endpoint success.

üîç Safety Monitoring
The agency acknowledged known safety issues, including elevated blood pressure and heart rate, but noted these were class effects typical of SNRIs and managed through updated labeling.",
FDA-2010-P-0051-0003_FDA_CDER_to_Lachman_Consultant_Services__Inc____Le.pdf,"Printed July 7, 2010; Stamped July 12, 2010",,CDER,Approved,"21 CFR 314.161, 21 CFR 314.162","The FDA reviewed its records and found no evidence that the drug was withdrawn due to safety or efficacy issues.
- The petitioner provided no data indicating withdrawal for such reasons.
- FDA independently evaluated postmarketing data and literature and found no reason to support a safety or efficacy withdrawal.
- Therefore, the drug remains listed in the Orange Book under the Discontinued Drug Product List allowing continued ANDA referencing",
FDA-2010-P-0052-0020_Memo_and_Combined_Responses_to_Dr_Edlich_Citizen_P.pdf,"April 4, 2018",,Center for Devices and Radiological Health (CDRH),"Partially Granted and Partially Denied
- Granted: Ban on powdered medical gloves (surgical and examination), removal of the ‚ÄúMedical Glove Powder Report,‚Äù recognition of petitions filed, and effective ban in IVF labs.
- Denied: Requests to establish new procedural guidelines for citizen petition handling, and device reclassification as it was deemed moot",81 FR 15173; 81 FR 91722,"FDA issued a final rule banning powdered surgeon‚Äôs gloves, powdered patient examination gloves, and absorbable powder for lubricating a surgeon‚Äôs glove based on scientific and legal findings.
- FDA considered information provided in Dr. Edlich‚Äôs petitions in developing this rule.
- The ban made several requests moot (e.g., powder removal, reclassification).
- FDA cited that existing regulations already govern petition responses (21 C.F.R. 10.30), and thus denied the request for new guidelines.
- FDA had already issued an interim response and completed required administrative steps.",
FDA-2010-P-0056-0012_Center_for_Device_and_Radiological_Health__to_Rich.pdf,"August 26, 2010",,Center for Devices and Radiological Health (CDRH),Other (Panel Hearing Notification),Not Mentioned,Notified petitioner of upcoming panel meeting to discuss scientific issues raised in the dental amalgam classification petition,
FDA-2010-P-0056-0029_Citizen_Petition_Closure_Memo_from_CDRH_dated_4_10.pdf,"April 10, 2018",,Center for Devices and Radiological Health (CDRH),Closed due to death of petitioner,"21 CFR ¬ß 10.30(b)(3), 21 CFR ¬ß 10.30(e)(3)","Petitioner Dr. Richard Edlich passed away in 2013, and co-signors lacked proper contact info; FDA closed the docket",
FDA-2010-P-0059-0004_FDA_CDER_to_EAS_Consulting_Group___LLC___Letter.pdf,"Printed July 7, 2010; Stamped July 12, 2010",,Center for Drug Evaluation and Research (CDER),Denied the implication of withdrawal due to safety or effectiveness; FDA concluded the product was not withdrawn for those reasons.,"21 CFR 314.161, 21 CFR 314.162","The FDA reviewed its records and found no evidence that the product Actonel with Calcium (risendronate sodium and calcium carbonate copackaged) Tablets, 35 mg/500 mg was withdrawn from the market for safety or effectiveness concerns.
- The petitioner (EAS Consulting on behalf of Aurobindo Pharmaceuticals) did not provide any data indicating such concerns.
- The FDA independently evaluated literature and postmarketing data and found no adverse information.
- The product will remain in the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book.",
FDA-2010-P-0069-0007_FDA_CDER_to_Foley___Lardner_LLP___Petition_Denial.pdf,"Stamped July 21, 2010",,Center for Drug Evaluation and Research (CDER),Denied,"21 U.S.C. 355(d)(3), 21 CFR 314.50(d)(1), 21 CFR 314.94(a)(9), 21 CFR parts 210 and 211, 21 CFR 10.115","FDA concluded that existing statutory requirements, CGMP regulations, and guidance are sufficient to ensure the safe production of highly potent pharmaceutical products.
- FDA emphasized that CGMP violations cited in warning letters do not justify new regulations or guidance.
- Responsibility for worker safety and environmental protection falls under OSHA and EPA, not FDA.
- Requests for advisory committee meetings and drug classification lists lacked supporting evidence and were deemed unnecessary.
- FDA reserves the possibility of future guidance but saw no urgent need based on the petition",
FDA-2010-P-0072-0007_Arent_Fox_LLP___Petition_Withdrawal.pdf,"March 22, 2010",Stamped date that is no legible ,Division of Dockets Management,Withdrawn by Petitioner,Not Mentioned,Petition was voluntarily withdrawn by the submitting law firm (Arent Fox LLP) on behalf of the petitioner,
FDA-2010-P-0076-0006_Interim_Response_to_Roxane_Laboratories__Inc_.pdf,"Stamped August 2, 2010 and August 5, 2010",,Center for Drug Evaluation and Research (CDER),Interim Response ‚Äî Decision Pending,21 CFR 10.30(e)(2),"The petition raised complex issues requiring extensive review and analysis by FDA officials.
- The FDA had not yet reached a conclusion and issued the interim response in accordance with regulatory requirements.",
FDA-2010-P-0081-0008_Interim_Response_to__Jim_Bates__Truth_in_Labeling_.pdf,"Stamped June 30, 2010 and May 30, 2012",,Center for Food Safety and Applied Nutrition (CFSAN),Interim Response ‚Äî Decision Pending,21 CFR 10.30(e)(2),"Due to competing agency priorities and limited resources, the FDA has not been able to respond within the first 180 days",
FDA-2010-P-0081-0009_Citizen_Petition_Denial_Response_from_FDA_CFSAN_to.pdf,"Stamped November 19, 2015",,Center for Food Safety and Applied Nutrition (CFSAN),Denied,"21 CFR 10.30, FDCA 21 U.S.C. 343(a)(1), 321(n)","FDA found no basis for concluding that bioengineered foods differ from conventional foods in any material way that would require labeling.
- The agency reaffirmed that it is not aware of any information showing that foods derived by genetic engineering differ from other foods in any meaningful or material way.
- FDA emphasized that requiring labeling based on the method of production, without a material difference, would be inconsistent with the FD&C Act.
- Voluntary labeling is permitted and guidance was previously issued for such labeling.
- FDA reviewed scientific evidence and concluded that genetically engineered ingredients do not pose greater health or safety risks than traditionally bred foods.",
FDA-2010-P-0082-0023_FDA_CDER_to_Donald_E__Segal_and_Julie_Tibbets__Als.pdf,"Stamped July 19, 2010",,Center for Drug Evaluation and Research (CDER),Granted in part and denied in part,"21 CFR parts 320, 314.127(a)(8), FDCA Section 505(j)","‚úÖ Granted Portions:
In Vitro Dissolution Testing for Dose-Dumping:
Required for all strengths referencing Kadian to mitigate risks of alcohol-induced dose-dumping, especially in light of historical issues like Palladone withdrawal.
(Pages 8‚Äì9)

Bioequivalence Across Pellet Formulations:
Required for ANDAs referencing 10 mg, 100 mg, and 200 mg strengths of Kadian, as each uses different pellet formulations.
(Pages 9‚Äì10)

‚ùå Denied Portions:
Additional Pharmacokinetic Parameters (e.g., Tmax, AUCpR, partial AUC):
FDA found no clear evidence linking these metrics to therapeutic effect or safety in extended-release morphine. Existing standards using Cmax and AUC are deemed sufficient.
(Pages 6‚Äì8)

Mandatory In Vivo Dose-Dumping Studies:
Denied as not always necessary; such studies are only required if in vitro testing shows elevated risk.
(Page 9)

üß† Additional Notes:
FDA found no clinically significant difference in Tmax between Kadian and other formulations like Avinza.

Cited lack of evidence to warrant changes to bioequivalence requirements beyond established statistical parameters.",
FDA-2010-P-0086-0011_FDA_CCDER_to_Hyman__Phelps___McNamara__P_C____Peti.pdf,,"Two dates stamped over each other. I think one says Jan 20, 2011",Center for Drug Evaluation and Research (CDER),"Denied
The FDA rejected the ANDA suitability petition due to safety and regulatory concerns regarding inactive ingredient changes in parenteral formulations","21 CFR 314.94(a)(9)(iii), 314.127(a)(8)(ii)","The petitioner proposed to change the diluent of the reference drug (Taxotere) from PS80 to Macrogol 15 hydroxystearate, an excipient not previously approved in any parenteral drug product by FDA.
- Under 21 CFR 314.94(a)(9)(iii), parenteral ANDAs must include the same inactive ingredients in the same concentration as the reference listed drug, with very limited exceptions (e.g., for preservatives, buffers, antioxidants).
- Since Macrogol 15 hydroxystearate is neither of these and lacks prior approval in injectable products, the proposed formulation raises serious safety and efficacy concerns.
- The FDA cited its prior decision in Docket No. FDA-2009-P-0272, where it rejected any docetaxel formulation differing in PS80 content from Taxotere.
- Therefore, the agency would not accept the proposed ANDA for review",
FDA-2010-P-0087-0004_FDA_CDER_to_Sandoz__Inc____Petition_Denial.pdf,"Stamped July 30, 2010 and August 3, 2010",,Center for Drug Evaluation and Research (CDER),Denied,"21 U.S.C. 355(j), 21 CFR 314.94(a)(8)(iv), 21 CFR 314.127(a)(7), Purepac Pharm. Co. v. Thompson","Carve-outs of protected indications from labeling (related to either seizures or pain) are permissible under FDA regulations if they do not make the generic product less safe or effective for the remaining conditions of use.
- The FDA determined that labeling changes could be made to omit patent-protected uses while retaining necessary safety information (e.g., suicide risk, peripheral edema).
- Section 5.4 and 5.5 of LYRICA‚Äôs labeling (regarding suicidal behavior and peripheral edema) can be retained with minor edits that do not disclose protected indications.
- The FDA cited prior precedents and legal interpretations (e.g., Purepac, Torpharm, Bristol Myers Squibb v. Shalala) to support their authority to permit carve-outs.
- Overall, the agency concluded that permitting carve-outs would not render the generic products less safe or effective than LYRICA for the remaining approved uses.",
FDA-2010-P-0089-0013_FDA_CDER_Interim_Response_to_Center_for_Tobacco_Re.pdf,"Stamped August 4, 2010 and August 6, 2010",,Center for Drug Evaluation and Research (CDER),Interim Response ‚Äî Decision Pending,21 CFR 10.30(e)(2)," The petition involved significant issues regarding how the FDA should regulate, review, and label nicotine replacement therapy (NRT) medications.
- These issues required extensive review and analysis by agency officials.
- As a result, FDA issued an interim response under regulatory guidelines until a final decision could be made",
FDA-2010-P-0089-0019_FDA_CDER_to_Center_for_Tobacco_Regulation_Litigati.pdf,"Stamped April 1, 2013",,Center for Drug Evaluation and Research (CDER),"The FDA provided a mixed response ‚Äî some parts of the petitions were granted, while others were denied","21 CFR Part 10, Section 918 of the Family Smoking Prevention and Tobacco Control Act","FDA provided detailed reasoning for each element of the petition. Key points include:

Insufficient Evidence: Many requests (e.g., for new indications, concomitant use, or claims of relative safety) lacked adequate scientific support. Literature cited did not justify regulatory changes without additional clinical trials (see pages 7‚Äì12).

Scientific Standards: Labeling changes require data from sponsors and rigorous review, not just citizen petitions (pages 5, 7, 23).

Population Risk Considerations: The FDA declined to support claims that OTC NRT is broadly safer for all populations (e.g., CVD, pregnancy, adolescents) without clinical validation (pages 16‚Äì21).

Regulatory Integrity: Decisions about labeling and indications must be based on well-controlled studies and regulatory standards, not opinion or advocacy alone.

Support for Smoking Cessation: FDA granted requests supporting trial design, regulatory flexibility, and access expansion (e.g., smaller packages, broader retail access) as part of its commitment to help people quit smoking (pages 24‚Äì26, 29‚Äì30).",
FDA-2010-P-0091-0122_Citizen_Petition_Denial_Response_from_FDA_CDER_to_.pdf,"Stamped June 12, 2015",,Center for Drug Evaluation and Research (CDER),Denied,"21 CFR 201.57, 21 U.S.C. ¬ß 355","The FDA provided the following key justifications for denying the petition:

Existing Labeling Already Adequate: Current benzodiazepine labeling already includes warnings for physical dependence, withdrawal, and long-term use. FDA believes these are sufficient for safe use.

Lack of Scientific Basis for 2‚Äì4 Week Limit: The requested universal duration limit was deemed overly restrictive and unsupported by clinical data, especially for chronic conditions like generalized anxiety disorder or panic disorder.

Rejection of ‚ÄúProtracted Withdrawal‚Äù Syndrome: The FDA‚Äôs literature review did not support the existence of a scientifically recognized ""protracted withdrawal"" syndrome.

Individualized Tapering: Tapering schedules must be tailored to individual patients; no one-size-fits-all approach could be mandated, and the proposed method lacked scientific support.

Boxed Warnings Unjustified: While physical dependence is acknowledged, evidence did not meet the threshold for a boxed warning, which is reserved for risks that may lead to death or serious injury.

No Need for Mandatory Outreach or Website Updates: Information is already publicly accessible through FDA websites and DailyMed; manufacturer compliance with additional web presence is not required",
FDA-2010-P-0092-0004_FDA_CDER_to_Leydig__Voit___Mayer__Ltd____Petition_.pdf,"Stamped August 13, 2010",,Center for Drug Evaluation and Research (CDER),Denied,"21 U.S.C. ¬ß 355(j), Section 505(q) of the FDCA","FDA‚Äôs key reasons for denying the petition include:

No Final Determination on ANDA: FDA had not yet decided whether Paddock‚Äôs ANDA would be approved, and therefore was not required to make a premature determination on a specific element of the application (i.e., dosage form) under ¬ß505(q)

Procedural Protections: The agency emphasized that ANDA review involves a structured process that includes notifying applicants of deficiencies and allowing them to respond or request hearings. The petition's request to resolve a specific issue outside of that framework was inconsistent with these statutory protections

Interpretation of ¬ß505(q): FDA does not interpret ¬ß505(q) to require a final decision on isolated technical elements (like dosage form classification) before a complete ANDA review is concluded

Regulatory Integrity: The FDA highlighted the need to avoid rendering piecemeal decisions that could compromise the integrity of the drug review process.",
FDA-2010-P-0111-0016_FDA_CDER_to_Shire_Pharmaceutical_Inc__Petition_Den.pdf,"Stamped November 8, 2019",,Center for Drug Evaluation and Research (CDER),Denied,"21 CFR 10.33, 21 CFR 10.30, FDCA Section 505(j)","The FDA denied the petition based on the following key points:

Request Did Not Meet Criteria for Reconsideration: The petitioner sought clarification and more detail about FDA's 2010 response but did not present new evidence that had not already been reviewed or considered. The petition therefore failed under ¬ß10.33(d) and ¬ß10.33(e)

Request Was Not to Reverse the Decision: FDA noted that the request essentially asked for elaboration rather than actual reconsideration of its conclusions.

Bioequivalence Determinations Already Justified: The FDA reiterated that its determinations about using pharmacokinetic (PK) metrics (AUC and Cmax) were scientifically valid for evaluating generic mesalamine products.

Agency Actions Already Taken: Since the petition was filed, the FDA had published new draft guidances (e.g., on September 14, 2012) regarding bioequivalence testing for delayed-release mesalamine tablets/capsules. These were available for public comment",
FDA-2010-P-0112-0007_Final_Response_Letter_from_FDA_CDER_to_Patrick_Fos.pdf,"December 11, 2024",Date from e-signature,Center for Drug Evaluation and Research (CDER),Denied,"21 CFR 10.30, FDCA Section 505(b)","FDA denied the petition based on the following key reasons:

Change in Strength Introduces Safety Risks: The proposed change from the listed drug‚Äôs strength and packaging raised concerns about:
Medication errors (e.g., preparation, dosing, expiration tracking)
Risk of incorrect administration
Potential for significant overdose

Labeling Would Require Significant Changes: To mitigate these risks, the drug would require updates to multiple labeling sections:
Dosage and Administration
Overdosage
Warnings and Precautions

These changes exceed what is permissible under the ANDA pathway, making the petition non-approvable under section 505(j)(2)(C) and 21 CFR 314.93.

Recommendation for NDA Pathway: The Agency suggested pursuing approval via a full NDA (section 505(b)) instead of an ANDA, due to the safety and labeling implications.",
FDA-2010-P-0111-0011_FDA_CDER_to_Warner_Chilcott_Company__LLC___Petitio.pdf,"Stamped August 20, 2010",,Center for Drug Evaluation and Research (CDER),Granted in part and denied in part,"FDCA Section 505(q), 21 CFR 314.94(a)(9)(iii), 21 CFR 314.127(a)(8)(ii)","The FDA provided the following reasoning:

Scientific Standards: FDA requires bioequivalence through appropriate scientific methods, and agreed with the need for both comparative clinical endpoint studies and in vitro dissolution data to ensure therapeutic equivalence for mesalamine products .

Statutory Discretion: FDA declined to delay ANDA approvals pending guidance publication, explaining that the law does not obligate FDA to issue guidance prior to approval decisions .

In Vivo Waivers: FDA agreed that waivers for in vivo bioequivalence studies between 400 mg and 800 mg tablets should be denied, as they are not directly substitutable due to formulation and dosing differences .

Labeling Decisions: FDA rejected labeling constraints and boxed warning requirements since such determinations must be based on safety and efficacy data evaluated case-by-case for the generic product .

Product Coding/Substitution Restrictions: FDA declined to enforce specific coding or limit pharmacy substitution, stating such decisions fall outside its regulatory scope and into the purview of state pharmacy boards or payers .",
FDA-2010-P-0111-0016_FDA_CDER_to_Shire_Pharmaceutical_Inc__Petition_Den.pdf,"Stamped November 8, 2012",,Center for Drug Evaluation and Research (CDER),Denied,"21 CFR 10.30, FDCA Section 505(j)","The FDA denied the reconsideration petition based on several reasons:

Request Was Not a Valid Reconsideration: FDA emphasized that the request did not meet the definition of a reconsideration petition because it:

Did not challenge the outcome of the 2010 decision.

Merely asked for additional scientific explanation and citations, which is not a permissible basis under ¬ß10.33

Agency Already Considered Relevant Information: FDA concluded that all relevant information and views were already part of the record when the original decision was made, thus satisfying the procedural requirements

Scientific Clarifications Provided Separately: Although denying the petition, the FDA did offer references to clinical studies and public resources (e.g., labeling and published studies) to support its original conclusions on the use of pharmacokinetic (PK) metrics for bioequivalence

Guidance Was Issued: FDA highlighted that it had since published draft guidance for bioequivalence of delayed-release mesalamine tablets/capsules in September 2012, which is available for public comment",
FDA-2010-P-0114-0007_FDA_CDER_Response_to_McGuff_Pharmaceuticals_Inc_Pe.pdf,"Stamped November 15, 2012 and November 16, 2012",,Center for Drug Evaluation and Research (CDER),Approved,"21 CFR 10.30, FDCA 505(j), 314.94(a)(9)(iii)","FDA approved the petition based on the following key points:

No New Safety or Efficacy Concerns: Despite the change in total strength (from 100 mg to 3000 mg per vial), the dose, route of administration, and usage of the proposed product were identical to the reference listed drug (RLD). FDA determined this change would not raise new safety or effectiveness issues.

No New Clinical Investigations Required: Since the change did not necessitate new studies, and assuming the product meets bioavailability standards, the proposed ANDA product could be expected to have the same therapeutic effect.

Standard Regulatory Pathway: FDA reminded the sponsor that the ANDA itself must still be reviewed and approved, and must refer to this petition‚Äôs docket number and include this approval letter.",
FDA-2010-P-0116-0003_Watson_Laboratories__Inc____Withdrawal.pdf,"Stamped August 23, 2010",,Division of Dockets Management,Withdrawn by Petitioner,Not Mentioned,Watson withdrew the petition after the FDA published a Federal Register notice stating BONIVA 2.5 mg was not withdrawn for safety or efficacy reasons,
FDA-2010-P-0125-0005_Samson_Medical_Technologies__LLC___Withdrawal.pdf,"Stamped March 22, 2010",,Division of Dockets Management,Withdrawn by Petitioner,Not Mentioned,Petitioner learned the requested determination was already published in the Federal Register; a formal response was no longer needed,
FDA-2010-P-0651-0012_Citize_Petition_Response_Letter_from_FDA_CBER,"October 1, 2018",,Center for Biologics Evaluation and Research (CBER),"Partially granted (some requests already granted), remainder denied","42 U.S.C. ¬ß 262(a)(2)(C)(i)(I)
- 21 CFR 10.30(e)(2)
- 21 CFR 600.3(p)
- 21 CFR 201.57(c)(6)(i)","Safety Evaluation: FDA determined that both the 2009 H1N1 and 2010/2011 seasonal vaccines were safe, pure, and potent, based on clinical data, past seasonal influenza vaccine performance, and post-marketing surveillance.
- No Scientific Evidence: The petitioners failed to provide scientific evidence to support their claims regarding vaccine safety risks such as adjuvants (e.g., squalene) or miscarriages.
- Labeling: Requested warnings were denied as false and unsupported; current labeling reflects known risks.
- Jurisdictional Limits: FDA denied requests related to mandatory vaccination policies and self-shielding recommendations as they fall outside FDA authority.
- Safety Monitoring: FDA and CDC conducted extensive safety surveillance (VAERS, VSD, CMS, PRISM, EIP), finding no substantial risks and only a very small elevated risk for GBS, consistent with historical influenza vaccine data.
- Moot Requests: Some requests were deemed moot due to the expiration of the public health emergency and the approval of vaccines in 2009.",
FDA-2010-P-0651-0011_FDA_CBER_Interim_Response_to_Natural_Solutions_Fou,"Stamped June 7, 2011",,Center for Biologics Evaluation and Research (CBER),Interim response: Final decision not yet completed; FDA plans to issue a combined response addressing this and a related earlier petition (FDA-2009-P-0418),21 CFR 10.30(e)(2),"FDA cites competing priorities that have delayed a final response.
- The issues raised in the 2010 petition overlap substantially with an earlier 2009 petition.
- The FDA intends to address both petitions together in a future combined final response",
FDA-2010-P-0648-0006_FDA_CDER_Response_to_G_Pohl_Boskamp_GmbH_and_Compa,"Stamped October 31, 2013",,Center for Drug Evaluation and Research (CDER),"Partially Granted and Partially Denied
‚Äì The request regarding in vitro pump functionality testing was granted.
‚Äì The remainder of the petition was denied.
‚Äì The associated petition supplement (PSA) was declared moot due to a substitute written response to an ANDA by the FDA (page 17).","Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(j)
‚Äì Section 505(q)(1)(A) and (B) of the FD&C Act
‚Äì 21 CFR 320.25 and 320.26 (Bioequivalence study requirements)","Scientific Basis: FDA carefully reviewed the petitioner‚Äôs requests involving pharmacokinetic measurements, bioequivalence requirements, in vitro testing, and component stability and extractables.
‚Äì Partial Agreement: The FDA agreed that testing pump functionality prior to distribution is essential to ensure delivery reliability for nitroglycerin lingual spray products.
‚Äì Grounds for Denial: The FDA denied other requests (e.g., mandatory use of specific pharmacokinetic parameters or in vitro-only bioequivalence testing) on the basis that current guidance and standards already ensure therapeutic equivalence. Additional requirements were considered unnecessarily restrictive or unsupported by sufficient scientific rationale.
‚Äì Regulatory Alignment: The agency maintained that existing ANDA requirements are adequate to assess bioequivalence, chemistry, manufacturing, and control standards without needing the proposed modifications.",
FDA-2010-P-0648-0005_FDA_CDER_Interim_Response_to_G__Pohl_Boskamp_GmbH_,"Stamped June 16, 2011",,Center for Drug Evaluation and Research (CDER) ,Interim response: Final decision not yet made. The Agency indicates that the petition raises complex issues requiring extensive review and analysis,21 CFR 10.30(e)(2) ‚Äì FDA regulations governing interim responses to citizen petitions,"The FDA states it has not resolved the issues raised in the December 21, 2010 petition.
‚Äì The petition concerns requests to block approval of abbreviated new drug applications (ANDAs) referencing Nitrolingual Pumpspray (NDA 18-705) unless specific conditions are met.
‚Äì The delay is attributed to the petition raising complex regulatory and scientific issues that require further review and analysis by FDA officials.",
FDA-2010-P-0644-0013_Meeting_Minutes___08_23_2018_FDA_meeting_with_IPIA,"August 23, 2018",,"Center for Food Safety and Applied Nutrition (CFSAN), FDA","Not applicable. The document summarizes a meeting and does not contain a formal petition decision (e.g., approval or denial). The citizen petition was discussed, but no regulatory action was issued.",Not Mentioned,"The FDA discussed the challenges of changing the Food Code and creating a standard of identity for packaged ice as requested by IPIA.
‚Äì FDA appreciated IPIA‚Äôs field observations and quality standards, and offered suggestions for future collaboration.
‚Äì The meeting was informative but did not result in a final regulatory decision.",
FDA-2010-P-0644-0012_Meeting_Minutes___06_15_2023_FDA_meeting_with_IPIA,"June 15, 2013",,Center for Food Safety and Applied Nutrition (CFSAN),No formal decision rendered. FDA stated that it could not provide substantive information regarding the pending citizen petition for a standard of identity for packaged ice but confirmed the petition is being addressed,Not Mentioned,"The FDA noted the pending nature of the Citizen Petition and did not discuss its substance.
‚Äì The agency acknowledged the importance of the issues raised and maintained openness to future engagement.
‚Äì FDA advised that specific questions should be submitted in writing ahead of any future meetings to facilitate more targeted discussions.",
FDA-2010-P-0644-0011_Final_Response_Letter_from_FDA_CFSAN_to_Internatio,"September 4, 2024",,Center for Food Safety and Applied Nutrition (CFSAN),Denied. All requests in the original 2010 citizen petition and the 2013 supplement were denied under 21 CFR 10.30(e)(3),"21 CFR Part 117 (CGMP and preventive controls)
- 21 CFR 117.80(c)(16)
- 21 CFR 117.37(a)
- 21 CFR 117.40(a)(2)
- 21 CFR 117.130
- Section 415 and Section 418 of the FD&C Act
- Section 401 of the FD&C Act (standards of identity and quality)
- FDA Food Code (2022 version referenced)","Existing Regulatory Coverage: The FDA determined that the CGMP and preventive control requirements in 21 CFR Part 117 already address the safety, sanitation, and quality concerns related to packaged ice.
- No Need for New Standards: The agency concluded that creating a new standard of identity or quality for packaged ice is unnecessary and unjustified under Section 401 of the FD&C Act, as the petitioners did not demonstrate how these standards would promote honesty and fair dealing or consumer protection.
- Redundancy with Existing Food Code: The FDA Food Code already includes ice as a food and contains provisions covering sanitation, contamination prevention, labeling, and employee hygiene relevant to packaged ice. Proposed modifications were therefore deemed unnecessary.
- Collaborative Mechanism Exists: FDA advised that any further proposals to amend the Food Code should be routed through the Conference for Food Protection (CFP) process.",
FDA-2010-P-0644-0009_Interim_Response_to_International_Packaged_Ice_Ass,"Stamped June 17, 2011 and January 17, 2012",,"Center for Food Safety and Applied Nutrition (CFSAN)
(Signed by Barbara O. Schneeman, Ph.D., Director, Office of Nutrition, Labeling and Dietary Supplements)","Interim response: No decision rendered. The FDA stated it had not yet been able to reach a decision on the December 3, 2010 petition due to other agency priorities and limited resources",21 CFR 10.30(e)(2) ‚Äì regulation governing the timing and nature of responses to citizen petitions,"The agency cited competing priorities and limited availability of resources as the reason for the delay.
‚Äì It affirmed that the petition was still under review and that potential amendments to FDA regulations would be considered in the context of other program priorities.",
FDA-2010-P-0642-0008_FDA_CDER_to_Teva_Neuroscience__Inc____Petition_Den,"Stamped and written June 8, 2011",,"Center for Drug Evaluation and Research (CDER)
Signed by Janet Woodcock, M.D., Director","Denied
The FDA formally denied the citizen petition submitted by Teva Neuroscience requesting that the FDA not approve any ANDA for a generic version of Copaxone without meeting stringent characterization and clinical equivalence requirements","Section 505(q) of the FDCA (21 U.S.C. ¬ß 355)
- Section 505(j) of the FDCA
- 21 CFR ¬ß 314.92(a)(1) ‚Äì ""same as"" active ingredient standard
- 21 CFR ¬ß 314.94(a)(5)(i) ‚Äì ANDA requirements
- 21 CFR ¬ß 314.127(a)(3) ‚Äì grounds for denying an ANDA
- 21 CFR ¬ß 320.1(c) ‚Äì pharmaceutical equivalents
- 21 CFR Part 314 ‚Äì application procedures
- 21 CFR ¬ß 210.3(b)(7) ‚Äì definition of active ingredient","FDA emphasized its broad discretion under the law to determine ‚Äúsameness‚Äù of active ingredients for ANDA approvals, supported by legal precedent (e.g., Serono Labs v. Shalala).
- The petition's requested criteria for equivalence (including full characterization of glatiramer acetate) were viewed as too restrictive and premature.
- FDA reaffirmed that it may require a multi-criteria scientific assessment to evaluate ‚Äúsameness‚Äù for complex products like Copaxone, but these must be developed through case-specific review.
- The agency argued that preemptively setting specific standards for generic Copaxone would effectively decide the approvability of future ANDAs without appropriate procedural review.
- FDA stated it has sufficient internal expertise to evaluate ANDAs for glatiramer acetate without convening an advisory committee.",
FDA-2010-P-0639-0006_FDA_CDER_to_Mike_Bernstein__MPH___Petition_Approva,"Stamped March 27, 2012 and March 29, 2012",,"Center for Drug Evaluation and Research (CDER)
Signed by Keith O. Webber, Ph.D., Deputy Director, Office of Pharmaceutical Science","Approved
The petition to allow submission of an Abbreviated New Drug Application (ANDA) for Docetaxel Injection Concentrate, 200 mg/10 mL (a new strength not matching the listed drug) was granted.","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(2)(C)(i)
- Section 505(j)(2)(A)(iv)
- Sections 505(j)(2)(A) and (B)","The proposed ANDA involves a different strength than the listed drug (Taxotere¬Æ 20 mg/mL and 80 mg/4 mL vs. proposed 200 mg/10 mL).
- FDA concluded that the change in strength does not pose questions of safety or effectiveness, since the use, dose, and route of administration remain the same.
- FDA determined that no additional investigations were needed to demonstrate safety or effectiveness for the proposed strength.
- If bioavailability requirements are met, the drug can be expected to provide the same therapeutic effect as the reference product.
- Approval of the petition allows for submission of an ANDA, but does not guarantee final ANDA approval, which depends on full review.",
FDA-2010-P-0638-0006_FDA_CVM_to_Dinsmore___Shohl__LLP___Petition_Approv,"Stamped March 22, 2011 and March 25, 2011",,"Center for Veterinary Medicine (CVM)
Signed by Steven D. Vaughn, DVM, Director, Office of New Animal Drug Evaluation","Approved
The FDA approved the suitability petition allowing the submission of an Abbreviated New Animal Drug Application (ANADA) for a generic omeprazole 570 mg tablet for horses.","Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- Section 512(n)(3)(C) of the Act
- 21 CFR 25.33(d)(1) (environmental assessment exclusion, prior reference)
- 21 CFR 25.30(h) (corrected citation for environmental exclusion)
- 21 CFR 25.15 (extraordinary circumstances clause)","The proposed drug differed from the reference drug (ULCERGARD Oral Paste, 37% w/w omeprazole) in dosage form (tablet) and strength (570 mg, 19% w/w).
- FDA determined that these differences did not require additional investigations to establish safety or effectiveness under the statutory criteria.
- Justification for approval was based on the inclusion of a pH-sensitive enteric coating and alkalinizing agent in the formulation, which protect the active ingredient (omeprazole) from gastric acid degradation.
- FDA noted concerns about bioavailability differences when administered with food, and recommended that fed versus fasted conditions be accounted for in the in-vivo bioequivalence study.
- Approval of the petition allows for ANADA submission, but does not guarantee final drug approval, which will depend on full review of the ANADA submission.",
FDA-2010-P-0632-0017_FDA_CDER_to_Sandoz_Inc_Petition_Denial,"Stamped September 20, 2011",,Center for Drug Evaluation and Research (CDER),Denied,"Federal Food, Drug, and Cosmetic Act (FD&C Act):

Section 505(j)(5)(D)(i)(III) ‚Äì Amendment of Certification

Section 505(j)(5)(D)(i)(IV) ‚Äì Failure to Obtain Tentative Approval

Section 505(b)(1) and (c)(2)

Section 505(j)(2)(A)(vii), (viii)

Section 505(j)(5)(B)(iii), (iv), (D)(iii)

21 CFR (Code of Federal Regulations):

21 CFR ¬ß 314.94(a)(9)(iii)

21 CFR ¬ß 314.99(b)

21 CFR ¬ß 314.122

21 CFR ¬ß 314.161

21 CFR ¬ß 314.94(a)(12)(i)(A)

21 CFR ¬ß 314.94(a)(12)(viii)

Statute:

Public Law 108-173, 117 Stat. 2066 (Medicare Prescription Drug, Improvement, and Modernization Act of 2003)","a. On Amendment of Certification (Section 505(j)(5)(D)(i)(III)):
FDA determined that Cobrek's resubmission of paragraph IV certifications after reformulating its generic drug product did not constitute an ‚Äúamendment or withdrawal‚Äù that would trigger forfeiture of 180-day exclusivity.

FDA emphasized that reformulation to meet Q1/Q2 equivalence to the reference listed drug does not equate to forfeiting exclusivity. Resubmitting certifications in response to changes in formulation is considered a lawful maintenance of exclusivity rights

b. On Failure to Obtain Tentative Approval (Section 505(j)(5)(D)(i)(IV)):
FDA concluded that Cobrek's failure to obtain tentative approval within 30 months was excused because the reference listed drug (Hectorol) had undergone a formulation change.

This constituted a ‚Äúchange in or review of the requirements for approval,‚Äù exempting Cobrek from forfeiture under this provision

c. Conclusion:
Since neither the certification amendments nor the delayed tentative approval met forfeiture conditions, FDA denied Sandoz Inc.‚Äôs petition asserting that Cobrek had forfeited 180-day exclusivity.",
FDA-2010-P-0632-0014_FDA_CDER_Interim_Response_to_Sandoz_Inc____Letter,"Stamped June 6 and June 9, 2011",,"Center for Drug Evaluation and Research (CDER)
Signed by Jane A. Axelrad, Associate Director for Policy","Interim Response: No final decision rendered.
FDA stated that the petition raises complex issues and remains under review","21 CFR 10.30(e)(2) ‚Äì Governing interim responses to citizen petitions
- 21 U.S.C. ¬ß 355(j)(5)(D)(i)(III)-(IV) ‚Äì Forfeiture provisions related to 180-day exclusivity","The FDA had not completed its review of the petition submitted by Sandoz on December 8, 2010.
- The petition requested that FDA declare Cobrek Pharmaceuticals forfeited its 180-day exclusivity for a generic Hectorol injection product.
- FDA cited the complexity of the issues raised and the need for extensive internal review before reaching a decision.",
FDA-2010-P-0630-0011_FDA_CDER_Response_to_Heyl_Chemisch_Pharmazeutische,"Stamped August 19, 2011",,"Center for Drug Evaluation and Research (CDER)
Signed by Alexis Reisin Miller, Office of Regulatory Policy","Approved (Favorable determination)
FDA concluded that PENTETATE ZINC TRISODIUM (Zn-DTPA) was not withdrawn from sale for reasons of safety or effectiveness, which allows abbreviated new drug applications (ANDAs) to be submitted referencing this product","21 CFR 10.30 ‚Äì Citizen petition process
- 21 CFR 314.161 ‚Äì Determination if a drug was withdrawn for safety/effectiveness
- 21 CFR 314.162 ‚Äì Removal of drug from Orange Book
- 21 U.S.C. 355(j)(7) ‚Äì Orange Book listing requirements
- Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417)","Heyl submitted a citizen petition requesting that FDA determine if Zn-DTPA was withdrawn for safety or effectiveness reasons.
- FDA reviewed its records, assessed postmarketing adverse events, and evaluated relevant literature.
- FDA found no evidence suggesting that the drug was withdrawn for safety or efficacy concerns.
- Therefore, the product remains listed in the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book, which includes drugs discontinued for reasons other than safety or effectiveness.
- ANDAs referencing Zn-DTPA are eligible for submission and approval if other requirements are met.",
FDA-2010-P-0630-0010_Determination_That_PENTETATE_ZINC_TRISODIUM__Zinc_,"August 19, 2011",,Center for Drug Evaluation and Research (CDER),"Approved (Favorable Determination)
FDA determined that PENTETATE ZINC TRISODIUM (Zn-DTPA) was not withdrawn from sale for reasons of safety or effectiveness, allowing ANDAs to be approved referencing the product.","21 CFR 314.161 ‚Äì Determination of withdrawal for safety or effectiveness
- 21 CFR 314.162 ‚Äì Drug removal from Orange Book for safety/effectiveness
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Orange Book listing authority
- Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98‚Äì417)","FDA reviewed the citizen petition from Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, submitted under 21 CFR 10.30.
- The agency conducted a comprehensive evaluation of internal records, literature, and postmarketing adverse event reports.
- No evidence was found to suggest that Zn-DTPA was withdrawn for safety or effectiveness reasons.
- The product was moved to the ‚ÄúDiscontinued Drug Product List‚Äù solely because the sponsor voluntarily ceased marketing.
- FDA concluded that ANDAs may be approved for Zn-DTPA if they meet all other applicable regulatory requirements.",
FDA-2010-P-0628-0010_FDA_CDER_Response_to_Heyl_Chemisch_Pharmazeutische,"Stamped August 19, 2011 and August 22, 2011",,"Center for Drug Evaluation and Research (CDER)
Signed by Alexis Reisin Miller, Office of Regulatory Policy","Approved (Favorable Determination)
The FDA determined that PENTETATE CALCIUM TRISODIUM (Ca-DTPA) was not withdrawn for reasons of safety or effectiveness, which allows for the submission and approval of ANDAs referencing the drug","21 CFR 10.30 ‚Äì Citizen Petition process
- 21 CFR 314.161 ‚Äì Determination of withdrawal for safety/effectiveness
- 21 CFR 314.162 ‚Äì Drug removal from Orange Book
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì ANDA listing authority
- Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98‚Äì417)","The FDA reviewed internal records, literature, and postmarketing data, and found no evidence suggesting that Ca-DTPA was withdrawn due to safety or effectiveness issues.
- The manufacturer, Hameln Pharmaceuticals GmbH, voluntarily discontinued marketing, prompting FDA to move the product to the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book.
- The discontinuation was for reasons other than safety or effectiveness, enabling ANDA approval if other requirements are satisfied",
FDA-2010-P-0628-0009_Determination_That_PENTETATE_CALCIUM_TRISODIUM__Tr,"August 19, 2011",,"Center for Drug Evaluation and Research (CDER)
Contact listed: Alexis Reisin Miller","Approved (Favorable Determination)
FDA concluded that PENTETATE CALCIUM TRISODIUM (Ca-DTPA) was not withdrawn from sale for reasons of safety or effectiveness, enabling the submission and approval of ANDAs.","21 CFR 10.30 ‚Äì Citizen petition process
- 21 CFR 314.161 ‚Äì Determination regarding withdrawal for safety or effectiveness
- 21 CFR 314.162 ‚Äì Drug removal from Orange Book
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Orange Book listing authority
- Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98‚Äì417)","The manufacturer, Hameln Pharmaceuticals GmbH, notified FDA that the drug was discontinued, and it was moved to the Orange Book's Discontinued Drug Product List.
- A citizen petition was filed by Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG requesting a determination on the reason for discontinuation.
- FDA reviewed internal records, evaluated relevant literature, and assessed for postmarketing adverse events.
- No evidence suggested the product was withdrawn due to safety or effectiveness concerns.
- FDA reaffirmed that the drug may be referenced in ANDAs provided all other legal and regulatory criteria are met.",
FDA-2010-P-0624-0009_FDA_CDER_to_Cubist_Pharmaceuticals___Petition_Part,"Stamped June 1, 2011 and June 6, 2011",,Center for Drug Evaluation and Research (CDER),Granted in part and denied in part,"21 CFR 314.92(a)(1)

21 CFR 314.94(a)(5), (6), (8), (9), (9)(iii)

21 CFR 320.1(c), 320.22(b)

21 CFR 210.3(b)(7), 314.3(b), 314.127(a)(3)

ICH Q3A, Q3B(R2), Q8(R2)

FDA Guidance for Industry on Impurities in Drug Substances (June 2009), Drug Products (Nov. 2010)","FDA agrees that impurity profiles must be qualified but denies requiring in vivo toxicology for all applicants if impurity data is adequate.

In vitro testing: HPLC assays are generally considered adequate for potency testing; bioassays may be required in limited cases.

Chemical characterization: FDA will not require peptide degradation or protein-binding studies, as conventional analytical methods are deemed sufficient.

Impurities: FDA will assess and ensure appropriate controls for impurities such as polymers and soyasaponins but does not find evidence these warrant extra controls beyond standard practice.

Infusion system compatibility: FDA expects generic and reference products to be materially identical in composition and thus does not require additional compatibility testing with infusion systems.",
FDA-2010-P-0617-0016_Citizen_Petition_Closure_Memo_from_CDRH_dated_4_10,"April 10, 2018",,"Center for Devices and Radiological Health (CDRH)
Signed by: Jeffrey Shuren, MD, JD ‚Äì Director","Other ‚Äì Administrative Closure
The petition was closed due to the death of the petitioner, Dr. Richard Edlich, and the absence of valid contact information for the co-signor. FDA did not render a decision on the petition‚Äôs merits","21 CFR ¬ß 10.30(e)(3) ‚Äì Requirement to notify the petitioner of the Commissioner‚Äôs decision
- 21 CFR ¬ß 10.30(b)(3) ‚Äì Requirements for providing contact information with petition submissions","The primary petitioner, Dr. Edlich, died on December 25, 2013.
- Although co-signed by Samantha Rhoads (his research assistant), she did not provide mailing address or phone number as required under 21 CFR ¬ß 10.30(b)(3).
- FDA determined Dr. Edlich was the intended sole petitioner, and his death precluded further action.
- The petition docket was closed without prejudice, allowing the co-signor to re-submit if she chooses, in accordance with regulatory requirements",
FDA-2010-P-0617-0015_Interim_Response_Letter,"Stamped June 2, 2011",,"Center for Devices and Radiological Health (CDRH)
Signed by: Nancy K. Stade, Deputy Director for Policy","Interim Response ‚Äì No final decision rendered
The FDA had not yet reached a decision due to the need for further review and analysis.",21 CFR ¬ß 10.30(c)(2) ‚Äì Interim responses to citizen petitions,"The petition raised multiple requests including banning the sale of liquid mercury, revising classification of dental materials, and banning mercury amalgam due to health concerns.
- An advisory committee (Dental Products Panel) met in December 2010 to evaluate scientific evidence related to dental amalgam.
- FDA stated that, based on the complexity of the issues and recommendations made, further action was under consideration.
- Because the analysis was ongoing, the agency issued this interim response as per regulatory requirement.",
FDA-2010-P-0614-0072_FDA_CDER_to_Sidley_Austin_LLP___Petition_Partial_A,"Stamped and Read May 25, 2011",,"Center for Drug Evaluation and Research (CDER)
Signed by: Janet Woodcock, M.D., Director","Partially Approved / Partially Denied
The FDA granted some of ViroPharma‚Äôs requests regarding review of ANDAs referencing Vancocin¬Æ (vancomycin HCl) Capsules, but denied others","21 CFR ¬ß 10.30 ‚Äì Citizen petition procedure
- 21 CFR Part 320 ‚Äì Bioequivalence requirements
- 21 CFR ¬ß 314.94 ‚Äì Content and format of ANDAs
- 21 CFR ¬ß 314.127(a) ‚Äì Grounds for denying an ANDA
- 21 U.S.C. ¬ß 355(j) ‚Äì Abbreviated new drug applications (ANDA)
- FDCA Sections 505(b)(2) and 505(j)
- Public Law 108-173 (MMA of 2003)","Granted Requests: FDA agreed to apply enhanced bioequivalence requirements (including in vitro dissolution, characterization, and physicochemical comparisons) to ANDAs referencing Vancocin¬Æ due to its locally acting nature and complex formulation.
- Denied Requests: FDA declined to require in vivo clinical trials, stating they were not necessary given the available scientific evidence.
- FDA also denied requests to withhold approval of ANDAs pending further rulemaking or advisory committee input, asserting that its current review and approval procedures for generics are legally and scientifically appropriate.
- The agency reaffirmed that its bioequivalence guidance already reflects appropriate safeguards and that new legislative requirements (e.g., for MMA-related exclusivity) do not support delaying ANDA review or approval.",
FDA-2010-P-0613-0004_Citizen_Petition_Denial_Response_from_FDA_CDER_to_,"Stamped February 10, 2014",,"Center for Drug Evaluation and Research (CDER)
Signed by: Janet Woodcock, M.D., Director",Denied,"21 U.S.C. ¬ß 355(j) ‚Äì Section 505(j) of the FD&C Act (Hatch-Waxman Amendments)
- 21 CFR Part 320, specifically 21 CFR 320.24
- FD&C Act section 505(j)(2)(A)(iv)
- FD&C Act section 505(j)(2)(A)
- FD&C Act section 505(j)(4)
- Legal references: Schering Corp. v. FDA, 51 F.3d 390 (3d Cir. 1995); Fisons Corp. v. Shalala, 860 F. Supp. 859 (D.D.C. 1994)","Tmax is a discrete variable and not suited for the same statistical bioequivalence evaluation as AUC and Cmax.
- FDA policy does not require statistical criteria for Tmax due to its high variability and lack of clinical significance shown in this case.
- DHT is not required for bioequivalence testing as testosterone is the main active compound; DHT is a metabolite and contributes minimally to efficacy/safety.
- Labeling of Androderm does not specify consistent timing for testosterone measurement, creating natural variability.
- Bioequivalence is assessed holistically in the ANDA process, including clinical pharmacokinetic profile reviews.
- Cited guidance recommends using the parent drug for bioequivalence, not metabolites like DHT.",
FDA-2010-P-0610-0007_Citizen_Petition_Closure_Memo_from_CDRH_dated_4_10,"April 10, 2018",,Center for Devices and Radiological Health (CDRH),Closed,21 CFR ¬ß 10.30(e)(3) ‚Äì FDA regulation requiring that ‚Äúthe petitioner is to be notified of the Commissioner's decision‚Äù,"The petitioner, Dr. Richard Edlich, passed away on December 25, 2013.
- As a result, the FDA determined there was no viable recipient for the decision notification, and therefore, the petition was closed administratively rather than acted upon substantively.",
FDA-2010-P-0610-0006_Interim_Response_Letter,"Stamped June 2, 2011",,Center for Devices and Radiological Health (CDRH),Interim Response,21 CFR ¬ß 10.30(e)(2) ‚Äì FDA regulation requiring interim response if a final decision has not been made within 180 days after receipt of the petition.,"The petition raised complex issues including a request to ban mercury amalgam and revise classification of dental materials.
- The Dental Products Panel advisory committee met in December 2010 to assess relevant scientific evidence.
- Due to the complexity and recommendations, further review is ongoing, and FDA has not yet reached a decision.",
FDA-2010-P-0604-0005_FDA_CDER_to_Lachman_Consultant_Services_Inc_Respon,"Stamped May 18 and May 21, 2012",,Center for Drug Evaluation and Research (CDER),Granted (Determination Made),"21 CFR 314.161 ‚Äì Procedure to determine whether a drug was withdrawn from sale for safety or effectiveness reasons.
- 21 CFR 314.162 ‚Äì Grounds for removal from the Orange Book.
- 21 U.S.C. 355(j)(7) ‚Äì Section 505(j)(7) of the FD&C Act.
- 21 CFR 10.30 ‚Äì Citizen petition process.","The drug was withdrawn from sale by the NDA holder (Parke-Davis) in 1993, and the NDA was withdrawn in 1998 (63 FR 51359).
- FDA found no evidence or data suggesting the withdrawal was due to safety or effectiveness concerns.
- FDA conducted an independent literature and adverse event review, confirming no postmarketing safety concerns.
- Therefore, the product remains eligible for ANDA submission, and its listing in the Orange Book is maintained.",
FDA-2010-P-0604-0004_Determinations_That_PITRESSIN_TANNATE_IN_OIL_Vasop,"Stamped May 18, 2012",,Center for Drug Evaluation and Research (CDER),Granted (Determination Made),"21 CFR 10.30 ‚Äì Citizen petition process
- 21 CFR 314.161 ‚Äì Process for determining if a drug was withdrawn for safety or effectiveness reasons
- 21 CFR 314.162 ‚Äì Removal of drugs from the Orange Book
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Section 505(j)(7) of the FD&C Act","FDA reviewed its internal records and found no data suggesting the withdrawal was due to safety or effectiveness.
- An independent review of postmarketing literature and data also revealed no safety concerns.
- The product will remain in the Discontinued Drug Product List of the Orange Book, allowing for ANDA submissions provided other requirements are met.",
FDA-2010-P-0593-0004_Determination_a_Product_Was_Not_Withdrawn_From_Sal,"April 11, 2011",,	Center for Drug Evaluation and Research (CDER),Granted (Determination Made),"21 CFR 314.161 ‚Äì Procedure for withdrawal review

21 CFR 314.162 ‚Äì Orange Book drug list removal

21 U.S.C. ¬ß 355(j)(7) ‚Äì Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act ","The petitioner (Watson Laboratories) submitted no data suggesting safety or effectiveness issues.

FDA independently reviewed its records, literature, and postmarketing data and found no evidence of withdrawal for safety or efficacy reasons.

FDA therefore concluded that the product was discontinued for reasons other than safety or effectiveness and ANDAs may be approved if all other conditions are met.",
FDA-2010-P-0592-0017_Interim_Response_Letter,"Stamped June 2, 2011",,"Center for Devices and Radiological Health (CDRH) ‚Äì Interim response signed by Nancy K. Stade, Deputy Director for Policy.
Office of the Commissioner ‚Äì Final response signed by Leslie Kux, Acting Assistant Commissioner for Policy.",Denied ‚Äì The FDA denied the petition to ban the sale of elemental mercury to consumers.,"21 CFR ¬ß 872.3070 ‚Äì Device classification for elemental mercury.
- 21 CFR ¬ß 801.5, ¬ß 801.109, ¬ß 801.110, ¬ß¬ß 801.109-.127 ‚Äì Labeling and prescription device exemptions.
- Section 201(h) of the Federal Food, Drug, and Cosmetic Act ‚Äì Definition of a medical device.
- Section 502(f)(1) of the Act (21 U.S.C. ¬ß 353(b)(1)) ‚Äì Labeling requirements.
- Section 301(a) of the Act (21 U.S.C. ¬ß 331(a)) ‚Äì Prohibition of interstate commerce of misbranded devices.","Elemental mercury used in dental amalgam is regulated as a Class II medical device, requiring prescription-only distribution.
- Such mercury is not sold directly to consumers under FDA regulations.
- Because it is already restricted to prescription use, the FDA concluded that a ban was unnecessary.
- Any sales not meeting prescription requirements would constitute misbranding and be prohibited from interstate commerce.",
FDA-2010-P-0582-0006_FDA_CDER_to_Lachman_Consultant_Services__Inc____Pe,"Stamped March 29, 2012",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Keith O. Webber, Ph.D., Deputy Director, Office of Pharmaceutical Science","Approved ‚Äì The FDA approved the petition to allow submission of an Abbreviated New Drug Application (ANDA) for Mercaptopurine Tablets, 25 mg","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- Section 505(j)(2)(C)(i)
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)","The proposed strength (25 mg) differs from the listed drug (50 mg) but poses no questions of safety or effectiveness.
- Uses, dose, and route of administration are identical to the listed drug (Purinethol¬Æ).
- No additional investigations were deemed necessary.
- If bioavailability requirements are met, the proposed product can be expected to have the same therapeutic effect.
- Approval of this petition allows ANDA submission but does not guarantee ANDA approval, which depends on subsequent review.",
FDA-2010-P-0581-0005_FDA_CDER_to_Lachman_Consulting_Services__Inc____Pe,"Stamped March 20, 2012",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director",Approved ‚Äì The FDA granted the petition to designate Teva‚Äôs Oxaliplatin (NDA 022160) as an additional Reference Listed Drug (RLD),"Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355)
- Sections 505(j)(2)(A), (j)(2)(C), and (j)(4)
- 21 CFR ¬ß 314.3
- 21 CFR ¬ß 314.94(a)(9)(iii)","The petition requested RLD designation for Teva‚Äôs Oxaliplatin to allow ANDA applicants to use it directly instead of Eloxatin.
- Though Teva‚Äôs product is AP-rated to Eloxatin, it contains lactose, unlike Eloxatin, making it qualitatively different.
- Because ANDAs must be qualitatively and quantitatively the same as the RLD, generic applicants could not reference Teva‚Äôs formulation if only Eloxatin was designated.
- The FDA agreed it is in the public interest to designate Teva‚Äôs Oxaliplatin as an additional RLD to promote fair competition and accessibility.",
FDA-2010-P-0581-0004_Interim_Response_to_Lachman_Consultant_Services__I,"Stamped May 4, 2011 and May 6, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Other (Interim Response) ‚Äì The FDA had not yet resolved the issues raised in the petition at the time of this letter.,21 CFR ¬ß 10.30(e)(2) ‚Äì Regulation governing FDA's process for issuing interim responses to citizen petitions.,"The FDA had not reached a decision due to the need to address other Agency priorities.
- The letter assured that a full response would follow once resources allowed.",
FDA-2010-P-0580-0006_Citizen_Petition_Response_from_FDA_CDRH_to_Houssie,"Stamped September 20, 2011",,"Center for Devices and Radiological Health (CDRH) ‚Äì While the signature is from Leslie Kux, Acting Assistant Commissioner, the content pertains to PMA approval, placing it under CDRH's purview",Denied ‚Äì The FDA denied the petition to amend the original PMA approval letter with additional limiting language regarding the device scope,"21 U.S.C. ¬ß 360e(d)(6)(A) ‚Äì Requirement for PMA supplement for changes affecting safety or effectiveness
- 21 U.S.C. ¬ß 360e(d)(6)(B)(i) ‚Äì Criteria for PMA supplement approval
- 21 C.F.R. ¬ß 814.39(a) ‚Äì PMA supplement regulations","The Paradigm Real Time System (Pump + Sensor) was approved as a whole through PMA supplement P980022/S013.
- Petitioners requested language to narrow the scope of approval.
- FDA found that the existing approval letter already sufficiently covers the scope and provides a reasonable assurance of safety and effectiveness for the entire system.
- Therefore, no amendment was necessary and the petition was denied.",
FDA-2010-P-0580-0004_FDA_Center_for_Devices_and_Radiological_Health___I,"April 14, 2011",,"Center for Devices and Radiological Health (CDRH) ‚Äì Signed by Nancy Stade, Deputy Director for Policy",Other (Interim Response) ‚Äì The FDA had not yet resolved the issues raised in the petition and indicated that further review and analysis were needed.,21 CFR ¬ß 10.30(e)(2) ‚Äì Governing interim responses to citizen petitions.,"The petition requested that FDA clarify the PMA approval letter dated April 7, 2006, for PMA supplement P980022/S013 to include language that expresses limitations.
- FDA had not made a decision because the petition raised complex issues requiring further review and analysis by agency officials.
- The interim response was issued due to delays stemming from other agency priorities.",
FDA-2010-P-0579-0007_FDA_2010_P_0579_let,"Stamped June 22 and June 27, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Molly M. Flannery, Office of Regulatory Policy","Approved ‚Äì The FDA determined that Nuvigil (armodafinil) Tablets, 100 mg and 200 mg, were not withdrawn for safety or effectiveness reasons, thereby granting the petition.","21 U.S.C. ¬ß 355(j)(7) ‚Äì Listing requirement for approved drugs.
- 21 CFR ¬ß 314.161 ‚Äì Determination that a drug was not withdrawn for safety or effectiveness.
- 21 CFR ¬ß 314.162 ‚Äì Removal of listed drugs.","FDA reviewed its internal records, literature, and postmarketing data.
- Found no evidence that Nuvigil 100 mg and 200 mg tablets were withdrawn for safety or effectiveness.
- As a result, the drug remains listed in the ""Discontinued Drug Product List"" section of the Orange Book, allowing ANDA submissions.",
FDA-2010-P-0579-0006_Determination_that_NUVIGIL___Armodafinil__Tablets_,"July 22, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Although not explicitly stated in the heading, the document references CDER officials and addresses drug product listing issues.","Approved ‚Äì FDA determined that NUVIGIL (armodafinil) 100 mg and 200 mg tablets were not withdrawn for reasons of safety or effectiveness, allowing ANDA approvals to proceed.","21 CFR ¬ß 314.161 ‚Äì Criteria for determining whether a drug was withdrawn for safety or effectiveness.
- 21 CFR ¬ß 314.162 ‚Äì Drug removal from the Orange Book.
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Drug listing requirement under the FD&C Act.","FDA reviewed internal records and postmarketing safety data, as well as literature, and found no evidence that NUVIGIL was withdrawn for safety or efficacy concerns.
- Petitioners (Actavis and Watson) provided no data to suggest otherwise.
- Therefore, the product will remain listed in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book, and ANDA applications may be approved if other requirements are met.",
FDA-2010-P-0579-0005_Interim_Response_to_Actavis__Inc____Letter,"Stamped May 4 and May 6, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Other (Interim Response) ‚Äì FDA had not yet resolved the issues raised in the petition due to other agency priorities.,21 CFR ¬ß 10.30(e)(2) ‚Äì Regulation requiring interim responses to citizen petitions if a decision cannot be reached promptly.,"The petition requested a determination that Nuvigil (armodafinil) 100 mg and 200 mg tablets were not voluntarily withdrawn for safety or efficacy reasons.
- FDA stated that it had not reached a decision because the petition required additional review and other priorities were pending.
- The response confirms FDA‚Äôs intent to issue a decision as soon as resources allow.",
FDA-2010-P-0578-0015_Interim_Response_to_Dwayne_A__Ratleff___Letter,"Stamped May 4, 2011 and May 6, 2011",,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Barbara O. Schneeman, Ph.D., Director, Office of Nutrition, Labeling, and Dietary Supplements",Other (Interim Response) ‚Äì FDA had not yet reached a decision on the petition due to competing priorities and limited resources.,21 CFR ¬ß 10.30(e)(2) ‚Äì Governs the issuance of interim responses when decisions cannot be reached within 180 days.,"The petition requested a new regulation requiring food manufacturers to display ‚ÄúIngredient Information Has Changed‚Äù on labels when a major allergen is newly added to the formulation.
- FDA acknowledged the request but explained that a final decision could not be made within the required timeframe due to other agency priorities and resource constraints.
- FDA confirmed the petition would remain under review and be considered in the context of broader program priorities.",
FDA-2010-P-0577-0006_FDA_CDER_to_Watson_Laboratories,"Stamped July 22 and July 27, 2011 ",,Center for Drug Evaluation and Research (CDER),"Denied ‚Äì FDA determined that NUVIGIL (armodafinil) Tablets, 100 mg and 200 mg, were not withdrawn from sale for reasons of safety or effectiveness. Thus, the drug remains listed in the ‚ÄúDiscontinued Drug Product List‚Äù and ANDAs may proceed if compliant","21 CFR 314.161
- 21 CFR 314.162
- 21 CFR 10.30
- Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7))","FDA reviewed its internal records and found no evidence that NUVIGIL (armodafinil) Tablets were withdrawn for reasons of safety or effectiveness.
- The Agency independently evaluated literature and postmarketing data and identified no adverse findings.
- The product was determined to be withdrawn for reasons other than safety or effectiveness, hence it stays on the ‚ÄúDiscontinued Drug Product List.‚Äù
- ANDAs may be approved if other regulatory requirements are met",
FDA-2010-P-0577-0005_Determinations_that_Products_Were_Not_Withdrawn_Fr,"July 22, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Contact listed is Molly Flannery, CDER, FDA","Approved ‚Äì FDA determined that NUVIGIL (armodafinil) Tablets, 100 mg and 200 mg, were not withdrawn for reasons of safety or effectiveness.","21 CFR ¬ß 314.161 ‚Äì Procedures for determining withdrawal from sale.
- 21 CFR ¬ß 314.162 ‚Äì Removal of drug products for safety or effectiveness reasons.
- 21 CFR ¬ß 10.30 ‚Äì Citizen petition process.
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Drug listing under the FD&C Act.","FDA reviewed citizen petitions and internal records, finding no data indicating withdrawal due to safety or effectiveness.
- Independent evaluation of postmarketing data and literature found no adverse information.
- Thus, NUVIGIL remains on the ‚ÄúDiscontinued Drug Product List‚Äù, allowing ANDA submissions if other requirements are met.",
FDA-2010-P-0577-0004_Interim_Response_to_Watson_Laboratories__Inc____Le,"Stamped May 4 and May 6, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Other (Interim Response) ‚Äì FDA stated that it had not yet resolved the petition due to prioritization of other matters.,21 CFR ¬ß 10.30(e)(2) ‚Äì Regulation requiring interim responses to citizen petitions if no decision is made within 180 days.,"The petition requested a determination on whether Nuvigil (armodafinil) 100 mg and 200 mg tablets were withdrawn for reasons of safety or effectiveness.
- FDA indicated that it could not reach a decision due to other agency priorities and resource constraints.
- The Agency affirmed it would respond as soon as feasible.",
FDA-2010-P-0574-0007_Citizen_Petition_Denial_Response_Letter_from_FDA_C,"Stamped May 6, 2015",,Center for Drug Evaluation and Research (CDER),Denied (Both the 2007 and 2010 Petitions were denied),"21 CFR 314.3
- 21 CFR 314.94(a)(7)
- 21 CFR 320.1(e)
- 21 CFR 320.22(d)
- 21 CFR 320.22(e)
- 21 CFR 320.24
- Section 505(j) and (j)(8)(B)(i) of the FD&C Act","General vs. Product-Specific Guidance: The petition relied on general FDA guidance for food-effect bioavailability studies. FDA emphasized that product-specific guidance for clozapine (due to its unique safety profile) supersedes general recommendations.

- Risks to Healthy Volunteers: FDA does not recommend administering clozapine to healthy individuals due to risks like agranulocytosis, seizures, bradycardia, and syncope.

- Use of Steady-State Studies in Patients: FDA advocates for multiple-dose, steady-state studies in schizophrenic patients, not single-dose fed/fasted studies, because these patients already take clozapine under real-world conditions. Strict fed or fasting requirements were deemed impractical and risky for this population.

- Labeling of FazaClo: FazaClo labeling indicates it can be taken without regard to meals, supporting that a fed bioequivalence study is unnecessary.

- 200-mg RLD Designation Denied: Petitioners requested that the 200 mg FazaClo ODT be designated as the Reference Listed Drug (RLD). FDA denied this because the 100 mg strength offers more dosing flexibility and supports safer and broader patient recruitment for studies. FDA maintained the 100 mg strength as the reference standard",
FDA-2010-P-0574-0006_Interim_Response_Letter_from_FDA_CDER_to_Beckloff_,"Stamped April 28 and May 2, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Other (Interim Response) ‚Äì FDA stated it had not yet resolved the petition due to the complexity of issues raised.,21 CFR ¬ß 10.30(e)(2) ‚Äì Governs the issuance of interim responses to citizen petitions,"The petition requested two actions:
‚ÄÉ(1) Designate the 200 mg FazaClo (clozapine) ODT as the Reference Listed Drug (RLD).
‚ÄÉ(2) Modify FDA guidance to require bioequivalence testing using the 200 mg ODT strength.
- FDA stated that the petition raised complex scientific and regulatory issues requiring further internal review and analysis.
- An interim response was issued due to the statutory requirement to respond within 180 days.",
FDA-2010-P-0570-0005_FDA_CDER_to_Nycomed__US__Inc____Petition_Denial,"Stamped April 27, 2011",,Center for Drug Evaluation and Research (CDER),Denied,"21 U.S.C. ¬ß 355(j) (FD&C Act section 505(j))
- 21 CFR ¬ß¬ß 314.3, 314.92(a), 314.94(a), 314.105, 314.107, 314.127(a), 314.93, 314.430(b)
- 21 CFR ¬ß¬ß 320.1(b), 320.1(c), 320.1(e), 320.21(b)(1), 320.24(b)(1)-(4), (6)","Scientific and Regulatory Basis:

FDA found no scientific evidence or regulatory requirement mandating that bioequivalence studies for topical corticosteroids be conducted in pediatric populations.

The vasoconstrictor assay (Stoughton-McKenzie skin blanching test) used in adults is considered a valid and scientifically acceptable method to establish bioequivalence for topical corticosteroids.

FDA emphasized that the ANDA process does not require new safety or efficacy data, only demonstration of bioequivalence to the RLD (Reference Listed Drug).

Petition's Concerns and FDA‚Äôs Rebuttal:

Lack of pediatric-specific data: FDA acknowledged that children may have physiological differences, but stated that bioequivalence demonstrated in adults is sufficient unless specific contrary evidence exists (which Nycomed did not provide).

Vehicle formulation differences: These are evaluated during ANDA review, and the vasoconstrictor assay is sensitive enough to detect differences in drug delivery due to formulation changes.

Pediatric skin differences: FDA found no credible evidence that pediatric skin physiology negates the adult assay‚Äôs reliability.

HPA Axis Suppression Risks: The NDA already evaluated safety in pediatric populations. Once the RLD is deemed safe, a bioequivalent generic is assumed to be comparably safe. The vasoconstrictor assay is not meant to assess safety, only bioequivalence.

Request for New Guidance:

FDA declined to issue new draft guidance specific to pediatric bioequivalence for topical corticosteroids, stating the 1995 Bioequivalence Guidance remains valid and effective.",
FDA-2010-P-0559-0008_Final_Response_from_FDA_CDRH_to_Saliwell_Ltd,"Stamped September 23, 2014",,"Center for Devices and Radiological Health (CDRH) ‚Äì Signed by William H. Maisel, MD, MPH, Deputy Director for Science","Closed (Superseded by FDA Initiative) ‚Äì Rather than grant the petition directly, FDA initiated its own rulemaking process to reclassify electrical salivary stimulatory systems from Class III to Class II (special controls), and closed the petition as part of that action","21 U.S.C. ¬ß 360c(f)(3) (FD&C Act Section 513(f)(3)) ‚Äì Reclassification procedures by administrative order
- 21 U.S.C. ¬ß 360c(a)(1)(B) (Section 513(a)(1)(B)) ‚Äì Special controls
- 21 CFR ¬ß 872.5560 ‚Äì Proposed classification regulation","FDA reviewed the petition, relevant literature, review submissions, and data from similar devices.
- Determined that electrical salivary stimulatory systems can be reclassified to Class II with special controls, providing reasonable assurance of safety and effectiveness.
- On September 18, 2014, FDA published a proposed order in the Federal Register (79 FR 56027) initiating this reclassification independently.
- Because this action addressed the request raised by Saliwell Ltd., FDA closed the petition without a separate approval or denial.",
FDA-2010-P-0552-0004_FDA_CVM_to_Kelly_W__Beers__Ph_D___U_S__Agent___Huv,"Stamped January 4 and January 11, 2011",,"Center for Veterinary Medicine (CVM) ‚Äì Signed by Steven D. Vaughn, DVM, Director, Office of New Animal Drug Evaluation","Approved ‚Äì FDA approved the suitability petition under section 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act","21 U.S.C. ¬ß 360b(n)(3)(C) ‚Äì FD&C Act section 512(n)(3)(C)
- 21 CFR ¬ß 514.5 ‚Äì ANADA pre-submission conference recommendation","The petition proposed a change in strength for a generic new animal drug (SACOX 90) compared to the reference listed new animal drug (BIO-COX 60), increasing salinomycin sodium concentration from 60 g/lb to 90 g/lb.
- The change did not alter indications, dosage form, route of administration, or final use concentrations in Type C feed.
- FDA determined that no additional safety or efficacy investigations were required for this change, and thus approval was mandatory under section 512(n)(3)(C).
- FDA noted that approval of the suitability petition does not guarantee approval of the subsequent Abbreviated New Animal Drug Application (ANADA).",
FDA-2010-P-0549-0006_FDA_CDER_to_Rakoczy_Molino_Mazzochi_Siwik__LLP___P,"Stamped May 25, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director, CDER","Denied ‚Äì The FDA denied the petition in full, stating: ‚ÄúFor the reasons described above, your petition is denied‚Äù","Section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act (FDCA) ‚Äì governing 180-day exclusivity.
- Section 505(j)(5)(D) ‚Äì detailing forfeiture provisions.
- 21 CFR 314.94(a)(12)(i)(A) ‚Äì addressing patent certifications in ANDAs.
- 21 CFR 314.430(b) ‚Äì confidentiality regarding ANDA status.
- Section 505(j)(2)(A)(vii) ‚Äì ANDA patent certification types.
- Section 505(j)(2)(B) ‚Äì notice requirements for Paragraph IV certifications.
- Section 505(j)(5)(D)(i)(VI) ‚Äì forfeiture upon patent expiration","Teva qualified as the first applicant because it submitted a substantially complete ANDA with a Paragraph IV certification for the ‚Äò021 patent before Lupin did.
- The MMA (Medicare Modernization Act) does not require simultaneous certification to all listed patents for exclusivity to attach‚Äîonly a valid initial Paragraph IV certification on the first day of filing is necessary.
- Teva‚Äôs later Paragraph IV certification to the ‚Äò082 patent did not affect its initial eligibility, although Teva‚Äôs exclusivity was limited to the ‚Äò021 patent.
- The FDA emphasized that exclusivity is patent-specific, and forfeiture only occurs if no valid Paragraph IV certifications remain.
- Since Lupin filed its certifications after Teva, and Teva retained eligibility through the ‚Äò021 patent, Lupin is not entitled to 180-day exclusivity.
- FDA found no legal basis in Lupin‚Äôs argument that Teva‚Äôs submission strategy invalidated its eligibility",
FDA-2010-P-0549-0005_Interim_Response_to_Rakoczy_Molino_Mazzochi_Siwik_,"Stamped April 8 and April 12, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Other (Interim Response) ‚Äì The FDA had not yet resolved the issues raised due to the complexity involved.,21 CFR ¬ß 10.30(e)(2) ‚Äì Pertains to FDA's obligation to issue an interim response if a final decision is delayed,"The petition sought confirmation that Teva was not entitled to 180-day exclusivity for generic lamivudine and zidovudine tablets (150 mg and 300 mg), and that Lupin was eligible instead.
- FDA stated that the matter involved complex issues needing extensive review and analysis by Agency officials.
- As such, a final decision had not been reached by the 180-day mark, prompting this interim response.",
FDA-2010-P-0545-0006_FDA_CDER_to_UCB_Inc_Petition_Denial,"Stamped February 24, 2011",,Center for Drug Evaluation and Research (CDER) ,Denied ‚Äî The FDA denied the request to refrain from granting tentative or final approval for any ANDA that omits Xyzal‚Äôs allergic rhinitis indications,"Section 505(b)(1), 505(c), 505(j), 505(j)(2)(A)(vii), 505(j)(2)(A)(viii), and 505(j)(4)(G) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.3, 314.53, 314.92(a)(1), 314.94(a)(8)(iv), 314.94(a)(12)(iii), and 314.127(a)(7)","Labeling carve-outs permitted: FDA found that labeling differences due to patent-protected indications (SAR, PAR) are allowed, as long as safety/effectiveness for remaining indications (e.g., CIU) is not compromised.
- Safety data applicability: Although most safety data originated from allergic rhinitis studies, they are deemed applicable to chronic idiopathic urticaria (CIU) due to the similarity of patient populations.
- Minimal labeling changes: Selective deletions and minor modifications in language (e.g., removing specific disease mentions) are sufficient and do not impair safety communication.
- BPCA pediatric exclusivity: FDA permits disclaimers that exclude mention of specific protected pediatric indications, ensuring compliance without violating exclusivity protections.
- Case law & precedent: Cited legal precedents and earlier decisions support FDA‚Äôs position on labeling carve-outs under patent protection.",
FDA-2010-P-0540-0023_FDA_CDER_to_Sheppard_Mullin_Richter_and_Hampton_LL,"Stamped April 16, 2013",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director .","Approved ‚Äì The FDA granted the request by determining that OXYCONTIN drug products approved under NDA 20-553 were withdrawn from sale for safety or effectiveness reasons, thus blocking ANDAs referencing these versions","21 U.S.C. ¬ß 355(j)(7) ‚Äì Listing and delisting of approved drugs
- 21 CFR ¬ß 314.162 ‚Äì Withdrawal of drug products from the Orange Book due to safety/effectiveness concerns","FDA determined, based on comments, data, postmarketing adverse event reports, and internal review, that original OxyContin (NDA 20-553) posed higher risks of abuse and misuse compared to reformulated versions.
- Reformulated OxyContin (NDA 22-272) was designed with abuse-deterrent properties that reduced tampering methods like crushing, snorting, or injecting.
- Data suggested reformulated OxyContin is harder to abuse and leads to slower and lower peak release of oxycodone, reducing potential for addiction or overdose.
- Abuse-related public health crises and opioid epidemic concerns were emphasized, citing CDC data showing a 300% rise in prescription opioid overdose deaths from 1999‚Äì2008.
- Based on totality of evidence, the original OxyContin was considered withdrawn for reasons of safety and effectiveness, disqualifying it as an RLD for future ANDAs ",
FDA-2010-P-0540-0014_FDA_CDER_Interim_Response_to_Sheppard__Mullin__Ric,"Stamped March 25 and March 28, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Other (Interim Response) ‚Äì FDA had not yet reached a decision due to the complexity of the issues.,21 CFR ¬ß 10.30(e)(2) ‚Äì Regulation governing interim responses to citizen petitions,"The petition requested a determination on whether certain strengths of oxycodone hydrochloride extended-release tablets (NDA 20-553) were voluntarily withdrawn for reasons other than safety or effectiveness.
- FDA stated it had not yet resolved the issues due to their complex nature, requiring extensive review and analysis.
- An interim response was issued as required under 21 CFR 10.30(e)(2), promising a full response once the evaluation was complete",
FDA-2010-P-0535-0006_FDA_CDER_to_Hyman__Phelps___McNamara__P_C____Petit,"Stamped April 18 and April 19, 2012",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Keith O. Webber, Ph.D., Deputy Director, Office of Pharmaceutical Science","Approved ‚Äì The FDA approved the citizen petition, allowing an ANDA to be submitted for Duloxetine Hydrochloride Delayed-release Capsules, 40 mg","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FDCA)
- Section 505(j)(2)(C)(i) ‚Äì Governing approval of suitability petitions for different strengths
- Section 505(j)(2)(A) and (B) ‚Äì General ANDA requirements
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirements","The requested change (40 mg) differs from the listed strengths (20, 30, 60 mg) of Cymbalta¬Æ (duloxetine hydrochloride).
- FDA determined that the change does not pose questions of safety or effectiveness, as the uses, dose, and route of administration remain the same as the listed drug.
- No new investigations are required to demonstrate safety or efficacy for the new strength.
- If the generic product meets bioavailability requirements, it can be expected to have the same therapeutic effect as the reference listed drug (RLD).
- Approval of the petition does not guarantee ANDA approval‚Äîthat depends on a full review of the ANDA submission itself",
FDA-2010-P-0533-0006_FDA_CDER_to_Zydus_Pharmaceuticals_USA_Inc__Petitio,"Stamped September 27 and October 1, 2012",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Gregory P. Geba, M.D., M.P.H., Director, Office of Generic Drugs","Approved ‚Äì The FDA approved the petition, permitting the submission of an Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Powder for Solution (500 mg, 850 mg, and 1 g)","Section 505(j)(2)(C) of the FD&C Act (suitability petition provision)
- Section 505(j)(2)(A) and (B) ‚Äì General ANDA requirements
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirements
- Pediatric Research Equity Act of 2007 (PREA)","The petition requested a change in dosage form (from oral tablet to powder for solution) for metformin hydrochloride, referencing Glucophage¬Æ as the listed drug.
- FDA found that the proposed change does not pose questions of safety or effectiveness because the dose, uses, and route of administration remain the same.
- No additional investigations were required under PREA for pediatric populations, as FDA determined it was PREA fulfilled.
- If the proposed product meets bioavailability standards, it can be expected to have the same therapeutic effect as the reference listed drug.
- FDA emphasized that approval of the petition does not guarantee approval of a submitted ANDA‚Äîapproval will depend on subsequent review.",
FDA-2010-P-0532-0013_FDA_CTP_s_Response_to_BBK_Tobacco_and_Food__LLP_an,"August 16, 2016",,"Center for Tobacco Products (CTP) ‚Äì Signed by Beverly Chernaik, J.D., Director, Office of Regulations",Denied ‚Äì The FDA declined to take enforcement discretion and declined to find that the Family Smoking Prevention and Tobacco Control Act does not authorize regulation of flavored rolling papers. The alternative requests were also denied,"21 CFR ¬ß 10.30(k) ‚Äì Regarding limitations of citizen petition procedures for enforcement discretion
- 21 CFR ¬ß 10.45 ‚Äì Clarifying that denial of a request for or against enforcement is not final agency action
- Section 907(a)(1)(A) of the FD&C Act ‚Äì Characterizing flavor ban for cigarettes
- Section 201 of the FD&C Act ‚Äì Definition of ""tobacco product"" and its components
- Deeming Rule (May 10, 2016) ‚Äì Guidance on tobacco product regulation","FDA explained that decisions about whether to enforce or refrain from enforcement are within agency discretion and not appropriate for resolution via citizen petition.
- The agency declined to interpret the Family Smoking Prevention and Tobacco Control Act as not applying to flavored rolling papers. FDA pointed to existing guidance stating that rolling paper or filters are considered component parts of roll-your-own cigarettes and thus cannot be flavored.
- The FDA also rejected the petitioner‚Äôs request to permit flavored papers labeled for use with legal non-tobacco herbs, stating it would require assessment of specific facts in context, which cannot be pre-determined outside a regulatory or enforcement action.
- The agency referenced its ‚ÄúDeeming Rule‚Äù (May 10, 2016) which clarified its approach to defining tobacco products and their components or accessories",
FDA-2010-P-0532-0011_FDA_CTP_Interim_Response_to_BBK_Tobacco___Foods__L,"Stamped April 4, 2011",,"Center for Tobacco Products (CTP) ‚Äì Signed by Lawrence R. Deyton, M.S.P.H., M.D., Director",Other (Interim Response) ‚Äì The FDA stated it had not yet resolved the issues raised in the citizen petition.,21 CFR ¬ß 10.30(e)(2) ‚Äì Governs issuance of interim responses for citizen petitions,"The petition requested that FDA refrain from administrative or enforcement action against flavored roll-your-own papers and find that the Family Smoking Prevention and Tobacco Control Act does not authorize their regulation.
- Alternatively, the petitioner asked that flavored papers labeled for use only with legal non-tobacco herbs be found permissible.
- FDA stated that it was still analyzing the issues and provided the interim response in compliance with regulatory obligations under 21 CFR 10.30(e)(2).",
FDA-2010-P-0531-0005_FDA_CDER_to_Peptimmune__Inc____Petition_Denial,"Stamped March 29, 2011",,Center for Drug Evaluation and Research (CDER),Denied,"Section 505(b)(2) and 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355)
- Section 505(q)(1)(F) of the Act
- 21 CFR Part 314
- 21 CFR 314.94(a)(5)(i)
- 21 CFR 314.127(a)(3)
- 21 CFR 314.92(a)(1)
- 21 CFR 314.105, 314.125, 314.127, 314.110, 314.200
- 21 CFR 210.3(b)(7), 314.3(b)
- Court case: Serono Laboratories, Inc. v. Shalala, 158 F.3d 1313 (D.C. Cir. 1998)","The FDA emphasized its broad statutory and regulatory discretion in determining whether the active ingredient in an ANDA is the ""same as"" that in the reference listed drug (RLD).
- The agency rejected Peptimmune's request to require preclinical and clinical PK and PD studies for generic glatiramer acetate (GA) due to lack of necessity and premature judgment.
- The Agency cited its precedent in the Serono case and reinforced that sameness of active ingredient does not require complete chemical identity.
- FDA stated it uses a flexible, science-based, and ingredient-specific approach and that any decision on sameness would depend on the particular data and the ‚Äúkind of drug at issue.‚Äù
- FDA maintained that granting the petition would essentially prejudge ANDA applications for GA without reviewing specific data or providing procedural protections to applicants.
- FDA acknowledged that information from the petition may inform its scientific evaluation of future applications, but it declined to impose the requested requirements at this time.",
FDA-2010-P-0526-0024_FDA_CDER_Response_to_Lachman_Consultant_Services_I,"Stamped April 16, 2013",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Gerald J. Dal Pan, M.D., M.S., Director, Office of Surveillance and Epidemiology.","Denied ‚Äì FDA determined that the drug products covered by NDA 20-553 (OxyContin, original formulation) were withdrawn from sale for reasons of safety or effectiveness, which prohibits the approval of ANDAs referencing these formulations","Section 505(j) of the FD&C Act (21 U.S.C. ¬ß 355(j))
- 21 CFR 314.161 (withdrawal determination criteria)
- 21 CFR 314.127(a)(11) (basis for ANDA denial)
- 21 CFR 314.3(b) (definition of listed drug)
- 21 CFR 314.94(a)(5)(i) (bioequivalence and labeling requirements)
- Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments)
- Reference to Serono Labs, Inc. v. Shalala as precedent","FDA reviewed information including citizen petitions, docket comments, adverse event reports, and clinical literature.
- It concluded that original OxyContin (NDA 20-553) was withdrawn due to its high abuse potential, particularly when crushed or manipulated, which bypassed the extended-release mechanism and led to overdose and fatal events.
- The newer reformulated OxyContin (NDA 22-272) incorporates abuse-deterrent properties.
- Studies reviewed suggested, but did not confirm, a reduction in non-oral abuse, yet showed enough evidence of elevated abuse risk in the original formulation to conclude it was removed for safety concerns.
- As a result, FDA concluded it may not approve ANDAs referencing the original OxyContin product.",
FDA-2010-P-0526-0015_FDA_CDER_Interim_Response_to_Lachman_Consultant_Se,"Stamped March 25 and March 28, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Other (Interim Response) ‚Äì FDA had not yet reached a decision on the petition due to complex issues requiring further review.,21 CFR ¬ß 10.30(e)(2) ‚Äì Regulation requiring the agency to issue an interim response if final action has not been taken within 180 days,"The petition requested that FDA determine whether multiple strengths of OxyContin (oxycodone hydrochloride extended-release tablets) under NDA 20-553 were withdrawn for reasons of safety or effectiveness.
- FDA noted that it had not yet completed review of the matter due to the complexity of the issues involved.
- The interim response was issued in compliance with 21 CFR 10.30(e)(2), committing to respond fully once a decision had been reached.",
FDA-2010-P-0520-0008_FDA_CDER_to_Extremity_Innovations__Inc____Letter,"Stamped March 9, 2011",,Center for Devices and Radiological Health (CDRH) ‚Äì Contact person mentioned is from CDRH‚Äôs Regulations Staff,Other (Interim Response) ‚Äì FDA had not yet reached a final decision on the petition due to pending internal review.,21 CFR ¬ß 10.30(e)(2) ‚Äì FDA regulation on issuing interim responses to citizen petitions,"The petition requested that FDA reclassify an Injectable Silicone device (used as a prosthetic pad for pressure-related foot disorders) from Class III to Class II.
- FDA explained that a final decision was pending because the request raised issues requiring further review and analysis by agency officials.
- The letter served as an interim response in compliance with regulatory obligations.",
FDA-2010-P-0520-0007_FDA_CDER__to_Extremity_Innovations__Inc____Petitio,"Stamped December 15, 2011",,"Center for Devices and Radiological Health (CDRH) ‚Äì Signed by Nancy Stade, Deputy Director for Policy",Denied ‚Äì FDA denied the request to reclassify injectable silicone from a Class III to a Class II device.,"Section 520(l) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 201(h) and Section 201(g) of the FD&C Act
- 21 CFR ¬ß 10.30(e)(3)
- 21 CFR Part 3
- Sections 563(a) and 503(g)(1) of the FD&C Act","FDA noted that injectable silicone has not been cleared or approved for the proposed indication (prosthetic pad for foot disorders).
- In contrast to its use as a lubricant or coating, the therapeutic effect in this petition relies on chemical action, not mechanical effect.
- Evidence suggested that silicone injections initiate an immunologic response, leading to fibrous tissue formation that provides cushioning‚Äînot the silicone itself.
- Because the effect is chemically mediated, the product does not meet the statutory definition of a device under section 201(h) and is instead considered a drug under section 201(g).
- Therefore, FDA concluded the reclassification request was not appropriate, and the product must follow drug approval pathways.",
FDA-2010-P-0518-0014_FDA_CDER_to_Pharmaceutical_Law_Group_PC__Petition_,"Stamped February 22, 2011",,Center for Drug Evaluation and Research (CDER),"Granted in part, and denied in part

FDA granted the request to apply a 30-month stay on ANDA 78-998 due to a timely paragraph IV certification and lawsuit by Roche.

However, FDA denied extending the stay beyond the expiration of the relevant patent.","Federal Food, Drug, and Cosmetic Act (FFDCA):

21 U.S.C. ¬ß 355(j)(5)(B)(iii)

21 U.S.C. ¬ß 355(j)(5)(F)(ii)

21 U.S.C. ¬ß 355(q)(1)(A)(ii)

Section 505(j)(2)(A)(vii)(I‚ÄìIV)

Section 505(b)(1), (c)(2)

21 CFR 314.94(a)(12)(i)(A)

21 CFR 314.108(b)(2)

21 CFR 314.430(b)","The FDA's decision to partially grant the petition is based on the following key reasons:

Timely Paragraph IV Certification and Lawsuit: Roche received Orchid‚Äôs Paragraph IV certification notice for U.S. Patent No. 4,927,814 on July 26, 2010, and initiated a patent infringement suit within 45 days. This satisfied the legal conditions under 21 U.S.C. ¬ß 355(j)(5)(B)(iii) for a 30-month stay of ANDA approval.

Patent Was Listed Before ANDA Filing: The '814 patent had been properly submitted for listing in the Orange Book prior to Orchid‚Äôs ANDA submission, satisfying the prerequisite for a stay.

FDA Policy on Certification Conversion: FDA supports a 30-month stay when a Paragraph III certification is converted to a Paragraph IV and litigation is timely filed.

Limit on Stay Duration: FDA clarified that the stay would terminate upon patent expiration (March 17, 2012), in accordance with policy and precedent.

Rebuttal to Orchid's Arguments: FDA rejected Orchid‚Äôs counterclaims that:

Delay must be justified on public health grounds,

The 7.5-year exclusivity under ¬ß505(j)(5)(F)(ii) overrides 30-month stay provisions,

Draft Guidance and court decisions like Teva v. Sebelius negate the stay,

Roche‚Äôs update to patent info post-ANDA filing invalidated the stay.",
FDA-2010-P-0507-0011_FDA_CDER_Response_to_Perrigo_Company__Denial_of_Re,"Stamped April 8 and April 19, 2013",,"CDER ‚Äì Center for Drug Evaluation and Research (inferred from the regulatory context, citations to 21 CFR 314, and NDA/ANDA discussion)",Denied ‚Äì The FDA denied Perrigo Company's Reconsideration Petition.,"21 CFR 314.161(a)(1)
- 21 CFR 314.162
- 21 CFR 10.33(d)
- 21 CFR 10.33(e)
- Federal Register citations:
‚ÄÉ‚ÄÉ‚Ä¢ 76 FR 51037
‚ÄÉ‚ÄÉ‚Ä¢ 75 FR 13292","The 10 mg bisacodyl HalfLytely product was determined to be withdrawn from sale for reasons of safety or effectiveness.
- Although only one case of ischemic colitis was reported in the study F38-27, FDA also found three additional cases in AERS and the literature.
- FDA emphasized that ischemic colitis is a known and labeled adverse drug reaction for the product.
- FDA asserted that the continued reporting of ischemic colitis associated with the 10 mg dose (and none for the 5 mg dose as of Jan 31, 2013) indicates an ongoing safety concern.
- The risk of ischemic colitis was deemed a sufficient ground for concluding the product was withdrawn for safety reasons, even apart from comparative study data.",
FDA-2010-P-0507-0008_FDA_CDER_to_Perrigo_Company___Letter,"Stamped August 18 and August 19, 2011",,"Center for Drug Evaluation and Research (CDER) (indicated in the sign-off line: ""Office of Regulatory Policy, Center for Drug Evaluation and Research"")",Denied ‚Äì The FDA determined that the product was withdrawn from sale for reasons of safety or effectiveness and will not accept or approve ANDAs referencing it,"21 CFR 314.161
- 21 CFR 314.162
- 21 CFR 10.30 (citizen petition regulation)
- 21 U.S.C. 355(j)(7) (FDCA section on drug listing)","FDA reviewed its records, clinical trials, literature, and postmarketing adverse event reports
.
- The 10 mg bisacodyl version was found to have comparable effectiveness to the 5 mg version, but with increased abdominal cramping and fullness, and potential association with ischemic colitis.
- FDA required additional clinical data and labeling changes for any reintroduction of the 10 mg version.
- As a result, it concluded that the product had been withdrawn from sale for reasons of safety or effectiveness and removed it from the Orange Book listing.",
FDA-2010-P-0507-0005_FDA_CDER_Interim_Response_to_Perrigo_Company___Let,"Stamped March 16 and 17, 2011",,Center for Drug Evaluation and Research (CDER) ‚Äì specified in the sign-off as part of Jane A. Axelrad‚Äôs title,Interim Response ‚Äì No Decision Yet ‚Äì The FDA acknowledged receipt of the petition but indicated it had not yet resolved the issues raised,21 CFR 10.30(e)(2) ‚Äì cited regarding FDA‚Äôs obligation to issue an interim response when a final decision has not been made within 180 days,"The petition raised complex issues requiring extensive review and analysis by Agency officials. Therefore, a decision could not yet be issued",
FDA-2010-P-0505-0006_FDA_CDER_to_Virginia_Commonwealth_University_Schoo,"Stamped June 6 and June 9, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Indicated in the signature block by ""Office of Regulatory Policy, Center for Drug Evaluation and Research""","Petition Denied ‚Äì FDA determined that ORLAAM (levomethadyl acetate HCl) oral solution, 10 mg/mL, was NOT withdrawn for reasons of safety or effectiveness","21 CFR 10.30 (citizen petition regulation)
- 21 CFR 314.161(a)(1)
- 21 CFR 314.162
- 21 U.S.C. 355(j)(7)","FDA reviewed internal records and postmarketing literature/data for adverse events related to ORLAAM.
- FDA found no evidence suggesting the product was withdrawn due to safety or effectiveness concerns.
- Therefore, the drug remains listed in the ""Discontinued Drug Product List"" in the Orange Book, indicating the withdrawal was not for safety or efficacy reasons.
- ANDAs referencing this product may be approved if all other legal and regulatory requirements are met",
FDA-2010-P-0505-0005_Determination_That_Product_Was_Not_Withdrawn_From_,"June 6, 2011",,Center for Drug Evaluation and Research (CDER) ‚Äì Referenced through the contact information for Sandra Park and regulatory citations,"Denied ‚Äì FDA concluded that ORLAAM (levomethadyl acetate HCl) oral solution, 10 mg/mL was not withdrawn for reasons of safety or effectiveness","21 CFR 314.161(a)(1)
- 21 CFR 314.162
- 21 CFR 10.30
- 21 U.S.C. 355(j)(7)","The petitioner presented no data suggesting the product was withdrawn for safety or effectiveness reasons.
- FDA reviewed internal records, conducted an independent review of literature, and analyzed postmarketing adverse event data.
- FDA found no evidence of withdrawal due to safety or efficacy concerns.
- Therefore, the product remains in the ""Discontinued Drug Product List"" as discontinued for reasons other than safety or effectiveness, and ANDAs may still be approved",
FDA-2010-P-0505-0004_Interim_Response_to_Virginia_Commonwealth_Universi,"Stamped March 17 and March 21, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Indicated in the sign-off by Jane A. Axelrad, Associate Director for Policy",Interim Response ‚Äì No Final Decision Yet ‚Äì The FDA acknowledged the petition but had not yet resolved the issue due to its complexity,21 CFR 10.30(e)(2) ‚Äì Regulation cited for issuing interim responses to citizen petitions when additional review is needed,"The petition raised complex issues.
- It required extensive review and analysis by FDA officials.
- Therefore, FDA was not yet able to reach a decision",
FDA-2010-P-0491-2181_FDA_CFSAN_Response_to_Corn_Refiners_Association_CR,"Stamped May 30, 2012",,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Michael M. Landa, Director of CFSAN (see signature on page 4).","Denied ‚Äì FDA denied the petition to authorize ""corn sugar"" as an alternate common or usual name for HFCS in accordance with 21 CFR 10.30(e)(3).","21 CFR 10.30(e)(3) ‚Äì Citizen petition regulation
- 21 CFR 102.5(a) ‚Äì Common or usual name criteria
- 21 CFR 168.111 ‚Äì Dextrose monohydrate identity
- 21 CFR 168.120, 168.130, 168.140, 168.160, 168.180 ‚Äì Syrup identity standards (glucose, cane, maple, sorghum, table syrup)
- 21 CFR 184.1854 ‚Äì Sucrose GRAS regulation
- 21 CFR 184.1857 ‚Äì Corn sugar GRAS regulation for dextrose
- 21 CFR 168.122 ‚Äì Lactose labeling","FDA's naming policy differentiates between sugars (solid, crystallized) and syrups (aqueous/liquid); HFCS is a syrup, not a sugar.
- Allowing HFCS to be labeled ‚Äúcorn sugar‚Äù would mislead consumers, as ‚Äúcorn sugar‚Äù has long referred to dextrose, not HFCS.
- FDA‚Äôs regulations have used ‚Äúcorn sugar‚Äù to mean dextrose for over 30 years.
- ‚ÄúCorn sugar‚Äù is rarely used on food labels; changing the term may create public health risks for individuals with hereditary fructose intolerance, who rely on labels to avoid HFCS.
- FDA found no compelling evidence that ‚Äúcorn sugar‚Äù is commonly understood to mean HFCS, or that existing naming conventions are misleading.",
FDA-2010-P-0491-0159_FDA_CFSAN_Response_to_the_National_Consumers_Leagu,"Stamped August 31, 2011; Read September 9, 2011",,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Grace Kim, Food Technologist, Office of Nutrition, Labeling and Dietary Supplements",Interim / Procedural Acknowledgment ‚Äì FDA acknowledged NCL‚Äôs comments on the citizen petition but did not issue a final decision in this letter,Not Mentioned ‚Äì No specific CFR or statutory regulations were cited in this procedural acknowledgment.,"FDA confirmed receipt of the NCL‚Äôs letter dated August 3, 2011, and earlier comments from February 10, 2011.
- FDA stated that all comments received on the petition would be considered in reaching a final decision.
- The letter serves as a filing acknowledgment and indicates that the comments were forwarded to the Division of Dockets Management",
FDA-2010-P-0491-0158_FDA_CFSAN_Response_to_the_Office_of_the_Governor_o,"Stamped August 31, 2011",,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signature block from Grace Kim, Food Technologist, Office of Nutrition, Labeling and Dietary Supplements",Procedural Acknowledgment / Interim ‚Äì FDA confirmed receipt of the Governor‚Äôs comments and stated they would be filed in the docket; no final decision was issued,Not Mentioned ‚Äì The letter does not cite any specific statutes or regulatory codes.,"FDA acknowledged the Governor's position in support of the petition to rename HFCS as ""corn sugar.""
- FDA noted that multiple comments were received and would be considered.
- The response simply forwarded the comments to the Division of Dockets Management, without issuing any evaluation or regulatory ruling at this stage",
FDA-2010-P-0491-0157_FDA_OC_Office_of_Legislation_to_the_Honorable_Char,"Stamped August 1, 2011",,"Office of Legislation, Food and Drug Administration (FDA) ‚Äì Signed by Jeanne Ireland, Assistant Commissioner for Legislation",Interim / Status Update ‚Äì The FDA acknowledged review of the Corn Refiners Association's citizen petition and stated the matter was under active consideration,21 CFR ¬ß 10.30 ‚Äì Regulation governing administrative procedures for citizen petitions,"FDA stated that it was reviewing the CRA petition using its technical and scientific staff.
- The evaluation included: petitioner-provided data, scientific information, consumer research, and applicable laws.
- The agency opened a public docket (FDA-2010-P-0491) to receive stakeholder input.
- No final action or decision had been taken at the time of this letter",
FDA-2010-P-0491-0155_FDA_OC_Office_of_Legislation_to_The_Honorable_Tom_,"Stamped May 24, 2011",,"Office of Legislation, Food and Drug Administration (FDA) ‚Äì Signed by Jeanne Ireland, Assistant Commissioner for Legislation.","Interim / Partial Response ‚Äì FDA acknowledged the citizen petition and stated the petition was under review; however, it denied co-labeling of HFCS with ‚Äúcorn sugar.‚Äù",21 CFR ¬ß 10.30 ‚Äì Governs administrative procedures for citizen petitions.,"FDA was actively reviewing CRA‚Äôs petition, including scientific data and consumer research.
- The agency opened a public docket (FDA-2010-P-0491) for stakeholder input.
- FDA stated that co-labeling of HFCS as ‚Äúcorn sugar‚Äù would not be allowed at that time, since the agency had not yet concluded that ‚Äúcorn sugar‚Äù is an appropriate alternative name.
- The decision emphasized that truthful and accurate labeling is essential and premature co-labeling would undermine this standard.",
FDA-2010-P-0491-0098_FDA_CFSAN_to_Corn_Refiners_Associaton___Letter,"Stamped April 29, 2011 and May 6, 2011",,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Barbara O. Schneeman, Ph.D., Director, Office of Nutrition, Labeling and Dietary Supplements",Procedural Request / Pause in Review ‚Äì FDA paused full review and asked petitioner to address a conflict with existing regulation before continuing.,"21 CFR 184.1866(a) ‚Äì GRAS regulation for HFCS
- 21 CFR 168.111(a)-(c) ‚Äì Standard of identity for dextrose monohydrate
- 21 CFR 184.1857 ‚Äì Existing GRAS affirmation for ‚Äúcorn sugar‚Äù (dextrose)","The Corn Refiners Association requested that FDA allow ‚Äúcorn sugar‚Äù as a new name for HFCS.
- FDA noted that ‚Äúcorn sugar‚Äù is already defined under 21 CFR 184.1857 as dextrose, which creates a conflict.
- The petition failed to address this existing definition or its regulatory implications.
- FDA requested clarification: whether CRA wanted to proceed with the current petition or amend it to address this regulatory conflict.",
FDA-2010-P-0491-0088_FDA_CFSAN_Interim_Response_to_Corn_Refiners_Associ,"Stamped March 14 and April 7, 2011",,"Center for Food Safety and Applied Nutrition (CFSAN) ‚Äì Signed by Barbara O. Schneeman, Ph.D., Director, Office of Nutrition, Labeling and Dietary Supplements",Interim Response ‚Äì FDA had not yet reached a decision on the petition due to competing agency priorities and limited resources.,21 CFR ¬ß 10.30(e)(2) ‚Äì Referenced implicitly through the 180-day review window; not cited verbatim but reflected in procedural context.,"FDA had not completed review within 180 days due to other agency priorities and limited resource availability.
- FDA committed to continue the review and consider warranted amendments in regulatory context and other program priorities.",
FDA-2010-P-0460-0004_FDA_CDER_to_Alaunus_Pharmaceutical__LLC__Petition_,"Stamped July 7 and July 8, 2012",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signature block from Dr. Keith O. Webber, Deputy Director, Office of Pharmaceutical Science",Approved ‚Äì The petition to allow submission of an Abbreviated New Drug Application (ANDA) for Midazolam Hydrochloride Injection (different total strength) was approved,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(2)(A) and (B) ‚Äì Requirements for ANDA submission
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirement","The proposed drug product has the same concentration (5 mg/mL) and route of administration as the listed drug, but differs in total drug content (500 mg vs. 50 mg).
- FDA found that the change in strength does not raise safety or efficacy concerns because uses, dose, and route are the same.
- No new investigations were needed.
- If shown to meet bioavailability requirements, the proposed product would have the same therapeutic effect as the listed reference drug",
FDA-2010-P-0454-0006_FDA_CDER_to_to_Campaign_for_Tobacco_Free_Kids__Pet,"Stamped April 1, 2013",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director of CDER, on page 33.","Partially Approved / Partially Denied ‚Äì As summarized on pages 31‚Äì32:
- Some requests were granted, such as collaboration with sponsors and alternate endpoints.
- Others, such as requests to allow new indications and transfer product review to a different division, were denied.","Family Smoking Prevention and Tobacco Control Act, Section 918 of the FD&C Act (21 U.S.C. 356)
- 21 CFR ¬ß 312.84 ‚Äì Addressing surrogate endpoints
- 21 CFR ¬ß 314.126 ‚Äì Adequate and well-controlled studies","Labeling Changes: FDA intends to revise labeling, but such changes must go through product sponsors and NDA amendments‚Äînot citizen petitions alone (pg. 5‚Äì7, 31).
- New Indications: Requests for new uses (e.g., long-term abstinence, combination therapy) lacked sufficient data to support approval (pg. 6‚Äì12).
- Scientific Evidence: Many cited studies were not robust enough (e.g., meta-analyses, review papers, and non-specific studies), failing to show statistically convincing support (pg. 8‚Äì13, 18‚Äì21).
- Specific Populations: FDA acknowledged concerns for CVD patients, pregnant women, and adolescents, but concluded that available evidence does not support broad safety labeling changes without more targeted research (pg. 16‚Äì21).
- Retail Access & Package Size: FDA agreed to expand access and support smaller package sizes (pg. 28‚Äì30).",
FDA-2010-P-0454-0005_Minutes_of_Meeting_with_the_Campaign_for_Tobacco_F,"June 8, 2012",,"Center for Drug Evaluation and Research (CDER) ‚Äì Represented by Janet Woodcock and Grail Sipes
- Center for Tobacco Products (CTP) ‚Äì Represented by Lawrence Deyton
- Office of Medical Products and Tobacco (OMPT) ‚Äì Represented by Stephen Spielberg",Not a formal response ‚Äì This was an informal stakeholder meeting. FDA listened and asked questions but did not issue any regulatory action or decision, Family Smoking Prevention and Tobacco Control Act (implicitly referenced as the regulatory authority for nicotine/tobacco product oversight),"The meeting was held to discuss FDA‚Äôs regulatory strategy for nicotine- and tobacco-containing products.
- CTFK shared public health perspectives on nicotine regulation, including nicotine replacement therapies (NRTs).
- The discussion also focused on improving communication between FDA and the public health community regarding product regulation",Meeting Minutes
FDA-2010-P-0454-0004_Interim_Response_to_Campaign_for_Tobacco_Free_Kids,"Stamped February 22 and February 24, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Interim Response ‚Äì FDA acknowledged receipt of the petition and stated that a decision had not yet been reached.,21 CFR 10.30(e)(2) ‚Äì FDA regulation requiring interim response if action is not taken within 180 days,"The petition raised complex issues that require extensive review and analysis by FDA officials.
- Due to this complexity, the FDA had not yet issued a final decision.",
FDA-2010-P-0446-0036_FDA_CDRH_to_University_of_Virginia_Health_System,"Stamped January 31, 2012",,Center for Devices and Radiological Health (CDRH) ‚Äì Contact reference provided for CDRH Regulations Staff; the response was issued from the Office of the Commissioner,Denied ‚Äì FDA denied the request to require a warning label on surgical gloves indicating a 1.5% glove hole leakage rate,"21 CFR 800.20(c)(2) ‚Äì Defines Acceptable Quality Level (AQL) for glove water leak testing
- 21 CFR 800.20(c)(3) ‚Äì Defines lot rejection criteria when defect count exceeds threshold","The 1.5 AQL is a minimum quality level, not a direct percentage leakage rate.
- Many gloves perform better than the 1.5 AQL limit; thus, labeling all gloves with a ‚Äú1.5% leakage rate‚Äù would be inaccurate.
- Such a label could mislead consumers and unfairly disadvantage manufacturers whose products perform better than the AQL standard.",
FDA-2010-P-0444-0003_FDA_CDER_Response_to_the_Mayo_Clinic__May_24__2011,"Stamped May 20, May 23, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Keith O. Webber, Ph.D., Deputy Director, Office of Pharmaceutical Science","Approved ‚Äì FDA approved the petition to allow submission of an ANDA for Fludeoxyglucose F18 Injection, 500 mCi/mL at End of Synthesis (EOS)","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) ‚Äì Basis for approving a petition involving a strength change
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirement","The proposed product (500 mCi/mL) differed in strength but had the same dose, dosage form, and route of administration as the listed product (300 mCi/mL).
- FDA concluded that investigations were not necessary because the difference in strength did not raise safety or efficacy concerns.
- The product must meet bioavailability requirements to be approved, but this would be evaluated during the ANDA review process.",
FDA-2010-P-0438-0003_FDA_CDER_Interim_Response_to__Dr__Reddy_s_Laborato,"Stamped February 11 and February 16, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Interim Response ‚Äì The FDA had not yet reached a final decision due to the complex nature of the issues raised in the petition.,21 CFR ¬ß 10.30(e)(2) ‚Äì Regulation requiring interim response to citizen petitions when a decision is not issued within 180 days,"The petition requested changes to FDA‚Äôs Manual of Policies and Procedures (MaPP 5240.3) to allow expedited review of certain ANDAs.
- FDA stated the request raised complex issues needing extensive internal analysis.
- Due to resource constraints and competing priorities, a final response had not yet been completed.",
FDA-2010-P-0430-0015_FDA_CDER_to_Hogan_Lovells_US_LLP__Eisai__Inc_____P,"Stamped November 26, 2010",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Janet Woodcock, M.D., Director","Granted in part and denied (or denied as moot) in part ‚Äì The FDA confirmed Ranbaxy‚Äôs exclusivity, converted Teva‚Äôs ANDA to tentatively approved, and denied some requests as moot","21 CFR ¬ß 10.30 ‚Äì Citizen petition procedures
- 21 CFR ¬ß 314.430(d)(1) ‚Äì Confidentiality of unapproved ANDAs
- 21 CFR ¬ß 314.107(c)(1) ‚Äì ANDA approval timing and exclusivity
- 21 U.S.C. ¬ß 355(j) ‚Äì FD&C Act, ANDA pathway
- 35 U.S.C. ¬ß 271(e)(2) ‚Äì Patent infringement related to ANDA filings","Ranbaxy was the first applicant eligible for 180-day exclusivity, which blocked Teva‚Äôs ANDA approval.
- Teva‚Äôs ANDA was originally approved in 2008 but was converted to tentative approval in Sept 2010.
- As of Nov 26, 2010, Ranbaxy‚Äôs ANDA was approved, and it alone was entitled to the exclusivity.
- FDA found no basis for Teva to waive exclusivity since it was not eligible for it.
- Some requests were denied as moot because the desired actions (e.g., conversion of Teva‚Äôs ANDA) had already occurred.",
FDA-2010-P-0413-0006_FDA_CDER_Response_to_Olsson_Frank_Weeda_Terman_Bod,"Stamped January 28 and January 30, 2013",,"Center for Drug Evaluation and Research (CDER) ‚Äì Response signed by Gregory P. Geba, M.D., M.P.H., Director, Office of Generic Drugs",Approved ‚Äì FDA approved the petition to allow submission of an ANDA for a new strength (50 mcg/1 mL vial) of Fentanyl Citrate Injection,"Section 505(j)(2)(C) of the FD&C Act ‚Äì Authority for petitioning ANDA submission with different strength
- Section 505(j)(2)(C)(i) ‚Äì Standard for approval unless safety/effectiveness questions require investigation
- Section 505(j)(2)(A) and (B) ‚Äì ANDA submission requirements
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirements","The change in strength (from 2 mL to 1 mL vials) does not raise safety or efficacy concerns, as dose, use, and route of administration remain the same.
- No new clinical investigations were necessary.
- If the product meets bioavailability criteria, it can be expected to have the same therapeutic effect as the listed reference product",
FDA-2010-P-0401-0006_FDA_CDRH__to_Steve___Gupta__M_D___J_D____Petition_,"Stamped December 2, 2011",,Center for Devices and Radiological Health (CDRH),Denied,"21 CFR 10.30(e)(3)
- FD&C Act ¬ß 515(e)(1)(A), (B), and (F)
- 21 CFR 814.46(a)","The FDA found no new data or rationale sufficient to warrant withdrawal of the PMA (premarket approval) for the Alair¬Æ Bronchial Thermoplasty System.
- The mechanism of action (i.e., reduction in smooth muscle mass) was not required to be proven for approval; instead, clinical outcomes (reduced emergency visits, exacerbations, etc.) justified approval.
- Concerns regarding a single ‚Äúoutlier‚Äù patient in the control group were found to be scientifically invalid and did not compromise study integrity.
- The AIR2 trial was well-controlled and showed meaningful benefit in relevant clinical endpoints.
- The AIR trial‚Äôs five-year data was not designed to evaluate long-term effectiveness comparatively and did not support revocation.
- The labeling already included precautions addressing the limitations of the patient population studied (e.g., exclusion of the most severe asthma cases).
- The FDA noted that the granting of expedited review status has no bearing on the validity of the approval. ",
FDA-2010-P-0401-0003_Interim_Response_to_Steve_Gupta__M_D___J_D__,"January 18, 2011",,"Center for Devices and Radiological Health (CDRH) ‚Äì Signed by Nancy K. Stade, Deputy Director for Policy",Interim Response ‚Äì FDA had not yet reached a decision on the petition at the time of this letter,21 CFR 10.30(e)(2) ‚Äì Regulation requiring an interim response when no decision has been made within 180 days,"The petition requested revocation of the April 27, 2010 PMA approval for the Alair¬Æ Bronchial Thermoplasty System.
- FDA stated that the petition raised issues requiring further review and analysis.
- The agency was not ready for a meeting, but was working toward a resolution",
FDA-2010-P-0396-0004_FDA_CDER_to_Fish___Richardson__P_C____Cephalon___I,"Stamped January 7, 2011",,Center for Drug Evaluation and Research (CDER),Denied,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(b)(2) of the FD&C Act
- 21 CFR Part 320 (Bioequivalence methodologies)
- FDA Guidance documents:
‚Ä¢ Bioavailability and Bioequivalence for Orally Administered Drug Products ‚Äì General Considerations
‚Ä¢ Bioequivalence Recommendations for Specific Products
‚Ä¢ Statistical Approaches to Establishing Bioequivalence","Fish & Richardson Petition: FDA reviewed the assertion that Watson's ANDA resulted in a new salt form (fentanyl starch glycolate) due to the wet granulation process. FDA found the risk of this conversion minimal and unsupported by Cephalon‚Äôs model study, which used unrealistic processing conditions (e.g., sonication instead of granulation). FDA determined Watson‚Äôs ANDA was acceptable and denied the request to reject it or require a 505(b)(2) NDA.

- Cephalon Petition: FDA denied the request to revise its bioequivalence guidance to require additional pharmacokinetic (PK) parameters (like AUC‚ÇÄ‚Äì‚ÇÉ‚ÇÄ or C‚ÇÉ‚ÇÄ). It concluded that standard measures‚ÄîAUC and Cmax‚Äîalong with routine analysis of early PK profiles, were sufficient for assessing therapeutic equivalence. FDA also argued that Fentora‚Äôs variability in patient tolerance and lack of a clear concentration-effect relationship makes additional PK criteria unnecessary. The agency reaffirmed that existing regulatory tools (e.g., Tmax evaluations, in vitro testing) and scientific reviews were adequate to safeguard patient safety and efficacy.",
FDA-2010-P-0393-0007_Interim_Response_to_Mr__Robert_Pack_and_Mr__Lance_,"Stamped January 6 and January 10, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äì Signed by Jane A. Axelrad, Associate Director for Policy",Interim Response ‚Äì FDA had not yet reached a final decision on the petition.,21 CFR 10.30(e)(2) ‚Äì Regulation requiring an interim response if a final decision is not made within 180 days,"The petition requested that FDA issue a public statement clarifying that there is insufficient in vivo clinical data to support news claims that reformulated OxyContin is less addictive or abusable than the original.
- It also asked FDA to direct Purdue Pharma to make a similar public statement.
- FDA noted that the petition raised complex issues requiring extensive internal review and analysis, and thus it had not yet reached a decision.",
FDA-2010-P-0392-0049_Memo_and_Combined_Responses_to_Dr_Edlich_Citizen_P,"April 4, 2018",,Center for Devices and Radiological Health (CDRH),"Partially Approved and Partially Denied:
- Petitions to ban powdered gloves and remove certain content were granted.
- Petition to establish new communication guidelines was denied.","21 CFR ¬ß 10.30(e)(2)
- Final Rule: 81 FR 91722 (Dec 19, 2016)
- Proposed Rule: 81 FR 15173 (Mar 22, 2016)","The FDA issued a final rule in December 2016 banning powdered surgeon‚Äôs gloves, powdered patient examination gloves, and absorbable powder for lubricating a surgeon‚Äôs glove due to risks associated with their use, particularly allergic reactions and complications in surgical wounds and healing processes.

- The rule rendered many of the petitions‚Äô requests moot or fulfilled.

- The FDA considered submitted information in the rulemaking process.

- The petition to establish additional administrative guidelines was denied because existing procedures under 21 CFR ¬ß 10.30 were deemed sufficient.",
FDA-2010-P-0383-0017_FDA_CDER_to_Fish___Richardson__P_C____Cephalon__In,"Stamped January 7, 2011",,Center for Drug Evaluation and Research (CDER),Denied,"Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) (21 U.S.C. 355(j))
- Section 505(b)(2) of the Act
- 21 CFR Part 320
- FDA Guidance documents:
¬†¬†¬†¬†‚Ä¢ Bioequivalence Recommendations for Specific Products
¬†¬†¬†¬†‚Ä¢ Bioavailability and Bioequivalence for Orally Administered Drug Products ‚Äì General Considerations
¬†¬†¬†¬†‚Ä¢ Statistical Approaches to Establishing Bioequivalence","Watson ANDA Petition: The FDA found insufficient evidence that Watson‚Äôs fentanyl buccal tablet contained a second salt form (fentanyl starch glycolate). Cephalon‚Äôs model study was not representative of Watson‚Äôs process and thus did not substantiate claims of an additional active ingredient.

- Bioequivalence Requirements Petition: The FDA determined that standard pharmacokinetic (PK) measures‚ÄîAUC and Cmax‚Äîalong with review of early time PK profiles, were sufficient to determine bioequivalence for ANDAs referencing Fentora.

- FDA disagreed with Cephalon‚Äôs request to mandate additional PK parameters (e.g., AUC‚ÇÄ‚Äì‚ÇÉ‚ÇÄ, C‚ÇÉ‚ÇÄ) or to revise the Fentanyl Guidance, noting no established PK/PD relationship for Fentora due to inter-patient variability and lack of PD data.",
FDA-2010-P-0377-0010_FDA_CDER_to_Great_Lakes_Environmental_Law_Center_a,"Stamped February 22, 2013",,"Center for Drug Evaluation and Research (CDER) ‚Äî Signed by Janet Woodcock, Director",Denied,"21 CFR 25.15(a) ‚Äì Requirement for EA or categorical exclusion
- 21 CFR Part 25, Subpart C ‚Äì Environmental assessments
- 21 CFR 25.21 (a) ‚Äì Extraordinary circumstances requiring EAs
- 21 CFR 25.31 ‚Äì Categorical exclusion criteria
- 21 CFR 25.33 ‚Äì Conditions for exclusions under IND, NDA, ANDA, etc.
- 42 U.S.C. ¬ß 4321 ‚Äì National Environmental Policy Act (NEPA) (cited indirectly via discussion of NEPA process)
- 81 FR 15173 and other Federal Register notices indirectly referenced for guidance","The petition requested FDA to repeal the 1 part per billion (ppb) Categorical Exclusion for environmental assessments and to establish a new, more stringent threshold for pharmaceutical pollutants in the environment.

- FDA denied this request, stating that the current exclusion standard is scientifically sound and supported by toxicity data. Their internal environmental analysis included:
‚Ä¢ A comprehensive review of aquatic toxicity data for over 1,300 active pharmaceutical ingredients (APIs), focusing on 16 with LOECs (Lowest Observed Effect Concentrations) < 1 ppb.
‚Ä¢ An evaluation of API metabolism, wastewater treatment efficiency, and ecological exposure dilution.
‚Ä¢ A conclusion that current environmental regulations and guidance, including the 1 ppb threshold, sufficiently mitigate potential environmental risks.

- FDA stated that concerns raised by the petition do not meet the threshold of ""extraordinary circumstances"" requiring a change in the categorical exclusion under 21 CFR 25.21(a).

- FDA concluded the petition did not provide scientific justification for modifying the categorical exclusion, and they reaffirmed plans to publish draft guidance addressing endocrine disruption potential of drugs in the future.",
FDA-2010-P-0377-0008_FDA_CDER_Response_to_Great_Lakes_Environmental_Law,"Stamped August 8 and August 12, 2011",,"Center for Drug Evaluation and Research (CDER) ‚Äî Signed by Jane A. Axelrad, Associate Director for Policy",Interim Response ‚Äî FDA had not yet reached a decision on the petition due to complexity.,21 CFR ¬ß 25.31(b) ‚Äî Pertains to categorical exclusion from the requirement to prepare an environmental assessment for certain actions with estimated aquatic concentration below 1 ppb,"The petition requested revocation of 21 CFR ¬ß 25.31(b), arguing that the 1 ppb threshold for environmental exclusion was inadequate.
- FDA noted that the petition raised complex scientific and legal issues requiring extensive review and analysis.
- The agency was evaluating existing regulations and guidance in light of recent scientific developments.
- FDA was also coordinating with other federal agencies, including the Environmental Protection Agency (EPA).
- Due to competing priorities and the complexity of the matter, FDA was unable to provide a timeline for completing its response.",
FDA-2010-P-0376-0004_FDA_CTP_Response_to_Rousseau_Research_Inc_Californ,"Stamped December 5, 2013",,"Center for Tobacco Products (CTP) ‚Äî Signed by Mitchell Zeller, Director",Denied,"Section 911 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. ¬ß 387k)
- Section 907 of the FD&C Act (21 U.S.C. ¬ß 387g)
- Section 906(d) of the FD&C Act","Modified Risk Recognition Request: FDA rejected the request to recognize E¬Æ brand cigarettes as a ‚Äúpotential‚Äù modified risk tobacco product (MRTP) because Section 911 of the FD&C Act does not allow for potential MRTPs‚Äîonly those formally approved via order after application and review.

- Ban on Marketing Practices: Petitioners‚Äô claims that discounting and rebates hinder market entry for safer products lacked supporting evidence. FDA concluded there was insufficient information to determine whether banning such practices would protect public health.

- Tocopherol Regulation: The request for a new rule mandating 300‚Äì350 ¬µg Tocopherol per cigarette (as MS-CSC) lacked supporting data or scientific studies. FDA found no evidence that such a standard was necessary to protect public health under Section 907 and ruled rulemaking unwarranted.

As such, FDA concluded that none of the requests were justified scientifically or legally and denied the petition.",
FDA-2010-P-0376-0003_FDA_CTP_Interim_Response_to_Rousseau_Research_Inc_,"Stamped December 14, 2010",,"Center for Tobacco Products (CTP) ‚Äî Signed by Lawrence R. Deyton, M.S.P.H., M.D., Director",Interim Response ‚Äî FDA had not reached a final decision due to complex issues.,21 CFR ¬ß 10.30(e)(2) ‚Äî Requires an interim response when the FDA has not completed review within 180 days,"The petition sought:
1. A ban on promotional discounts for modified risk tobacco products.
2. A ban on rebates/penalties imposed on distributors of such products.
3. A new regulation setting tocopherol (Vitamin E) levels in cigarette smoke condensate (MS-CSC) between 300‚Äì350 ¬µg.
4. Recognition of E¬Æ brand cigarettes as a potential modified risk tobacco product.

- FDA stated it had not yet resolved the issues because the petition raised significant and complex regulatory and scientific questions requiring further analysis by agency officials.",
FDA-2010-P-0359-0004_Interim_Response_to_Goodwin_Procter_LLP__from_CDRH,"Stamped December 10, 2010",,"Center for Devices and Radiological Health (CDRH) ‚Äî Signed by Nancy Stade, Deputy Director for Policy",Interim Response ‚Äî The FDA had not yet reached a final decision.,21 CFR ¬ß 10.30(e)(2) ‚Äî Governs interim responses for citizen petitions pending beyond 180 days,"The petition requested finalization of the 2006 proposed rule and draft guidance concerning reclassification of absorbable hemostatic devices.
- FDA stated that it was unable to reach a decision at the time due to the complexity of issues involved and the need for additional review and analysis by agency officials.
- The agency assured it would respond as soon as a final determination was made.",
FDA-2010-P-0352-0049_Memo_and_Combined_Responses_to_Dr_Edlich_Citizen_P,"Stamped April 4, 2018",,Center for Devices and Radiological Health (CDRH),"Partially Approved / Partially Denied
Some petitions granted in part; one denied in part.","21 CFR 10.30(e)(2)
- 81 FR 15173 (March 22, 2016)
- 81 FR 91722 (December 19, 2016)","Petitions contributed to the final rule banning powdered surgeon's gloves, patient exam gloves, and absorbable powder for lubricating a surgeon‚Äôs glove.
- The requested removal of the ‚ÄúMedical Glove Powder Report‚Äù was executed as part of that final rule.
- FDA declined to address specific cancer-growth claims due to coverage in final rule justification.
- Requests to reclassify devices considered moot because of the complete ban.
- Request to create new guidelines for petition processing was denied citing existing adequate regulations (21 CFR 10.30).",
FDA-2010-P-0341-0006_FDA_CDER_Response_to_Hyman_Phelps_and_McNamara_P_C,"Stamped November 15 and November 16, 2012",,"Center for Drug Evaluation and Research (CDER) ‚Äî Signed by Gregory P. Geba, M.D., M.P.H., Director, Office of Generic Drugs","Approved ‚Äî Petition to allow submission of an ANDA for imatinib mesylate tablets (50 mg, 200 mg, and 600 mg) was granted.","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(2)(C)(i)
- Section 505(j)(2)(A)
- Section 505(j)(2)(A)(iv)","The requested change in drug strength (to 50 mg, 200 mg, and 600 mg) was deemed acceptable under the FD&C Act.
- The FDA concluded that the proposed changes in strength did not raise concerns of safety or effectiveness, since the use, dosage, and route of administration remained the same as the listed drug (Gleevec¬Æ Tablets, 100 mg and 400 mg).
- As such, no new investigations were required.
- The proposed generic product, if shown to meet bioavailability standards, would have the same therapeutic effect as the listed drug.",
FDA-2010-P-0339-0058_FDA_CDRH_to_University_of_Virginia_Health_System__,"Stamped January 13, 2012",,"Center for Devices and Radiological Health (CDRH)
Signed by Leslie Kux, J.D., Acting Assistant Commissioner for Policy, Office of the Commissioner",Denied,"21 CFR 10.30(e) (regarding petition processing)
- 21 CFR 800.20(c)(2) & (c)(3) (glove quality requirements)
- FD&C Act (21 U.S.C. 301 et seq.)
- 71 FR 75865 (Dec. 19, 2006)","FDA concluded that existing premarket review, performance standards, and quality regulations (such as the 1.5 AQL standard) are sufficient to ensure the safety and effectiveness of surgeon‚Äôs gloves.
- The petitioner requested mandatory use of a powder-free double glove hole indicator system during procedures involving HIV, Hepatitis B, or Hepatitis C patients.
- FDA determined that no new regulatory requirements were warranted and that no compelling evidence was provided showing that existing standards posed an unreasonable risk or needed to be changed.
- FDA emphasized that glove lots not meeting the AQL are considered adulterated under current regulations.",
FDA-2010-P-0338-0005_FDA_CDER_to_Lachman_Consultant_Services__Inc____Le,"Stamped October 6, 2010",,Center for Drug Evaluation and Research (CDER),"Denied (The FDA determined that the drug was not withdrawn for reasons of safety or effectiveness; thus, it denied the implicit request to remove it from the Orange Book‚Äôs discontinued list.)"," 21 CFR 314.161 (Determination of voluntary withdrawal for safety or effectiveness)
- 21 CFR 314.162 (Listing of withdrawn drugs)
- 21 U.S.C. 355(j)(7) (Federal Food, Drug, and Cosmetic Act section on ANDA listing)","The FDA reviewed its own records and found no evidence that Azdone (hydrocodone bitartrate and aspirin) was withdrawn for safety or efficacy reasons.
- The petitioner did not provide any such evidence.
- FDA also conducted an independent evaluation of postmarketing safety data and literature and found no indication of withdrawal for safety or efficacy.
- Therefore, Azdone remains listed in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book, allowing ANDAs referencing it to be submitted",
FDA-2010-P-0326-0004_FDA_CDER_to_JRRapoza_Associates__Inc____Response_L,"Stamped December 29, 2010",,Center for Drug Evaluation and Research (CDER),"Other ‚Äî The FDA determined that Trandate (labetalol hydrochloride) tablets, 300 mg and 400 mg, were not withdrawn for reasons of safety or effectiveness.","21 U.S.C. 355(j)(7) (Section 505(j)(7) of the FD&C Act)
- 21 CFR 314.161(a)(1)
- 21 CFR 314.161(a)(2)
- 21 CFR 314.162","The FDA reviewed agency records and literature.
- No data or postmarketing reports suggested withdrawal was for safety or efficacy reasons.
- Therefore, the products will remain listed in the ""Discontinued Drug Product List"" in the Orange Book.
- FDA will continue to approve ANDAs referring to these products if they meet applicable standards.",
FDA-2010-P-0317-0003_Interim_Response_to_Teva_Pharmaceutical_Industries,"Stamped December 13 and December 15, 2010 ",,"Center for Drug Evaluation and Research (CDER)
Signed by Jane A. Axelrad, Associate Director for Policy",Interim Response ‚Äî No decision yet; the petition is still under review.,21 CFR 10.30(e)(2) (FDA regulation governing citizen petition interim responses)," The FDA stated it had not resolved the issues raised in the petition submitted by Teva on June 16, 2010.
- The petition asked that all albuterol sulfate HFA inhalation aerosol NDAs or 505(b)(2) NDAs bear approved trade names as a condition of approval.
- The delay is due to the complexity of the issues, which require extensive review and analysis.",
FDA-2010-P-0312-0014_FDA_CDER_to_Natural_Resources_Defence_Council__Pet,"Stamped November 20, 2012",,Center for Drug Evaluation and Research (CDER),Denied," Federal Food, Drug, and Cosmetic Act (FD&C Act), Sections 505(e), 505(e)(2), and 505(e)(3)
- 21 CFR 314.150(a)(2)(ii)
- 21 CFR Part 7, Subpart C
- The Stockholm Convention on Persistent Organic Pollutants (POPs)","FDA concluded that current data do not show that the risk-benefit profile of lindane has changed.
- Available evidence does not demonstrate that lindane is unsafe when used as directed.
- Adverse event reporting rates have declined since boxed warnings and a Public Health Advisory were implemented.
- The data cited by the petitioner (NRDC) were found to be anecdotal or not meeting the standard of ‚Äúsubstantial evidence‚Äù from adequate and well-controlled studies.
- Resistance to lindane, while noted, was not sufficient to warrant withdrawal, as some patients may still benefit.
- Environmental and global regulatory concerns (e.g., EPA‚Äôs pesticide assessments, Stockholm Convention) do not override FDA‚Äôs authority to assess safety and effectiveness for pharmaceutical uses.
- FDA emphasized that lindane is approved as a second-line treatment, with appropriate warnings and restricted indications.
- No persuasive evidence was provided that the risks of lindane, as labeled, outweigh its therapeutic benefits for patients intolerant to or failing first-line treatments.",
FDA-2010-P-0312-0013_FDA_CDER_to_Natural_Resources_Defence_Council___Re,"Stamped May 4, 2012",,"Center for Drug Evaluation and Research (CDER) ‚Äî Signed by Jane A. Axelrad, Associate Director for Policy",Interim Response ‚Äî The FDA had not yet reached a final decision on the petition.,21 CFR 10.30 ‚Äî Regulation governing citizen petitions,"FDA acknowledged receipt of the March 28, 2012 follow-up from NRDC regarding the petition.
- The agency noted that it had previously issued an interim response on January 28, 2011.
- FDA reiterated that the petition is still under active review, and a final response would be issued once a decision is reached.
- No new substantive justification for delay was provided other than the ongoing review process.",
FDA-2010-P-0312-0009_Interim_Response_to_Natural_Resources_Defense_Coun,"Stamped January 28, 2011; Read January 31, 2011",,"Center for Drug Evaluation and Research (CDER)
Signed by Jane A. Axelrad, Associate Director for Policy",Interim Response ‚Äî The FDA had not yet resolved the petition at that time.,21 CFR 10.30(e)(2) ‚Äî Governing interim responses to citizen petitions,"The petition raised complex issues requiring extensive review and analysis.
- The FDA acknowledged the petition (submitted June 15, 2010) requested the withdrawal of lindane approvals and a prohibition on its pharmaceutical use for lice and scabies.
- FDA noted this interim response was delayed due to an administrative error and should have been issued on December 12, 2010.",
FDA-2010-P-0309-0010_FDA_CDER_to_Shire_Development_Inc____Petition_Part,"Stamped December 8 and December 10, 2010",,Center for Drug Evaluation and Research (CDER),"Partially Granted and Partially Denied
- Granted: Requests related to limiting total lanthanum hydroxycarbonate and trace metal impurities.
- Denied: Requests for mandatory pharmacodynamic (PD) or clinical studies for bioequivalence, and separate polymorph testing.","Section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. 355)
- Section 505(q)(1)(F) and (F)(ii) of the FD&C Act
- 21 CFR 320.1(e), 320.23(b), 320.24(b)(4), 320.24(b)(6), and 314.101(b)(9)","Bioequivalence (BE): In vitro dissolution and binding studies are sufficient and appropriate to demonstrate BE, as Fosrenol acts locally in the GI tract with minimal systemic absorption. PK studies are not required; clinical trials are considered less sensitive.
- Hardness Testing: Required to ensure similar ‚Äúchewability‚Äù and particle pulverization.
- Impurities and Degradants: Applicants must control and monitor trace metal impurities and total lanthanum hydroxycarbonate. No need to test each polymorph individually due to lack of evidence for differential toxicity.
- Hydration State: Clinical studies not required for products with different hydration levels, as BE can still be established through appropriate in vitro or PD studies.",
FDA-2010-P-0275-0003_Determinations_that_Product_Withdrawal_From_Sale_W,"December 7, 2010",,Center for Drug Evaluation and Research (CDER),"Denied ‚Äì The FDA determined that the drug was not withdrawn for reasons of safety or effectiveness, allowing continued ANDA referencing.","21 CFR ¬ß 314.161
- 21 CFR ¬ß 314.162
- Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7))","The FDA reviewed the citizen petition and conducted an independent review of agency records and literature.
- No data or adverse event reports indicated that GLEEVEC 50 mg or 100 mg capsules were withdrawn from sale due to safety or effectiveness concerns.
- Therefore, these products remain listed in the Discontinued Drug Product List in the Orange Book, and ANDAs referencing them may still be approved if they meet all other requirements.",
FDA-2010-P-0271-0014_FDA_CDER_to_Buchanan_Ingersoll_and_Rooney_PC__Peti,"Stamped May 20, 2013",,Center for Drug Evaluation and Research (CDER),Denied,"21 U.S.C. ¬ß 321(p)(1) ‚Äì Definition of ‚Äúnew drug‚Äù under the FD&C Act
- 21 U.S.C. ¬ß 355(a) ‚Äì Drug approval requirement
- 21 CFR 314.126 ‚Äì Adequate and well-controlled studies
- 21 CFR 10.30 ‚Äì Citizen petition process
- 21 CFR 10.35 ‚Äì Stay of action pending petition resolution
- 21 CFR 330.10(a)(4)(ii) ‚Äì OTC drug evaluation
- Multiple references to section 505 of the FD&C Act","The FDA provided extensive reasoning for denying the petition, including:

- Insufficient Clinical Evidence: The petition failed to demonstrate that Auralgan is ‚ÄúGenerally Recognized As Safe and Effective‚Äù (GRAS/E) through adequate and well-controlled studies.
- Product Variability: The formulation of Auralgan referenced was not consistent across cited studies, and differences in active ingredients and concentrations weakened claims of GRAS/E status.
- Disqualification of Supporting Evidence: Many cited studies lacked control groups or failed to meet FDA standards for clinical adequacy.
- Legal Interpretation: The FDA interpreted the FD&C Act to mean that each product as a whole‚Äînot just its components‚Äîmust be shown to be GRAS/E.
- Prior Enforcement Actions: FDA had already seized unapproved Auralgan products and enforced compliance with new drug application (NDA) requirements.
- Procedural Grounds: Requests to allow marketing pending NDA approval or to halt enforcement were denied under 21 CFR 10.30 and 10.35 as procedurally unsupported.",
FDA-2010-P-0271-0012_FDA_CDER_to_Buchanan_Ingersoll___Rooney_PC,"Stamped February 15 and February 16, 2011",,Center for Drug Evaluation and Research (CDER),Partially Denied,"21 CFR 10.30 ‚Äì Governing citizen petitions
- 21 CFR 10.3 ‚Äì Defines ‚Äúadministrative action‚Äù
- 21 CFR 10.30(k) ‚Äì Limits of citizen petition applicability
- 21 CFR 10.45 ‚Äì Final administrative actions
- FD&C Act
- Ewing v. Mytinger & Casselberry, Inc., 339 U.S. 594 (1950)
- Heckler v. Chaney, 470 U.S. 821 (1985)","Procedural Grounds: The FDA found that the petition‚Äôs request to halt enforcement action was not a proper subject of a citizen petition under 21 CFR 10.30.
- Legal Restrictions: Under 21 CFR 10.3 and 10.30(k), enforcement referrals are explicitly excluded from citizen petition processes.
- Judicial Precedent: Courts lack jurisdiction to review FDA‚Äôs enforcement decisions (Ewing, Heckler), so such requests fall outside reviewable administrative action.
- Enforcement Discretion: FDA emphasized its discretion in deciding whether and when to initiate enforcement actions.",
FDA-2010-P-0271-0003_Interim_Response_to_Buchanan_Ingersoll___Rooney_PC,"Stamped November 24 and November 26, 2010",,Center for Drug Evaluation and Research (CDER),Interim Response ‚Äì No Decision Yet,21 CFR 10.30(e)(2) ‚Äì Regulation requiring an interim response if no decision has been made within 180 days on a citizen petition," Complexity of Issues: The FDA noted that the petition raised ‚Äúsignificant issues requiring extensive review and analysis by Agency officials.‚Äù Therefore, a final decision could not yet be provided.",
FDA-2010-P-0263-0005_Letter_re_Closing_of_Citizen_Petition_from_FDA_CFS,"August 18, 2020",,Center for Food Safety and Applied Nutrition (CFSAN),Closed,21 CFR 101.13(b)(3) ‚Äì Regulation the petitioner sought to amend (regarding ‚Äúless sugar‚Äù nutrient content claims on labeling for children under two),"Company Inactivity: FDA determined that First Juice, Inc. was no longer operational (website offline, phones disconnected, and emails undeliverable).
- No Means of Contact: Multiple attempts to reach the petitioner failed.",
FDA-2010-P-0263-0004_Interim_Response_to_First_Juice_Inc_,"Stamped November 23, 2010 and December 7, 2010",,Center for Food Safety and Applied Nutrition (CFSAN),Interim Response ‚Äì No Decision Yet,21 CFR 10.30(e)(2) ‚Äì Requirement to issue an interim response if a petition decision is delayed beyond 180 days,"Agency Workload: The delay was attributed to ‚Äúother agency priorities and the limited availability of resources.‚Äù
- The review of the petition was still underway and would be completed as part of broader program priorities.",
FDA-2010-P-0255-0013_FDA_CDER_to_Osmotica_Pharmaceutical___Petition_Den,"Stamped November 187 and November 18, 2010",,Center for Drug Evaluation and Research (CDER),Denied,"21 U.S.C. ¬ß 355(j)(2)(C) ‚Äì Suitability petitions
- 21 CFR 314.93 ‚Äì Suitability petitions
- 21 CFR 314.94(a)(3) ‚Äì ANDA content requirements
- 21 CFR 320 ‚Äì Bioequivalence and bioavailability studies
- 21 CFR 314.50(d)(3) and 314.94(a)(7) ‚Äì NDA and ANDA content requirements
- 21 CFR 320.25(a)(1) ‚Äì Study conduct ethics","FDA Guidance Compliance: FDA cited its own guidance which permits waiver of fasting bioequivalence studies for venlafaxine HCl due to safety concerns (notably nausea and vomiting during fasted studies).
- Clinical Equivalence: The FDA concluded there was no significant clinical difference in pharmacokinetics between Osmotica‚Äôs product and the reference under fed conditions.
- Safety Risks: Fasting conditions posed greater adverse event risks (vomiting), and ethical considerations weighed against conducting unnecessary human trials.
- Consistency with Precedent: FDA noted it had issued similar fed-only recommendations for other drugs when warranted by safety profiles (e.g., indomethacin, nisoldipine).
- Labeling and Scientific Rationale: The labeling and PK data supported the conclusion that food does not affect bioavailability materially, making fasting studies unnecessary for generic evaluation purposes.",
FDA-2010-P-0243-0003_FDA_CDER_to_Endo_Pharmaceuticals__Inc____Petition_,"Stamped November 8 and November 16, 2010",,Center for Drug Evaluation and Research (CDER),"Granted in part and denied in part
- Granted: The request that applicants for oxymorphone HCl products referencing Opana or Opana ER be required to meet the specification of NMT 0.001% for certain impurities.
- Denied: Requests regarding batch and stability data, additional bioequivalence testing criteria, and denial of a specific ANDA"," 21 CFR 314.3(b) ‚Äì Reference Listed Drug (RLD) definition
- Also referenced: FDA‚Äôs 2008 draft guidance on Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches","Impurity Control: FDA requires potentially genotoxic impurities (ABUKs like 14-hydroxycodeinone and 14-hydroxymorphinone) to be limited to ‚â§0.001% in the API or to be adequately qualified for safety. This requirement is consistent across opioid APIs derived from thebaine.
- Technical Feasibility: FDA acknowledged that lower impurity limits (e.g., 0.00015%) are not technically feasible at this time, hence 0.001% remains acceptable.
- Stability Testing Not Required: The FDA denied the request for batch and stability testing because these impurities are process-related, not degradation products, so their levels are not expected to increase over time.
- Bioequivalence Testing: FDA found no clinical justification to require plasma concentration matching over 12 hours in addition to AUC and Cmax; these pharmacokinetic parameters, along with others (e.g., Tmax, metabolite profiles), are sufficient to establish bioequivalence.
- Impax ANDA: The FDA rejected the request to deny Impax's ANDA based on court filings, asserting that therapeutic equivalence is evaluated through FDA‚Äôs regulatory framework, not litigation documents",
FDA-2010-P-0234-0005_FDA_CDER_to_Lachman_Consultant_Services__Inc____Re,"Stamped October 19 and October 20, 2010",,Center for Drug Evaluation and Research (CDER),"Approved / Affirmative Determination
The FDA determined that BUSPAR (buspirone hydrochloride) Tablets, 10 mg, 15 mg, and 30 mg were not withdrawn from sale for reasons of safety or effectiveness. Therefore, these products remain listed in the ‚ÄúDiscontinued Drug Product List‚Äù and are still eligible for ANDA referencing","21 CFR 10.30 ‚Äì Citizen petition procedures
- 21 CFR 314.161 ‚Äì Procedure for determining withdrawal of listed drugs from sale
- 21 CFR 314.162 ‚Äì Removal of drug products from the list
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Listing of approved drugs (Orange Book requirements)
- Drug Price Competition and Patent Term Restoration Act of 1984","Review of Records: FDA reviewed internal records and found no evidence suggesting that the withdrawal of BUSPAR was related to safety or efficacy issues.
- Independent Literature Review: FDA evaluated relevant literature and postmarketing data and found no indication that BUSPAR posed safety risks.
- Regulatory Consistency: Because the withdrawal was not safety-related, BUSPAR remains eligible as a reference listed drug for ANDA purposes.",
FDA-2010-P-0234-0004_Determinations_that_Drugs_were_Not_Withdrawn_from_,"October 19, 2010",,Center for Drug Evaluation and Research (CDER),"Approved / Affirmative Determination
The FDA determined that BUSPAR (buspirone hydrochloride) Tablets, 10 mg, 15 mg, and 30 mg were not withdrawn from sale for reasons of safety or effectiveness, and thus remain eligible for ANDA referencing","21 CFR 10.30 ‚Äì Citizen petition procedures
- 21 CFR 314.161 ‚Äì Procedures for determining withdrawal from sale for safety or effectiveness
- 21 CFR 314.162 ‚Äì Drug removal from the Orange Book
- 21 U.S.C. ¬ß 355(j)(7) ‚Äì Requirements for ANDA referencing listed drugs","Review of Records: FDA reviewed internal documentation and found no indication that the BUSPAR product was withdrawn due to safety or efficacy concerns.
- Independent Assessment: FDA evaluated postmarketing data and literature and found no safety-related rationale for the market withdrawal.
- Regulatory Implication: The drug will remain on the ""Discontinued Drug Product List"" and may still be referenced by ANDA applicants if legal and regulatory requirements are met",
FDA-2010-P-0231-0006_FDA_CDER_Response_to_Hyman_Phelps_and_McNamara_PC_,"Stamped January 28 and January 30, 2010",,Center for Drug Evaluation and Research (CDER),"Approved
The FDA approved the petition to allow submission of an Abbreviated New Drug Application (ANDA) for Fexofenadine Hydrochloride Oral Suspension, 15 mg/5 mL, which differs in strength from the listed drug Allegra (30 mg/5 mL)","Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(2)(A)(iv) ‚Äì Bioavailability requirements
- Sections 505(j)(2)(A) and (B) ‚Äì Required ANDA submission content","No Safety or Effectiveness Concerns: FDA concluded that the strength difference (15 mg/5 mL vs. 30 mg/5 mL) does not raise new safety or effectiveness issues because the use, dose, and route of administration are the same as for the listed drug.
- Therapeutic Equivalence: If the proposed product meets bioavailability criteria, it is expected to have the same therapeutic effect as the reference drug.
- Regulatory Compliance: The petition met all applicable statutory criteria allowing ANDA submission for a different strength version of a listed product",
FDA-2010-P-0223-0010_FDA_CDER_to_Covington___Burling_LLP__Genzyme_Corpo,"Stamped and written October 19, 2010",,Center for Drug Evaluation and Research (CDER),"Granted. FDA confirmed that the Act requires a 30-month stay of ANDA 90-040 approval from November 24, 2009, based on a paragraph IV certification and subsequent patent infringement litigation by Genzyme","21 U.S.C. ¬ß 355(j)(5)(B)(iii) (Section 505(j)(5)(B)(iii) of the FD&C Act)
- 21 CFR ¬ß 314.94(a)(12)(i)(A)
- 21 CFR ¬ß 314.161
- Pub. L. No. 108-173 (Medicare Prescription Drug, Improvement, and Modernization Act of 2003)","All statutory conditions for a 30-month stay were met: Genzyme listed the ‚Äò116 patent in the Orange Book before ANDA submission, Cobrek submitted a paragraph IV certification, and Genzyme sued within 45 days.
- Whether the 2003 MMA applied or not, the result remained unchanged: the criteria for a stay were satisfied.
- FDA clarified that although successive 30-month stays are generally restricted under MMA, exceptions like this (related to distinct formulations and litigation triggers) are still permissible.
- FDA emphasized it cannot override statutory mandates based on perceived policy implications, such as potential delays in generic approvals",
FDA-2010-P-0216-0027_FDA_CDER_to_Frommer_Lawrence___Haug_LLP___Partial_,"Stamped October 15, 2010",,Center for Drug Evaluation and Research (CDER),Granted in Part and Denied in Part,"21 U.S.C. 355(j), 355(b)(2), 355(q) (Sections 505(j), 505(b)(2), and 505(q) of the FDCA)
- 21 CFR 320.1(e), 320.23(b), 320.24, 314.94(a)(7), 314.101(d)(9), 314.54(a)
- FDA Guidance Documents Cited:
‚Ä¢ Bioavailability and Bioequivalence Studies for Orally Administered Drug Products ‚Äì General Considerations (2003)
‚Ä¢ Bioequivalence Recommendations for Specific Products (2010 draft guidance)
‚Ä¢ Statistical Approaches to Establishing Bioequivalence","Scientific Basis: FDA found the hypothetical PK profile proposed by the petitioner (Profile A) physiologically infeasible for carvedilol due to its known pharmacokinetics (multi-compartment or flip-flop kinetics).

- Cmin Importance Acknowledged: FDA agreed Cmin is important for therapeutic efficacy, especially for heart failure patients, but noted that reliable estimation can be done through modeling based on single-dose studies rather than requiring multiple-dose studies.

- Use of Simulation: FDA used physiologically based PK modeling to determine that equivalence in AUC and Cmax from single-dose studies can predict equivalent Cmin at steady state.

- Precedent from Coreg CR Approval: FDA did not apply strict pass/fail statistical criteria to Cmin in the original Coreg CR NDA (some strengths were outside 80‚Äì125% range).

- Alcohol Dose Dumping: The request for mandatory clinical testing to rule out alcohol-induced dose dumping was denied, with FDA stating that in vitro ethanol dissolution testing was sufficient.

Conclusion: Standard AUC and Cmax criteria from single-dose studies are sufficient to evaluate bioequivalence, with no new requirements for additional Cmin-specific tests",
FDA-2010-P-0201-0008_FDA_CDER_Interim_Response_to_Paddock_Laboratories_,"Stamped October 8 and October 22, 2010",,Center for Drug Evaluation and Research (CDER),Interim Response ‚Äì No Final Decision Made,21 CFR 10.30(e)(2),"The FDA had not yet reached a decision on the petition due to competing Agency priorities.
- This was explicitly described as an interim response, not a resolution on the merits of the petition.
- The agency committed to responding ‚Äúas soon as possible given the numerous demands on the Agency‚Äôs resources‚Äù",
FDA-2010-P-0201-0007_Determinations_That_Products_Were_Not_Withdrawn_fr,"March 2, 2011",,Center for Drug Evaluation and Research (CDER),Approved ‚Äì NILSTAT was not withdrawn for reasons of safety or effectiveness,"21 CFR 10.30 ‚Äì Citizen petition procedure
- 21 CFR 314.161 ‚Äì Determination of withdrawal for safety/effectiveness
- 21 CFR 314.162 ‚Äì Removal from the Orange Book
- 21 U.S.C. 355(j)(7) ‚Äì Requirements related to listed drugs and ANDA approval under the FDCA","No evidence of withdrawal due to safety or effectiveness: FDA reviewed internal records and independently evaluated literature and postmarketing data.
- Petitioner did not submit any contrary data: Paddock Laboratories, who submitted the petition, did not provide evidence suggesting safety or efficacy concerns.
- Regulatory Implication: As a result, NILSTAT will remain listed in the Discontinued Drug Product List in the Orange Book, indicating it was discontinued for reasons other than safety or effectiveness. ANDAs referring to it may be approved if all conditions are satisfied",
FDA-2010-P-0196-0006_FDA_CDER_to_Hogan___Hartson__LLP__Abbott_Laborator,"Stamped October 4 and October 8, 2010",,Center for Drug Evaluation and Research (CDER),Granted in part and denied in part,"Section 505(b)(2) and 505(j) of the FD&C Act (21 U.S.C. 355)
- 21 CFR Part 208 ‚Äì Medication Guides
- 21 CFR ¬ß¬ß 314.50(i), 314.52, and 314.54(a)(1)(vi) ‚Äì Requirements for 505(b)(2) NDAs
- 21 CFR ¬ß¬ß 314.94(a)(12), 314.95 ‚Äì Applicable to ANDAs
- 21 CFR 314.107 ‚Äì Applicable to both NDAs and ANDAs","Risk of Secondary Exposure: The petition addressed the risk of testosterone gel transferring from adult users to children, resulting in adverse effects such as early puberty and aggressive behavior. FDA previously mandated boxed warnings and Medication Guides for products like AndroGel and Testim.

- Requirement for 505(b)(2) NDAs: FDA upheld that any generic TTG (transdermal testosterone gel) products with different penetration enhancers than the RLD (e.g., AndroGel) require submission as a 505(b)(2) NDA, not an ANDA, due to the need for safety studies.

- Mandatory Studies: FDA requires:
‚Ä¢ Body transfer studies
‚Ä¢ Hand-washing studies
‚Ä¢ Skin irritation and sensitization studies
‚Ä¢ Standard pharmacokinetic (bioequivalence) studies
‚Ä¢ Showering studies when applicable based on other study results

- Patent Certifications: FDA agreed that a 505(b)(2) NDA must include new patent certifications even if a prior ANDA had them, and notifications must be re-issued to the patent holder.

- Reconsideration Possible: FDA reserves the right to revise these requirements if new scientific information arises concerning the relationship between penetration enhancers and testosterone transfer risk",
FDA-2010-P-0188-0015_Interim_response_to_AXIN__Veltrop___Harkrider_LLP_,"Stamped October 4 and October 6, 2010",,Center for Drug Evaluation and Research (CDER),Interim Response ‚Äì No Final Decision Rendered,21 CFR 10.30(e)(2) ‚Äì Regulation governing interim responses to citizen petitions,"The FDA has not completed its review due to the need to prioritize other matters.
- The response is issued as an interim response, as required under regulatory timelines, and the agency indicates it will respond ‚Äúas soon as possible given the numerous demands on the Agency‚Äôs resources‚Äù",
FDA-2010-P-0179-0007_FDA_CDER_to_Stradley_Ronon_Stevens___Young__LLP___,"Stamped December 20, 2010",,Center for Drug Evaluation and Research (CDER),"Stradley Petition: Denied
Semelka Petition: Granted in part and denied in part","21 CFR part 201
- 21 CFR 201.57(c)(1), (6)
- Section 505(o)(4) of the FD&C Act (21 U.S.C. 355(o))
- Section 505-1(b)(3) of the FD&C Act
These appear throughout pages 2‚Äì5 in discussions of statutory authority and FDA procedures for labeling changes. ","Risk Stratification Supported by Data: The FDA concluded that certain gadolinium-based contrast agents (GBCAs)‚Äîspecifically Omniscan, OptiMARK, and Magnevist‚Äîcarry higher risks of Nephrogenic Systemic Fibrosis (NSF) for patients with chronic severe kidney disease or acute kidney injury.
- Scientific Analysis: This decision was informed by extensive review of clinical data, AERS reports, physiochemical properties of contrast agents, and recommendations from external experts (e.g., EMEA, ACR).
- Regulatory Authority: FDA invoked its authority under section 505(o)(4) to require labeling changes based on new safety information.
- Public Health Considerations: The FDA determined that differential risk-based labeling enhances patient safety and better informs prescribers, rejecting speculative arguments against such labeling. ",
FDA-2010-P-0179-0006_Interim_Response__to_Stradley_Ronon_Stevens___Youn,"Stamped September 27 and September 29, 2010",,Center for Drug Evaluation and Research (CDER),Interim Response ‚Äì No Final Decision Rendered,21 CFR 10.30(e)(2) ‚Äì Regulation governing interim responses to citizen petitions,"Petition Still Under Review: FDA has not completed its evaluation of the issues raised.
- Prioritization and Resource Constraints: Although not detailed, the interim nature of the response suggests that timing and prioritization of agency resources are influencing factors. A final response will be issued after the review is complete",
FDA-2010-P-0177-0005_FDA_CDER_to_EAS_Consulting_Group__LLC___Response_L,"Stamped December 7 and December 9, 2010",,Center for Drug Evaluation and Research (CDER),Approved,"21 CFR 10.30 ‚Äì Citizen petition procedure
- 21 CFR 314.161(a)(1) & (a)(2) ‚Äì Procedures to determine if drug was withdrawn for safety/effectiveness
- 21 CFR 314.162 ‚Äì Removal from the Orange Book due to withdrawal for safety/effectiveness
- 21 U.S.C. 355(j)(7) ‚Äì Drug listing requirements under the FDCA","The FDA reviewed agency records and determined there was no evidence that the specified AUGMENTIN (amoxicillin; clavulanate potassium) products were withdrawn due to safety or effectiveness concerns.
- The petitioner (EAS Consulting Group, LLC) submitted a citizen petition requesting clarification for three formulations, and FDA voluntarily included additional formulations.
- FDA also independently evaluated relevant literature and postmarketing adverse event data and found no safety signals.
- As a result, these drugs will remain in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book, confirming they were discontinued for reasons other than safety or effectiveness",
FDA-2010-P-0177-0004_Determination_That_AUGMENTIN__125___Amoxicillin__C,"December 7, 2010",,Center for Drug Evaluation and Research (CDER),"Approved (i.e., FDA determined the products were not withdrawn for safety or effectiveness reasons)
FDA explicitly states it will not initiate procedures to withdraw ANDA approvals and will continue approving ANDAs referencing these AUGMENTIN products","21 CFR 314.161(a)(1), (a)(2), (d) ‚Äì Determinations on whether a drug was withdrawn for safety/effectiveness reasons
- 21 CFR 314.162 ‚Äì Withdrawal of ANDA if the RLD is withdrawn
- 21 U.S.C. 355(j)(7) ‚Äì ANDA and Orange Book listing authority
- 21 CFR 10.30 ‚Äì Citizen petition procedure","FDA received citizen petitions from EAS Consulting Group requesting withdrawal determinations for several AUGMENTIN formulations.
- FDA reviewed:
‚Ä¢ Its internal records
‚Ä¢ Literature
‚Ä¢ Postmarketing adverse event data
- No data suggested any of the drug products were withdrawn for safety or effectiveness reasons.
- Accordingly, the drugs will remain in the ‚ÄúDiscontinued Drug Product List‚Äù in the Orange Book, indicating they were discontinued for business or manufacturing reasons, not due to risk concerns.
- FDA also stated that additional ANDAs may be approved if all other requirements are met",
FDA-2010-P-0177-0003_Intermin_Respponse_to_EAS_Consulting_Group__LLC,"Stamped September 13 and September 15, 2010",,Center for Drug Evaluation and Research (CDER),Interim Response ‚Äì No Final Decision Rendered,21 CFR 10.30(e)(2) ‚Äì Governs FDA‚Äôs issuance of interim responses to citizen petitions,"The petition concerns whether Augmentin ES-600 (amoxicillin; clavulanate potassium) was withdrawn for safety or effectiveness reasons.
- FDA has not reached a decision due to the need to address other agency priorities.
- The interim response was issued in compliance with procedural regulations and the Agency pledged to respond as soon as resources allow",
FDA-2010-P-0176-0083_FDA_CDRH_Ombudsman_to_Ethicon_Endo_Surgery__Inc___,"Stamped October 31, 2011",,Center for Devices and Radiological Health (CDRH),"Procedural Response ‚Äì Not a final petition decision
This letter was a procedural communication addressing the format and content of ‚ÄúPanel Packs‚Äù submitted by both parties for an upcoming Advisory Committee review regarding the SEDASYS PMA denial. It does not represent a formal approval or denial of a citizen petition","21 CFR 10.30 ‚Äì (Referenced in background context)
- Medical Devices 515(g)(2) ‚Äì Governs Advisory Committee review under PMA dispute resolutions (referenced in the header of the summary of scientific issues)","The document addresses logistical and procedural clarifications related to Panel Packs for an Advisory Committee meeting reviewing the scientific and clinical issues behind CDRH‚Äôs denial of the SEDASYS System PMA.
- FDA clarified:
‚Ä¢ Advisory Committee will focus only on scientific and clinical issues, not legal or regulatory arguments about drug labeling (e.g., propofol).
‚Ä¢ Each party may present its objections during the public meeting but may not revise the other‚Äôs Panel Pack.
‚Ä¢ Certain questions proposed by the parties were removed because they were not aligned with the scope of review.
‚Ä¢ Administrative contact, rebuttal time limits (15 mins), and final formatting of advisory committee materials were confirmed.
- The summary also outlines key scientific issues in dispute, such as:
‚Ä¢ Whether the SEDASYS system poses an increased risk of deeper-than-intended sedation
‚Ä¢ Adequacy of proposed user training
‚Ä¢ Appropriateness of the clinical control arm in the pivotal trial",
FDA-2010-P-0176-0076_FDA_Office_for_Policy_to_the_Division_of_Dockets_M,"September 26, 2011",,"Office of the Commissioner (with support from CDRH)
Memo is from Leslie Kux, Acting Assistant Commissioner for Policy; it designates Nancy J. Pluhowski of CDRH to support the Commissioner during advisory committee proceedings","Administrative Assignment ‚Äì Not a Petition Decision
This memorandum is not a formal decision on a petition, but an internal administrative assignment of personnel for managing advisory committee proceedings related to PMA P080009 (SEDASYS)","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Governs Commissioner and Advisory Committee reviews in PMA proceedings","The agency elected to maintain separation of functions during the review process for PMA P080009 (SEDASYS System).
- Nancy J. Pluhowski of CDRH was designated to assist the Office of the Commissioner in connection with the Advisory Committee and Commissioner‚Äôs review.
- The action reflects FDA‚Äôs policy to avoid conflicts or bias in regulatory decision-making by maintaining appropriate separation between policy, scientific, and legal review functions",
FDA-2010-P-0176-0075_FDA_CDRH_Ombudsman_to_Ethicon_Endo_Surgery__Inc___,"September 13, 2011",,"Center for Devices and Radiological Health (CDRH)
Communicated by the FDA Ombudsman on behalf of the Commissioner's Team","Procedural Response ‚Äì Summary of Scientific Issues Issued
This letter did not resolve the petition itself but issued the finalized Summary of Scientific Issues governing the upcoming Advisory Committee review of CDRH's PMA denial for the SEDASYS system. No final decision on the petition was rendered at this stage","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Governs advisory committee reviews of PMA decisions","The document provides a scientific dispute summary to guide the Advisory Committee's evaluation of CDRH‚Äôs denial of the SEDASYS PMA.
- Two main clinical issues were identified:
1. Safety of sedation: CDRH cited a ‚Äúserious safety signal‚Äù due to increased incidence of deeper-than-intended sedation in the SEDASYS group (including general anesthesia in 5 patients), versus the control group (1 patient).
2. Appropriateness of control arm: CDRH challenged the trial design, arguing it should have compared SEDASYS-assisted propofol administration by gastroenterologists to propofol given by anesthesia-trained personnel, not to benzodiazepine/opioid sedation.
- CDRH also questioned the adequacy of the proposed training program, stating it was not validated by outcome-based clinical studies.
- In contrast, Ethicon Endo-Surgery (EES) argued:
‚Ä¢ No patients experienced apnea or oxygen desaturation
‚Ä¢ Safety features of the device mitigated risks
‚Ä¢ Trial design reflected real-world ‚Äústandard of care‚Äù practices
‚Ä¢ Their proposed training protocol was supported by study outcomes
- The summary posed six questions for the Advisory Committee related to safety, control arm design, and training adequacy",
FDA-2010-P-0176-0072_FDA_CDRH_Ombudsman_to_Ethicon_Endo_Surgery__Inc___,"September 9, 2011",,Center for Devices and Radiological Health (CDRH),"Procedural Response ‚Äì Issuance of Schedule and Agenda
This letter is not a decision on the petition, but the final issuance of the Schedule of Events and Agenda for the upcoming Advisory Committee review of CDRH‚Äôs denial of the PMA for the SEDASYS system","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Governs advisory committee reviews of PMA denials"," The response reflects FDA‚Äôs procedural step in preparing for a formal Advisory Committee meeting to evaluate the scientific and clinical basis for denying PMA P080009 (SEDASYS).
- It includes a detailed Schedule of Events (pages 2‚Äì3) outlining submission deadlines, meeting logistics, timelines for Advisory Committee report drafting and response opportunities for the parties.
- The Agenda (page 4) specifies a full-day session (8:00 a.m.‚Äì6:00 p.m.) on December 14, 2011, for public hearings, presentations by EES and CDRH, rebuttals, discussions, and a committee vote.
- The process underscores transparency, fairness, and structured scientific deliberation in the PMA review process.",
FDA-2010-P-0176-0065_FDA_Office_for_Policy_to_the_Division_of_Dockets_M,"September 1, 2011",,"Office of the Commissioner, with designated support from CDRH (Center for Devices and Radiological Health)","Administrative Action ‚Äì Staff Assignment
This document is not a decision on the petition, but a procedural designation assigning named CDRH employees to support the Commissioner in connection with the Advisory Committee review of PMA P080009.","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Governs advisory committee and Commissioner reviews of PMA decisions","The FDA issued this memorandum to formalize the assignment of CDRH employees to assist the Office of the Commissioner during the Advisory Committee and Commissioner‚Äôs review of the SEDASYS PMA (P080009).
- The document explicitly states that ‚ÄúThe agency has elected to adhere to separation of functions as a matter of policy in this matter.‚Äù This means that those involved in the original decision will be separate from those supporting the Commissioner‚Äôs independent review",
FDA-2010-P-0176-0064_FDA_CDRH_Response_to_the_Summary_of_Scientific_Iss,"Stamped September 2, 2011",,Center for Devices and Radiological Health (CDRH),"Procedural Input ‚Äì Not a Final Petition Decision
This letter constitutes a formal response to procedural and content issues related to the Summary of Scientific Issues, questions to the advisory panel, and schedule of events for the upcoming Advisory Committee meeting. It does not decide the citizen petition or PMA itself.","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Reference to the type of Advisory Committee review being conducted (mentioned in context, not formally cited)","Panel Question Design: CDRH objects to limiting questions to yes/no format and insists panel members should be asked to explain their reasoning individually.
- Panel Question Order: CDRH recommends that questions on risks and benefits of the SEDASYS System be asked last, after thorough discussion of detailed preceding questions.
- EES Proposals Rejected:
‚Ä¢ CDRH opposes EES‚Äôs proposed changes to question wording, stating they assume inappropriate user competence and would present data in a biased way.
‚Ä¢ CDRH maintains references to propofol are essential, as the safety concerns stem from its use.
‚Ä¢ Objections by EES to a 24-hour meeting summary are rejected‚ÄîFDA sees it as valuable for transparency.
‚Ä¢ FDA rejects extended rebuttal time requested by EES, citing concerns about fostering an adversarial environment.
- Overall, CDRH stresses the need for a balanced, scientifically rigorous, and procedurally fair process for both parties and the Commissioner‚Äôs Office",
FDA-2010-P-0176-0063_FDA_Office_for_Policy_and_Goodwin_Proctor_LLP_to_L,"August 29, 2011",,Center for Devices and Radiological Health (CDRH),"Scheduling Request ‚Äì Not a Petition Decision
This document is a request for a telephone conference to discuss the submission date for the Advisory Committee Panel Package. It is not a decision or interim response on the citizen petition.",Not Mentioned,"The letter notes that Dr. David Buckles is unavailable that week.
- Nancy K. Stade and Mark A. Heller (from Goodwin Procter LLP) request a short phone meeting before August 30 at 10am to finalize a submission timeline for the Advisory Committee materials",
FDA-2010-P-0176-0062_FDA_CDRH_letter_to_Mr__Buckley_dated_8_26_2011,"August 26, 2011",,"Center for Devices and Radiological Health (CDRH)
","Collaborative Procedural Input ‚Äì Not a Decision
The letter outlines points of agreement between CDRH and Ethicon Endo-Surgery (EES) regarding proposed questions and scheduling for the upcoming Advisory Committee meeting under Section 515(g)(2). It does not represent a final decision on the PMA or the citizen petition","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Referenced as the statutory basis for the advisory committee proceeding","Consensus on Panel Questions: CDRH and EES jointly recommend removing two of the proposed questions (Nos. 4 and 6) from the Advisory Committee agenda because they either asked for input on study designs (not within the panel‚Äôs purview) or duplicated the scope of another question.
- Question Rewording: They recommend rephrasing Question 5 to more clearly assess the adequacy of training protocols in light of adverse events observed in the pivotal trial (e.g., deeper-than-intended sedation).
- Schedule Adjustments: Both parties agree to a revised submission and event schedule that includes delays to accommodate holiday impacts, and request clarification on potential legal issues raised in the schedule template.
- Enclosure Provided: A detailed multi-page ‚ÄúSchedule of Events‚Äù is enclosed, outlining key submission and response deadlines leading up to and following the Advisory Committee meeting scheduled for December 14, 2011",
FDA-2010-P-0176-0061_FDA_CDRH_List_of_Attendees__Docket_No__FDA_2010_P_,"August 23, 2011",,Center for Devices and Radiological Health (CDRH),"Administrative Update ‚Äì Not a Petition Decision
This letter serves as an update to the personnel list for the upcoming Advisory Committee meeting related to the SEDASYS system. It is not a decision or procedural response to the petition itself.","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Cited as the basis for the Advisory Committee Meeting","The initial list of attendees submitted on August 19, 2011, was incomplete.
- This updated list includes additional CDRH personnel across departments such as:
‚Ä¢ Office of Device Evaluation
‚Ä¢ Office of Surveillance and Biometrics
‚Ä¢ Office of Chief Counsel
‚Ä¢ Division of Anesthesiology, General Hospital, Infection Control, and Dental Devices
- Notably includes high-level policy and scientific personnel such as Nancy K. Stade (Deputy Director for Policy) and William Maisel (CDRH Chief Scientist).
- The letter also states that additional experts in anesthesiology and intensive care medicine may be added, and a further update will be provided upon confirmation",
FDA-2010-P-0176-0060_FDA_CDRH_List_of_Attendees__Docket_No__FDA_2010_P_,"August 19, 2011",,Center for Devices and Radiological Health (CDRH),"Administrative Update ‚Äì Not a Petition Decision
This letter provides a list of FDA/CDRH attendees scheduled to participate in the December 14, 2011 Advisory Committee Meeting under Section 515(g)(2). It is not a decision on the petition itself.","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Cited as the legal basis for the Advisory Committee review"," This update is issued ‚Äúin accordance with the published Schedule of Events‚Äù to notify stakeholders of CDRH‚Äôs internal delegation to the advisory meeting.
- The listed attendees include senior scientific, legal, and regulatory staff such as:
‚Ä¢ Nancy K. Stade (Policy)
‚Ä¢ William Maisel (Science and CDRH Chief Scientist)
‚Ä¢ Christy Foreman (Office of Device Evaluation)
‚Ä¢ Anthony Watson, Lex Schultheis (Anesthesiology & Respiratory Devices)
‚Ä¢ Ann Wion, Joy Dawson, Gayatri Rao (Office of Chief Counsel)
‚Ä¢ Surveillance and Biometrics team members (e.g., Richard Kotz, Martin Ho)
- CDRH also indicated plans to involve additional clinical experts in anesthesiology and intensive care medicine and stated it would submit an updated participant list upon confirmation",
FDA-2010-P-0176-0059_FDA_CDRH_Ombudsman_to_Ethicon_Endo_Surgery__Inc___,"August 15, 2011",,Center for Devices and Radiological Health (CDRH),"Finalization of Scientific Summary ‚Äì Not a Decision on Petition
This letter transmits the finalized ‚ÄúSummary of the Scientific Issues in Dispute‚Äù for the upcoming Advisory Committee Meeting under Section 515(g)(2). It does not represent a final decision on the PMA or petition outcome, but serves to frame deliberations and ensure neutrality in the presentation of issues","Section 515(g)(2)(A) of the Federal Food, Drug, and Cosmetic Act ‚Äì Governing the Advisory Committee‚Äôs authority and procedure","The Summary incorporates feedback from both CDRH and EES submissions (dated June 2, July 11, July 21, 2011).
- Key principles used in finalizing the Summary include:
‚Ä¢ Neutral presentation of information
‚Ä¢ Inclusion of useful factual background
‚Ä¢ Structuring committee questions for clarity (yes/no format)
‚Ä¢ Focus on scientific/clinical rather than regulatory issues
‚Ä¢ Ensuring questions address the specific bases for the CDRH denial of the PMA

- CDRH's denial was based on two main concerns:
1. Safety concerns ‚Äì SEDASYS showed an increased incidence of deeper-than-intended sedation (including general anesthesia), which CDRH deemed a ""serious safety signal."" EES argued those incidents were not clinically significant as no apnea or desaturation occurred, and the system includes safety controls
.
2. Study design limitations ‚Äì CDRH found the control arm in the pivotal study inappropriate and objected to EES‚Äôs proposed training program due to lack of validation in an outcome-based study. EES defended both the comparator and the training based on investigator experience in the pivotal trial
.
- The summary includes six specific questions to guide the Advisory Committee‚Äôs discussion on safety, comparator appropriateness, and training mitigation",
FDA-2010-P-0176-0058_FDA_CDRH_and_Ethicon_Endo_Surgery__Inc____Goodwin_,"Written and Stamped August 10, 2011",,Center for Devices and Radiological Health (CDRH),"Preliminary Procedural Coordination ‚Äì Not a Decision
This letter documents a joint agreement between CDRH and EES to meet and attempt to finalize the issues for consideration by the Advisory Panel. It does not contain a decision regarding the PMA or petition.","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Implicitly referenced in context as the statutory basis for the Advisory Committee meeting. Not directly quoted or cited in full.","Both parties submitted comments on the FDA Ombudsman‚Äôs June 2, 2011 draft ‚ÄúSummary of the Scientific Issues in Dispute.‚Äù
- There remain unresolved disagreements regarding what issues should be posed to the Advisory Committee.
- The parties believe that a meeting to discuss and narrow these issues will enhance the clarity and fairness of the panel briefing materials.
- They commit to providing a joint update to the Ombudsman after the meeting, including a list of agreed-upon issues and those still in dispute",
FDA-2010-P-0176-0057_FDA_CDRH_Ombudsman_to_Ethicon_Endo_Surgery__Inc___,,"unknown date for letter, attached agenda is for December 14, 2011",Center for Devices and Radiological Health (CDRH),"Scheduling Notice ‚Äì Not a Decision on Petition
This document transmits the revised Schedule of Events and the agenda for the December 14, 2011 Advisory Committee meeting reviewing CDRH‚Äôs denial of the SEDASYS PMA. It does not represent an approval, denial, or partial decision on the petition itself.","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì cited as the statutory basis for convening the Advisory Committee","The FDA granted EES‚Äôs request for review of CDRH‚Äôs denial of PMA P080009 for the SEDASYS system under Section 515(g)(2).
- To facilitate a fair and organized review, the letter provides a detailed multi-stage timeline and procedural requirements for both FDA and the sponsor.
- Key milestones include:
‚Ä¢ Submission of attendees (by August 19, 2011)
‚Ä¢ Draft and final Advisory Committee Panel Packages (Panel Packs)
‚Ä¢ Slide submissions
‚Ä¢ Meeting summary drafts and final report from Advisory Committee Chair
‚Ä¢ Post-meeting actions, including exception filings and a final FDA order
.
- The agenda on page 4 outlines the full-day structure of the December 14, 2011 meeting, including public hearings, sponsor and FDA presentations, and Advisory Committee deliberations and vote",
FDA-2010-P-0176-0056_FDA_CDRH_Ombudsman_to_Dockets_Management_re_Separa,"August 8, 2011",,Center for Devices and Radiological Health (CDRH),"Procedural Assignment ‚Äì Not a Petition Decision
This is an internal memorandum assigning named CDRH staff to assist the Office of the Commissioner in preparation for an Advisory Committee and Commissioner-level review of PMA denial. It is not an approval, denial, or modification of the petition.","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì Basis for the Commissioner‚Äôs review of the PMA denial","To maintain procedural fairness, the FDA elects to adhere to separation of functions as a matter of policy.
- This means staff involved in the original PMA decision will not participate in the Commissioner‚Äôs review.
- The memorandum lists the CDRH employees designated to support the Office of the Commissioner, including Tonja J. Adams, Frances Adogu, Margaret J. Ames, James Clark, Sandra Oquendo, Keyonna Queen, and Ann Marie Williams",
FDA-2010-P-0176-0054_FDA_CDRH_Ombudsman_to_Ethicon_Endo_Surgery__Inc___,,no date,Center for Devices and Radiological Health (CDRH),"Procedural Guidance ‚Äì Not a Decision
This letter outlines the schedule of events and meeting agenda for the Advisory Committee convened under Section 515(g)(2) to review CDRH‚Äôs denial of the SEDASYS PMA. It does not include a final decision on the petition.","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act ‚Äì cited as the statutory basis under which the Advisory Committee was convened to review the PMA denial","The FDA previously granted Ethicon Endo-Surgery‚Äôs request for review under Section 515(g)(2) of CDRH‚Äôs denial of the Pre-Market Approval (PMA) for the SEDASYS System.
- This document includes a comprehensive timeline (pages 2‚Äì3) outlining the deadlines for submissions by the sponsor and CDRH, the structure of the panel review process, and the flow of communications between the involved parties.
- It also contains the detailed agenda (page 4) for the Advisory Committee meeting, including presentations, rebuttals, public hearing segments, and final deliberations and vote",
FDA-2010-P-0176-0044_CDRH_Statement_of_issues_response,,no date,Center for Devices and Radiological Health (CDRH),"Ongoing Review / Response with Attached Summary ‚Äì This is a procedural and scientific position statement, not a final decision (thus considered a pre-decision communication)."," 21 C.F.R. ¬ß 14.82: Procedures for nominating voting members of the advisory panel.
- 18 U.S.C. ¬ß 208 and 21 U.S.C. ¬ß 379d-1(c)(2): Conflict of interest and disqualification of individuals from participation","The panel process must follow official procedures including Federal Register nominations.
- CDRH expressed concern over conflict of interest, reinforcing disqualification rules for economic interests.
- The CDRH denied EES‚Äô proposal to allow gastroenterologists to be added as voting members directly without Federal Register notice.
- It also disputed the safety of the SEDASYS system, highlighting increased incidence of unintended deep sedation/general anesthesia, with episodes of general anesthesia observed in 5 SEDASYS patients vs. 1 control patient.
- The pivotal study was deemed inadequate to demonstrate safety, and CDRH questioned the effectiveness of proposed training and mitigation measures",
FDA-2010-P-0176-0043_FDA_Office_for_Policy_to_the_Division_of_Dockets_M,"Stamped July 1 and July 6, 2011",,Center for Devices and Radiological Health (CDRH),Procedural and Scientific Clarification ‚Äì Not a Final Decision. This is a response addressing procedural concerns and presenting CDRH's revisions to the draft statement of issues for the advisory committee review.,"21 C.F.R. ¬ß 14.82: Nomination of advisory committee members
- 18 U.S.C. ¬ß 208: Conflict of interest statute
- 21 U.S.C. ¬ß 379d-1(c)(2): Conflict of interest disqualification in FDA advisory committees","CDRH objected to EES's direct nomination of gastroenterologists due to lack of Federal Register notice, as required under 21 C.F.R. ¬ß 14.82.
- Affirmed that panelist selection must follow standard FDA procedures and guidance on conflicts of interest.
- Clarified that economic conflicts of interest must be evaluated per law and guidance but that no heightened measures were necessary in this case.
- Rejected the proposal for an extended 1.5‚Äì2 day panel meeting, stating that a single day with one hour presentations per party is sufficient.
- Restated the scientific dispute: the adequacy of safety evidence for the SEDASYS system and whether untrained providers can safely operate it.
- Provided eight structured questions for the advisory panel to consider regarding safety, mitigation strategies, and overall benefit-risk profile",
FDA-2010-P-0176-0042_FDA_2010_P_0176_Response_to_June_3__2011_Letter,"Stamped June 22, 2011",,Center for Devices and Radiological Health (CDRH),Acknowledged input and suggestions but did not grant a meeting or make any final decision on the petition itself,"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act","Advisory committee will include expertise from gastroenterology, anesthesiology, and statistics as suggested.
- Committee members will be selected from the existing pool of Special Government Employees with appropriate qualifications.
- Time allotment suggestions for the advisory hearing are being considered during schedule refinement.
- All advisory committee candidates will be screened for conflicts of interest.
- A specific CDRH contact (Nancy Stade) was provided for correspondence.
- No additional comment on ex parte communications; affirmed current regulatory interpretation.
- Meeting request denied; FDA deemed it unnecessary at the time.",
FDA-2010-P-0176-0038_FDA_CDRH_Ombudsman_to_Ethicon_Endo_Surgery__Inc___,"Stamped June 2, 2011",,Center for Devices and Radiological Health (CDRH),Acknowledged petition for review and framed the issues for advisory committee consideration. No final approval/denial decision was rendered in this document.,"Section 515(g)(2) and 515(g)(2)(A) of the Federal Food, Drug, and Cosmetic Act","The response includes a draft Statement of Issues to guide the Medical Devices Advisory Committee's discussion.
- FDA acknowledged granting Ethicon Endo-Surgery‚Äôs request for review of the CDRH‚Äôs denial of the Pre-Market Approval (PMA) application for the SEDASYS system.
- The purpose is to frame clinical and scientific issues (e.g., deeper-than-intended sedation, adequacy of control arm in trials, sufficiency of safety assurance, and training mitigation).
- Two principal disputed issues were outlined:
¬†¬†1. Safety concerns due to unintended deep sedation episodes.
¬†¬†2. Whether the clinical trial‚Äôs control arm was appropriate.
- A targeted training program was proposed by the petitioner, and the advisory committee was asked to assess its adequacy and validation needs",
FDA-2010-P-0176-0034_FDA_Office_for_Policy_to_Staff_Attorneys_re_Separa,"April 28, 2011",,Office of the Commissioner (Policy) in coordination with Center for Devices and Radiological Health (CDRH),Other ‚Äì Administrative designation: CDRH employee Kathleen L. Walker was appointed to support the Office of the Commissioner in connection with the advisory committee and Commissioner‚Äôs review of the PMA denial. No decision was made on the petition itself,"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act","The memorandum formalizes the agency‚Äôs adherence to separation of functions as a matter of policy.
- This step ensures procedural fairness during the advisory committee and Commissioner-level review of CDRH‚Äôs denial of PMA P080009.
- It explicitly designates a staff member to support the Commissioner independently of the petition review process",
FDA-2010-P-0176-0033_FDA_Office_for_Policy_to_Goodwin_Proctor_LLP__Apri,"April 28, 2011",,"Office of the Commissioner (OC), coordinated with CDRH",Other ‚Äì The letter acknowledges receipt of correspondence and outlines procedures being considered. It reiterates the agency‚Äôs stance on no ex parte communication and states no meeting is deemed necessary at this stage. No final decision on the petition is made in this response.,21 CFR 10.3(a) ‚Äì defines ex parte communication,"The letter was issued in response to EES‚Äôs April 7 and 25, 2011 letters regarding procedural aspects of their petition to review CDRH‚Äôs PMA denial.
- The Office of the Commissioner is evaluating matters such as advisory committee member selection, timing, briefing documents, and scope of review.
- Emphasizes adherence to separation of functions, and prohibits any ex parte communications beyond status requests.
- Clarifies that only written communications submitted to the docket or status update requests are allowed.
- States that no meeting is currently warranted on procedural issues",
FDA-2010-P-0176-0031_FDA_CDRH_Ombudsman_to_Dockets_Management_re_Teleco,"April 21, 2011",,Center for Devices and Radiological Health (CDRH) ‚Äì Specifically from the CDRH Ombudsman,"Other ‚Äì The document summarizes a teleconference held to discuss procedural matters related to the advisory panel review. It does not provide a formal decision on the petition (e.g., approval or denial).","21 CFR 14.35(c) ‚Äì regarding submission of documents prior to a panel meeting
- Part 14 ‚Äì referred to generally in the context of advisory panel procedures","This memorandum records the topics discussed during an April 20, 2011 teleconference between Goodwin Procter (on behalf of EES) and CDRH representatives.
- Topics included scheduling, panel member nomination timing, procedural expectations, concerns about summer scheduling conflicts, and the scope of ex parte communication restrictions.
- The agency clarified that the schedule for the advisory panel meeting was still in development, and reiterated that no off-process communications were occurring related to SEDASYS",
FDA-2010-P-0176-0029_FDA_Office_for_Policy_to_Staff_Attorneys_re_Separa,"February 17, 2011",,Office of the Commissioner (Policy) in collaboration with CDER and CDRH,Other ‚Äì The memorandum documents an internal procedural action: the designation of CDER staff to advise and participate with CDRH in connection with the advisory committee and Commissioner review. There is no final petition decision in this document.,"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act","The FDA formally documented its decision to adhere to separation of functions as a matter of policy in this proceeding.
- Named CDER staff were designated to support the Commissioner‚Äôs review of CDRH‚Äôs denial of PMA P080009, ensuring proper procedural boundaries during the advisory committee and review process",
FDA-2010-P-0176-0028_FDA_Office_for_Policy_to_Staff_Attorneys_re_Separa,"Stamped February 9, 2011",,"Office of the General Counsel, Chief Counsel‚Äôs Office ‚Äì in connection with CDRH (Center for Devices and Radiological Health) and the Commissioner","Other ‚Äì The document designates legal counsel for separation of functions in relation to a pending petition review. No decision (approval, denial, etc.) was issued.","Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 814.44(f) ‚Äì referenced as the basis for the original PMA denial by CDRH","Although no legal requirement mandates separation of functions in this proceeding, the FDA voluntarily implemented it to maintain procedural fairness.
- Attorneys were designated separately for the Commissioner and for CDRH to preserve integrity in the advisory and decision-making process.
- This followed FDA‚Äôs grant of Ethicon's petition for review of the CDRH‚Äôs prior PMA denial for the SEDASYS system",
FDA-2010-P-0176-0027_FDA_Office_for_Policy_Response_to_Goodwin_Proctor_,"Stamped March 17, 2011",,"Office of the Commissioner (Policy), coordinated with CDRH (Center for Devices and Radiological Health)",Other ‚Äì The FDA reaffirmed its decision to continue with the advisory committee review process via the Medical Devices Dispute Resolution Panel for the denial of PMA P080009. No final decision to approve or deny the petition was made in this letter.,"Section 515(g)(2) of the Federal Food, Drug, and Cosmetic Act
- Section 515(d)(2)(A) and 515(d)(4)
- 21 CFR 814.44(f) and 814.45(e)(3)
- 21 CFR 10.33 and 21 CFR Part 14
- 21 CFR 10.75(b)(2) and 10.55(b)(2)(i)
- Section 562 (addressed but not applied)","FDA reviewed objections raised in a December 9, 2010 letter regarding the use of the Medical Devices Dispute Resolution Panel rather than chartering a new advisory committee.
- The agency concluded that the Panel is lawfully authorized under section 515(g)(2)(B) to conduct review of PMA denials and that no statutory or regulatory barrier prevents this referral.
- FDA rejected EES's arguments invoking Section 562, clarifying that the proceeding was being handled under Section 515(g)(2) and that Section 562 regulations were not applicable.
- Dr. David Buckles' role was defended, noting that he was properly designated to advise the Office of the Commissioner as part of the separation-of-functions policy adopted voluntarily (not mandated).
- The agency reaffirmed its intent to move forward with the referral and requested EES to designate a contact representative for ongoing proceedings",
FDA-2010-P-0176-0025_FDA_CDRH_Ombudsman_Response_to_Ethicon_Endo_Surger,"Stamped November 18, 2010",,Center for Devices and Radiological Health (CDRH) ‚Äì from the Office of the Ombudsman,Other ‚Äì Confirmation of process: FDA acknowledged that the petition for reconsideration was granted and outlined the next procedural step‚Äîreferral to the Medical Devices Dispute Resolution Panel. No final decision on the petition itself was rendered.,"Not explicitly cited in this document. Reference made to the Guidance Document: ‚ÄúResolving Scientific Disputes Concerning the Regulation of Medical Devices, A Guide to Use of the Medical Devices Dispute Resolution Panel‚Äù (July 2, 2001)"," The FDA, through the Commissioner's Office, granted the March 25, 2010 petition to review the denial of PMA P080009.
- The matter is being referred to the Medical Devices Dispute Resolution Panel as per established FDA guidance.
- The CDRH Ombudsman, Dr. David Buckles, was designated to convene the panel and serve as liaison.
- Sponsors were instructed to avoid direct contact with agency employees and instead route communications through the Ombudsman to preserve integrity during the Panel process.
- Tentative scheduling for the Panel meeting was proposed for the week of April 4, 2011",
FDA-2010-P-0176-0024_FDA_Office_for_Policy_Response_to_Ethicon_Endo_Sur,"Stamped November 5, 2010",,Office of the Commissioner (Policy) in collaboration with CDRH (Center for Devices and Radiological Health),Other ‚Äì The FDA granted the petition for review of the denial of PMA P090009 and referred the matter to an advisory committee (Medical Devices Dispute Resolution Panel) for further evaluation. No final decision (approval/denial) on the PMA was issued in this letter.,"Section 515(d)(2)(A) and 515(d)(4) of the FD&C Act
- Section 515(g)(2)(A) and 515(g)(2)(B) of the FD&C Act
- 21 CFR 814.44(f)(2) and 21 CFR 814.45
- 21 CFR 10.33","FDA determined the PMA was not approvable due to insufficient evidence of safety under proposed conditions of use.
- EES sought reconsideration, which FDA treated as a request for administrative review under section 515(g)(2).
- FDA followed the regulatory procedure to issue a formal order of denial, which was then referred to the advisory committee as required by regulation.
- FDA referenced the Medical Devices Dispute Resolution Panel Guidance (July 2, 2001) as the basis for using the Panel to review this dispute.
- The Panel will ultimately submit a report and recommendation to the Chief Scientist and Deputy Commissioner for Science and Public Health",
FDA-2010-P-0176-0001_FDA_CDRH_to_Ethicon_Endo_Surgery__Inc____Denial_of,"Stamped October 26, 2010",,Center for Devices and Radiological Health (CDRH),Denied ‚Äì The FDA formally denied the PMA (Premarket Approval) application P080009 for the SEDASYS‚Ñ¢ system,"Section 515(d)(2) of the FD&C Act (21 U.S.C. 360e(d)(2))
- 21 CFR 814.44(f)
- 21 CFR 814.45(e)(3)
- 21 CFR 10.33
- Section 515(d)(4) of the FD&C Act
- 21 CFR 860.7(d)(1)
- 21 CFR 814.45(b) and 814.45¬©","The FDA concluded that the sponsor failed to provide reasonable assurance of safety for the SEDASYS System under the proposed labeling conditions.
- The pivotal clinical study lacked a direct comparison of SEDASYS use by gastroenterologists vs. anesthesiologists administering propofol under the FDA-approved label, making it impossible to assess relative safety risks.
- The device showed a higher incidence of deeper-than-intended sedation, including episodes of general anesthesia, compared to the control arm (‚ÄúCurrent Standard of Care‚Äù), which FDA flagged as a serious safety signal.
- The proposed training programs (Amendments 12 and 15) were not backed by outcome-based clinical studies and considered speculative, inadequate to mitigate the safety concerns associated with broader use by less-trained clinicians.
- FDA advised that additional clinical studies are needed comparing outcomes across provider types and proposed that the sponsor develop and validate targeted training programs based on those findings.
- Notice of this denial would be published online and in the Federal Register, per 21 CFR 814.45(c)",
FDA-2010-P-0175-0007_FDA_CDER_to_Centrix_Pharmaceutical__Inc___Buchanan,"Stamped and Read March 1, 2011",,Center for Drug Evaluation and Research (CDER),Denied (on procedural grounds) ‚Äì The FDA denied Centrix‚Äôs request for a stay of enforcement action relating to certain tannate-containing products.,"21 CFR 10.35 ‚Äì stay procedures
- 21 CFR 10.3 ‚Äì definition of administrative action
- Section 201(p) of the FD&C Act (21 U.S.C. 321(p))
- Sections 505(b), 505(j) of the FD&C Act (21 U.S.C. 355(b), 355(j))
- Sections 301(d), 505(a) (21 U.S.C. 331(d), 355(a))
- Section 502(f)(1) (21 U.S.C. 352(f)(1))
- Sections 301(a), 301(d) (21 U.S.C. 331(a), 331(d))
- Section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B))
- Cited case law: Ewing v. Mytinger & Casselberry, Inc. (1950) and Heckler v. Chaney (1985)","The requested stay of enforcement did not qualify under 21 CFR 10.35, as the action (enforcement discretion) does not fall within the scope of reviewable administrative actions.
- FDA determined that decisions to initiate or refrain from enforcement actions are within the agency‚Äôs discretion and not subject to stay or judicial review.
- The underlying Warning Letter (Feb 24, 2010) found Centrix‚Äôs products to be unapproved new drugs, misbranded, and adulterated, and required prompt corrective actions.
- The petition's claim that Centrix was being denied due process was not persuasive under current law and regulation.
- FDA reaffirmed that courts have repeatedly held agency enforcement discretion is not reviewable",
FDA-2010-P-0172-0006_FDA_CDER_to_Lachman_Consultant_Services__Inc__Resp,"Stamped December 7, 2010; Read December 9, 2010",,Center for Drug Evaluation and Research (CDER),"Denied (in substance) ‚Äì FDA determined that the referenced AUGMENTIN products were not withdrawn for reasons of safety or effectiveness. Therefore, the citizen petition requesting withdrawal from the Orange Book was effectively denied.","21 CFR 314.161(a)(1) and 314.161(d) ‚Äì regarding determination of withdrawal for safety/effectiveness
- 21 CFR 314.162 ‚Äì list maintenance rules for Orange Book
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7))
- 21 CFR 10.30 ‚Äì citizen petition rule","After reviewing its own records and independently evaluating postmarketing data and literature, FDA concluded there was no evidence indicating that any of the listed AUGMENTIN (amoxicillin/clavulanate potassium) formulations were withdrawn for safety or efficacy reasons.
- Although the petitioner did not raise safety concerns directly, FDA conducted a voluntary review of all seven formulations, including those not mentioned in the original petition.
- Based on this review, FDA stated it would continue listing these products in the ""Discontinued Drug Product List"" section of the Orange Book, allowing their use as reference listed drugs for ANDA submissions
.",
FDA-2010-P-0172-0005_Determinations_that_Drug_Products_Not_Withdrawn_fr,"December 7, 2010",,Center for Drug Evaluation and Research (CDER),"Denied (implicitly) ‚Äì FDA determined that the seven AUGMENTIN (amoxicillin; clavulanate potassium) drug products were not withdrawn from sale for reasons of safety or effectiveness, and thus rejected the premise of the petition to delist them."," 21 CFR 314.161(a)(1) and 314.161(d) ‚Äì withdrawal determinations
- 21 CFR 314.162 ‚Äì Orange Book listings
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7))
- 21 CFR 10.30 ‚Äì citizen petition provision","Petitioners requested FDA to determine whether specific AUGMENTIN formulations were withdrawn for safety or efficacy reasons.
- FDA reviewed internal records, postmarketing data, and relevant literature.
- The Agency found no evidence of safety or effectiveness issues associated with the withdrawal of the drug products.
- FDA concluded these were withdrawn for reasons other than safety or efficacy (e.g., commercial reasons).
- The products will remain listed in the Discontinued Drug Product List section of the Orange Book and remain referenceable for ANDA submissions",
FDA-2010-P-0172-0004_Intermin_Respponse_to_EAS_Consulting_Group__LLC,"Stamped September 13, 2010 and September 15, 2010",,Center for Drug Evaluation and Research (CDER),"Other ‚Äì Interim Response
FDA acknowledged receipt of the petition but stated it had not yet resolved the issues due to prioritization of other matters. A final decision would be issued at a later time.",21 CFR 10.30(e)(2) ‚Äì regulation governing interim responses to citizen petitions,"The petition, submitted on behalf of Aurobindo Pharmaceuticals, requested a determination on whether certain AUGMENTIN formulations were withdrawn for safety or effectiveness reasons.
- FDA explained that it had not completed its review due to the need to address other agency priorities.
- The interim response was provided to comply with regulatory requirements pending a full decision",
FDA-2010-P-0171-0008_FDA_CDER_to_Sun_Pharmaceutical_Industires__Inc____,"July 7, 2010; Stamped July 12, 2010",,Center for Drug Evaluation and Research (CDER),"Denied (Petition Rejected) ‚Äì FDA determined that ACCUTANE capsules were not withdrawn for reasons of safety or effectiveness, and therefore denied the implication behind the petition. The product will remain listed in the Discontinued Drug Product List."," 21 CFR 314.161(a)(1) ‚Äì withdrawal determinations
- 21 CFR 314.162 ‚Äì Orange Book delisting criteria
- 21 CFR 10.30 ‚Äì citizen petition provisions
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7))","The petitioner (Sun Pharmaceutical) requested FDA to determine if ACCUTANE capsules were withdrawn for safety or effectiveness reasons.
- FDA reviewed internal records, the literature, and postmarketing adverse event data.
- FDA found no evidence of withdrawal due to safety or effectiveness concerns.
- Therefore, the agency will continue to list ACCUTANE capsules (10 mg, 20 mg, 40 mg) in the Discontinued Drug Product List of the Orange Book, meaning they may still serve as reference listed drugs for ANDAs.
- No procedures will be initiated to withdraw existing ANDAs or prevent future ones that comply with legal and regulatory standards",
FDA-2010-P-0171-0007_Determinations_that_Products_Were_Not_Withdrawn_Fr,"July 7, 2010",,Center for Drug Evaluation and Research (CDER),"Denied (Implicit) ‚Äì FDA determined that ACCUTANE capsules were not withdrawn for reasons of safety or effectiveness, which preserves their use as reference listed drugs for ANDA submissions.","21 CFR 314.161(a)(1) ‚Äì Withdrawal review standard
- 21 CFR 314.162 ‚Äì Criteria for removing drugs from the Orange Book
- 21 CFR 10.30 ‚Äì Citizen petition procedure
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7))","FDA reviewed its records and evaluated relevant literature and postmarketing data.
- No evidence indicated that ACCUTANE (isotretinoin) 10 mg, 20 mg, and 40 mg capsules were withdrawn from sale for safety or effectiveness reasons.
- The petitioner (Sun Pharmaceutical Industries) presented no data suggesting safety/efficacy issues with the product‚Äôs withdrawal.
- Therefore, ACCUTANE remains listed in the ‚ÄúDiscontinued Drug Product List‚Äù section of the Orange Book, allowing reference for ANDA applications.
- FDA may still revise isotretinoin labeling to meet current standards, but this does not affect the withdrawal determination",
FDA-2010-P-0170-0006_FDA_CVM_to_Lannett_Comany__Inc____Petition_Denial,"Stamped June 15 and June 18, 2010",,"Center for Veterinary Medicine (CVM) ‚Äì specifically, the Office of New Animal Drug Evaluation","Denied ‚Äì FDA denied the suitability petition submitted by Lannett Company, Inc., for an abbreviated new animal drug application (ANADA) due to a non-approvable change in active ingredient.","Section 512(n)(3) and 512(n)(1) of the FD&C Act
- 21 CFR 25.33 (incorrectly cited by petitioner)
- 21 CFR 25.30(h) ‚Äì correct citation for environmental assessment exclusion
- 21 CFR 25.15 ‚Äì requirement to state no extraordinary environmental circumstances
- 21 CFR Part 10 and 10.33 ‚Äì procedures for petition reconsideration
- 21 CFR 10.25(a) ‚Äì submitting new petitions","The proposed generic product included sulfamethoxazole, which is not an approved active ingredient in any currently approved animal drug product.
- Under section 512(n)(1) of the FD&C Act, the substitution of a different active ingredient requires supporting data to show it is already an approved active ingredient, which was not provided.
- Because sulfamethoxazole is not approved for animal use, studies would be required to demonstrate its safety and effectiveness.
- As a result, the change in formulation does not qualify for a suitability petition under section 512(n)(3)(C).
- Additionally, the petitioner‚Äôs environmental exclusion citation was incorrect; FDA provided the proper regulatory citation and noted required statements under 21 CFR 25.15",
FDA-2010-P-0162-0007_FDA_CDER_to_Unisource__Inc___Buchanan_Ingersoll___,"Stamped and Read March 1, 2011",,Center for Drug Evaluation and Research (CDER),Denied (on procedural grounds) ‚Äì The FDA denied the request for a stay of enforcement action concerning Unisource‚Äôs tannate-containing products. The petition was rejected as it did not fall under reviewable ‚Äúadministrative actions‚Äù as defined by FDA regulations.,"21 CFR 10.3 ‚Äì Definition of administrative action
- 21 CFR 10.35 ‚Äì Procedures for requests for stay
- Section 201(p) of the FD&C Act (21 U.S.C. 321(p))
- Sections 505(b), 505(j) (21 U.S.C. 355(b), 355(j))
- Sections 301(d), 505(a) (21 U.S.C. 331(d), 355(a))
- Section 502(f)(1) (21 U.S.C. 352(f)(1))
- Section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B))
- Section 301(a) (21 U.S.C. 331(a))
- Case law: Ewing v. Mytinger & Casselberry, Inc., 339 U.S. 594 (1950); Heckler v. Chaney, 470 U.S. 821 (1985)","The petition requested a stay of enforcement regarding unapproved tannate-containing drug products pending resolution of a related citizen petition (the TWG Petition).
- FDA stated that the action sought‚Äîa stay of enforcement‚Äîis not an administrative action under its regulations and thus cannot be granted under 21 CFR 10.35.
- Enforcement decisions (such as whether to initiate action based on a Warning Letter) are within FDA‚Äôs discretion and not subject to judicial or administrative review.
- The agency emphasized that no legal mechanism exists to stay enforcement discretion via petition in this context.
- FDA had already concluded that the tannate-containing products were unapproved new drugs and misbranded, and that their continued marketing violated multiple sections of the FD&C Act",
FDA-2010-P-0157-0006_FDA_CDER_to_Rakoczy_Molino_Mazzochi_Siwik_LLP___Le,"Stamped September 14 and September 15, 2010",,Center for Drug Evaluation and Research (CDER),"Denied (in effect) ‚Äì FDA determined that VESANOID (tretinoin) Capsules, 10 mg, were not withdrawn for reasons of safety or effectiveness. This allows continued use of VESANOID as a reference listed drug for ANDA submissions.","21 CFR 10.30 ‚Äì Citizen petition regulation
- 21 CFR 314.161(a)(1) ‚Äì Determining if a drug was withdrawn for safety or effectiveness reasons
- 21 CFR 314.162 ‚Äì Conditions for removal from the Orange Book
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) ‚Äì Publication of approved drug list","The petitioner requested a determination regarding the withdrawal status of VESANOID Capsules, 10 mg.
- FDA reviewed agency records and independent literature for postmarketing safety issues.
- No evidence was found to suggest the product was withdrawn for reasons of safety or effectiveness.
- The discontinuation by the NDA holder (Roche) was voluntary, and the product was placed in the ‚ÄúDiscontinued Drug Product List‚Äù of the Orange Book.
- The FDA affirmed that new ANDAs referencing VESANOID may still be approved if they meet other legal and regulatory criteria.",
FDA-2010-P-0157-0005_Determinations_That_Products_Were_Not_Withdrawn_Fr,"September 14, 2010",,Center for Drug Evaluation and Research (CDER),"Denied (in substance) ‚Äì FDA determined VESANOID (tretinoin) Capsules, 10 mg, were not withdrawn for reasons of safety or effectiveness. Therefore, ANDAs referencing this product may continue to be submitted and approved.","21 CFR 314.161(a)(1) ‚Äì Drug withdrawal determination standard
- 21 CFR 314.162 ‚Äì Orange Book delisting
- 21 CFR 10.30 ‚Äì Citizen petition provision
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) ‚Äì Drug listing requirement"," A citizen petition requested FDA determine whether VESANOID was withdrawn for safety or efficacy reasons.
- FDA reviewed agency records, independent literature, and postmarketing adverse event data.
- No information suggested that the product‚Äôs withdrawal was related to safety or effectiveness.
- The sponsor, Hoffman-La Roche Inc., had voluntarily discontinued marketing the product in 2009.
- The drug remains listed in the Discontinued Drug Product List of the Orange Book, allowing it to serve as a reference listed drug (RLD) for ANDAs.",
FDA-2010-P-0150-0004_Interim_Response__to_United_States_Pharmacopeial_C,"September 16, 2010; Stamped September 20, 2010",,"Center for Food Safety and Applied Nutrition (CFSAN)
Specifically, from the Office of Food Additive Safety","Other ‚Äì Interim Response
The FDA acknowledged receipt of the petition and informed the petitioner that it had not yet reached a decision within the 180-day window.",21 CFR 10.30(e)(2) ‚Äì Governs FDA‚Äôs issuance of interim responses to citizen petitions when no decision is reached within 180 days,"The citizen petition, filed March 15, 2010, requested the FDA amend regulations in 21 CFR Parts 170 and 184 to incorporate by reference the Food Chemicals Codex, 7th Edition.
- FDA issued the interim response solely to comply with regulatory timelines, indicating that review was still ongoing and no final decision had been made.
- The Agency invited the petitioner to submit additional supplemental materials for further consideration while the review remained open",
FDA-2010-P-0149-0005_FDA_CTP_Response_to_the_House_of_Oliver_Twist__Kle,"Stamped May 16, 2011",,Center for Tobacco Products (CTP),Denied ‚Äì The FDA denied the request for exemption from health warning label placement requirements under the Smokeless Tobacco Act,"Section 204 of the Tobacco Control Act
- 15 U.S.C. ¬ß 4402(a)(2) ‚Äì Warning label placement on smokeless tobacco packages
- Section 3 of the Smokeless Tobacco Act
- Guidance for Industry: Enforcement Policy Concerning Rotational Warning Plans for Smokeless Tobacco Products","Oliver Twist requested exemption based on the small size and design of the product packaging (Chewing Tobacco Bits).
- FDA emphasized that no provision in the TCA or Smokeless Tobacco Act supports granting such an exemption.
- FDA found that Oliver Twist failed to show that alternative placements (e.g., smaller fonts, off-package labeling) would be ‚Äúequally effective.‚Äù
- The property interest in branding and trade dress on the package‚Äôs top panel did not override public health concerns.
- The Agency reiterated that the statutory requirement serves an important public health purpose by ensuring consumers are aware of the risks associated with smokeless tobacco use",
FDA-2010-P-0149-0004_FDA_CTP_Interim_Response_to_the_House_of_Oliver_Tw,"Stamped September 9, 2010",,Center for Tobacco Products (CTP),"Other ‚Äì Interim Response
FDA acknowledged receipt of the petition and issued a tentative response indicating that a final determination would follow upon completion of their review.","Family Smoking Prevention and Tobacco Control Act (general reference)
‚Äî No specific statutory or regulatory citations are listed in this interim letter.","The House of Oliver Twist A/S submitted a citizen petition on March 15, 2010, seeking exemption from certain health warning label requirements due to the small size of the Oliver Twist Chewing Tobacco Bits packaging.
- The FDA stated it was actively reviewing the issues raised and would issue a final response once the review was completed.
- The interim response was issued to acknowledge the petition and maintain compliance with response timelines",
FDA-2010-P-0138-0012_FDA_CDER_to_Buchanan_Ingersoll_and_Rooney_PC__Peti,"Stamped February 11, 2013",,Center for Drug Evaluation and Research (CDER),"Denied
The FDA denied the petition requesting recognition of certain oral iron forms as Generally Recognized as Safe and Effective (GRAS/E) without an NDA.","21 U.S.C. ¬ß 355(a) ‚Äì New drug application (NDA) requirement
- 21 U.S.C. ¬ß 321(p) ‚Äì Definition of ‚Äúnew drug‚Äù
- 21 CFR 314.126 ‚Äì Adequate and well-controlled investigations
- 21 CFR 314.125(b) ‚Äì Substantial evidence and effectiveness standards
- 21 CFR 314.200(e)(1) ‚Äì Administrative hearing regulations
- 21 CFR 310.6(b)(2) ‚Äì Drug efficacy study implementation (DESI)
- Federal Register and case law citations: Premo Pharm. Labs., Weinberger v. Bentex, United States v. Generix Drug Corp., etc.","The petition requested FDA to confirm that various oral iron forms (ferrous sulfate, ferrous fumarate, ferrous asparto glycinate, ferrous gluconate) are GRAS/E within the range of 60‚Äì180 mg/day under physician supervision.
- FDA rejected the blanket GRAS/E classification for a class of drugs based solely on their active ingredient, emphasizing that GRAS/E determinations must be product-specific.
- FDA maintained that adequate and well-controlled clinical studies must support each individual product‚Äôs safety and efficacy under labeled conditions.
- The Agency noted that this approach is consistent with regulatory precedent and court rulings, including Generix Drug Corp., where GRAS/E determination applied to entire finished drug products, not just active moieties.
- FDA distinguished this case from the Over-the-Counter (OTC) Drug Review, where GRAS/E can apply to classes of products; this does not extend to prescription products like oral iron, which require individual evaluation.
- The agency also addressed and rejected related arguments concerning DESI reviews and radioactive drug GRAS/E precedents as not applicable to this case.",
FDA-2010-P-0138-0011_Interim_Response_to_Buchanan_Ingersoll___Rooney_PC,"Stamped September 2 and September 7, 2010",,Center for Drug Evaluation and Research (CDER),Other ‚Äì Interim Response,21 CFR 10.30(e)(2) ‚Äì FDA‚Äôs regulation permitting interim responses to citizen petitions when a decision is not yet available within the 180-day timeframe,"The petition (submitted March 11, 2010) requested that FDA issue an order confirming that certain oral iron compounds (e.g., ferrous sulfate, ferrous fumarate, ferrous asparto glycinate, and ferrous gluconate) are generally recognized as safe and effective (GRAS/E) in daily doses of 60‚Äì180 mg when administered under physician supervision to treat iron deficiency anemia.
- FDA explained that the petition raises complex issues requiring extensive internal review and analysis.
- Therefore, an interim response was issued while FDA continues evaluating the request",
FDA-2010-P-0114-0006_FDA_DDM_to_McGuff_Pharmaceuticals__Inc____Correcti,"February 25, 2010",,"Division of Dockets Management (DDM) under the Office of Public Information and Library Services, FDA
Note: This is an administrative office, not a regulatory review division like CDER or CDRH","Other ‚Äì Acknowledgment of Petition Filing
This was not a substantive decision on the merits of the petition. It simply acknowledged receipt and corrected a typographical error in a prior letter.",Not Mentioned,"The FDA acknowledged receipt of a citizen petition submitted by McGuff Pharmaceuticals, Inc. on February 25, 2010, requesting permission to file an Abbreviated New Drug Application (ANDA) for Pyridoxine Hydrochloride Injection, USP at a strength of 3g/30 mL (100 mg/mL).
- The letter replaced an earlier acknowledgment due to a typographical error.
- The agency clearly stated that filing the petition is procedural only and does not reflect any decision on the substantive merits of the petition",
FDA-2010-P-0105-0032_Interim_Response_to_National_Chicken_Council__NCC_,"August 17, 2010; Stamped August 19, 2010",,Center for Food Safety and Applied Nutrition (CFSAN),"Other ‚Äì Interim Response
FDA acknowledged receipt of the citizen petition and stated it had not reached a decision within 180 days due to limited resources and competing priorities.",21 CFR 10.30(e) ‚Äì Authorizes interim responses to citizen petitions when decisions are delayed beyond 180 days,"The citizen petition (submitted February 19, 2010) requested that FDA either:
1. Amend 21 CFR 118.4(e) to exclude surplus hatching eggs sold for use in egg products from refrigeration requirements, or
2. Reopen the comment period on the single refrigeration requirement for surplus hatching eggs, or
3. Re-propose the Final Rule as it pertains to this specific issue.
- The FDA stated it had not been able to make a determination within 180 days because of limited availability of resources and competing agency priorities",
FDA-2010-P-0089-0019_FDA_CDER_to_Center_for_Tobacco_Regulation_Litigati,"Stamped April 1, 2013",,"Center for Drug Evaluation and Research (CDER) ‚Äî Signed by Janet Woodcock, Director, CDER","Partially Approved / Partially Denied: The FDA granted or denied different parts of the petition as follows:
- Denied: Requests to modify labeling restrictions, allow new indications, and transfer evaluation to OHOP.
- Granted: Requests to collaborate with sponsors, consider surrogate endpoints, prioritize development under section 918, allow sale in cigarette outlets, and approve smaller package sizes","Tobacco Control Act (P.L. 111-31)
- FD&C Act Section 918 (21 U.S.C. 356)
- 21 CFR 312.82(a), 312.84
- Pediatric Research Equity Act (PREA)","The FDA evaluated all scientific data and literature cited in the petitions and found much of it insufficient to support the requested labeling changes or new indications.
- Some requests (like smaller package sizes and broader retail availability) aligned with already existing practices and were thus granted.
- The agency emphasized that substantive labeling or indication changes must follow formal regulatory review and be supported by sponsor data through the NDA process.
- Specific data cited by petitioners (e.g., from studies by Piper, Kozlowski, Sweeney, and others) were deemed inconclusive, insufficient, or inapplicable to the requested changes.
- FDA committed to collaborating with sponsors on development and evaluation of NRT therapies to improve public health outcomes.",
FDA-2010-P-0089-0017_Minutes_of_Meeting_with_SRNT_and_ATTUD_dated_June_,"June 4, 2012",,Center for Drug Evaluation and Research (CDER) ‚Äî Represented at the meeting by Denise Esposito and Grail Sipes (CDER/ORP). Additional FDA participation included Stephen Spielberg (OMPT),Informational / Listening Session ‚Äì Not a Formal Decision ‚Äî This meeting was held to hear the positions of petitioners. FDA asked questions but did not issue a ruling or determination on the petition during this meeting.,Not Mentioned ‚Äî The minutes do not reference any statutes or regulations directly.,"FDA convened this meeting to hear presentations from SRNT and ATTUD, both co-petitioners on FDA Docket No. 2010-P-0089.
- Four presentations were delivered:
‚Ä¢ ‚ÄúBuilding a Comprehensive Nicotine Regulatory Policy‚Äù (Zeller, SRNT)
‚Ä¢ ‚ÄúClinicians‚Äô Perspective of Tobacco Dependence Treatment‚Äù (Steinberg, ATTUD)
‚Ä¢ ‚ÄúPerspectives From a Quit Line Provider‚Äù (Wassum)
‚Ä¢ Presentation by Gary Swan (SRNT)
- FDA engaged with questions but offered no conclusions or commitments at this meeting",
FDA-2010-P-0089-0014_Minutes_of_Meeting_with_SRNT_and_ATTUD_dated_March,"March 9, 2012",,Center for Drug Evaluation and Research (CDER),Informational / Listening Session ‚Äì Not a Final Decision ‚Äî The meeting was convened for FDA to hear and discuss petitioners‚Äô positions. No decision was issued during or as a result of the meeting,Not Mentioned ‚Äî No specific statutes or regulations were cited during the meeting or in the meeting minutes,"The meeting served to allow SRNT and ATTUD to present their views on treatments for tobacco dependence and to raise issues related to pending citizen petitions.
- The presentation by Robert West and follow-up remarks from ATTUD members provided clinical and public health perspectives.
- FDA participated by asking clarifying questions but did not offer any policy conclusions or commitments",
FDA-2010-P-0059-0003_Determination_That_ACTONEL__Risendronate_Sodium__T,,no date,Center for Drug Evaluation and Research (CDER),"Approved ‚Äî The FDA determined that the drug products were not withdrawn for reasons of safety or effectiveness, allowing the agency to approve Abbreviated New Drug Applications (ANDAs) referencing them if other legal and regulatory requirements are met","21 U.S.C. ¬ß 355(j)(7) ‚Äî Requirement to publish a list of approved drugs (Orange Book)
- 21 CFR 314.161(a)(1) ‚Äî Process for determining whether a drug was withdrawn from sale for safety or effectiveness reasons
- 21 CFR 314.162 ‚Äî Grounds for removing drugs from the Orange Book","FDA reviewed its records and the relevant literature for any postmarketing adverse events.
- None of the citizen petitions provided data indicating the drugs were withdrawn for safety or effectiveness reasons.
- FDA found no evidence to suggest safety or efficacy concerns.
- As a result, the products remain in the ‚ÄúDiscontinued Drug Product List,‚Äù confirming discontinuation for non-safety reasons",
FDA-2010-P-0056-0029_Citizen_Petition_Closure_Memo_from_CDRH_dated_4_10,"April 10, 2018",,"Center for Devices and Radiological Health (CDRH) ‚Äî Signed by Dr. Jeffrey Shuren, Director of CDRH","Closed (Procedural Grounds) ‚Äî FDA closed the docket without a decision on the substance of the petition due to the death of the petitioner, Dr. Richard Edlich, and the absence of appropriate contact details for the co-signers","21 CFR ¬ß 10.30(e)(3) ‚Äî Notification of the Commissioner‚Äôs decision regarding a citizen petition
- 21 CFR ¬ß 10.30(b)(3) ‚Äî Requirements for petitioner contact information in citizen petitions","The original petitioner, Dr. Edlich, passed away on December 25, 2013.
- Although co-signers were listed (Jill Dahlstrom, Jamie Clark, Tiffany Wisecarver), they did not provide mailing addresses or contact information, as required under 21 CFR ¬ß 10.30(b)(3).
- Therefore, FDA concluded Dr. Edlich was the sole petitioner and closed the docket.
- The FDA noted that any of the co-signers could resubmit the petition in accordance with 21 CFR ¬ß 10.30",